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Kinetic Studies of HIV-1 Reverse Transcriptase Nucleotide Selectivity, 
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Supervisor:  Kenneth Allen Johnson 
 
Mechanisms of nucleotide selectivity and drug resistance by HIV-1 Reverse 
Transcriptase (HIVRT) were examined using rapid kinetic methods and global data 
fitting. Thymidine analog resistance mutations provide only two-fold discrimination 
against the incorporation of AZT-triphosphate; therefore, it is generally believed that 
resistance arises from nucleotide excision, where ATP reacts with the 3’ terminal base to 
produce a dinucleotide tetraphosphate and a 3’-OH terminated primer capable of 
subsequent extension. Single turnover kinetic analysis with global data fitting revealed 
the intrinsic rate and equilibrium constants governing each step leading to resistance to 
chain terminators. Our data suggested the net resistance to AZT arises from nearly equal 
contributions involving discrimination during incorporation (2x), enhanced ATP-
dependent excision (2-5x), reduced binding of the next correct nucleotide (2.6-5x) and 
more favored binding of the DNA primer in the N-site (5-20x). 
Chemistry is generally the only rate-limiting step for product formation during 
DNA polymerization with a DNA template, but with an RNA template we show that 
pyrophosphate (PPi) release was rate-limiting. Due to the slow PPi release step, the rate 
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of reversal of chemistry could also be determined affording the first measurement of the 
equilibrium constants governing polymerization and the first complete free energy profile 
for HIVRT. Although PPi release is rate-limiting, nucleotide binding remains as the 
specificity-determining step. However, PPi release becomes exceedingly slow following 
mis-incorporation and thereby contributes to the specificity constant. Our data 
demonstrate that the fidelity of HIVRT has been underestimated by >20-fold in the past 
20 years since the slow PPi release has been overlooked.  
The rate-limiting PPi release allows synchronization and coordination of the 
polymerase and RNase-H activities. Studies were undertaken to examine proposed 
coordination between the polymerase and RNase-H activities. Direct, simultaneous 
measurement of the two activities established a mechanism by which polymerization and 
RNase-H activities are coordinated by working independently at comparable rates, but 
with different efficiencies. In contrast to polymerization, RNase-H requires ~4–6 base 
pairs extending beyond the active site for optimal reactivity, providing fast but infrequent 
cleavage events. Consequently, the polymerase and RNase-H activities are seamlessly 
coordinated without any direct communication between the two sites. 
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Chapter 1: Introduction 
1.1 PROJECT SUMMARY 
In this thesis several projects were completed to understand the nucleotide 
selectivity and drug resistance by HIV-1 Reverse Transcriptase (HIVRT). Mechanistic 
perspectives of HIVRT were also explored in this dissertation. These studies provide 
insights into the design and evaluation of new drugs needed to manage HIV infections. 
Chapter 1 provides a comprehensive review of HIVRT. Chapter 2 reports that AZT drug 
resistance conferred by dipeptide insertions in the fingers of HIVRT involves multiple 
mechanisms that sum to define the net resistance. Chapter 3 explores effects of AZT 
resistance mutations and dipeptide insertions in the fingers of HIVRT on ATP-dependent 
excision of thymidine analogues. Chapter 4 reports that the polymerase and RNase H 
active sites of HIVRT work simultaneously and independently. Chapter 5 presents the 
rate-limiting pyrophosphate release by HIVRT and its effect on enzyme specificity. 
Chapter 6 explores effects of an R72A mutation on kinetics and fidelity of HIVRT. 
1.2 AN OVERVIEW OF HIV 
Since the discovery of Human Immunodeficiency Virus (HIV) as the causative 
agent of Aquired Immune Deficiency Syndrome (AIDS) in the early 1980s (1-2), HIV 
infection has been a severe public health problem over all the world. According to the 
2014 report of the World Health Organization (WHO), 36.9 million people were living 
with HIV, with 2.0 million new infections occurring in 2014 (3). Without effective 
antiretroviral therapy, the immune system of an infected individual will be impaired 
gradually over time, making them more vulnerable to other infections, causing a series of 
2	  
	  
complications leading to death (4). Although the global HIV response has been 
remarkably transformed in the past 15 years and HIV treatment reached almost 16 
million people in mid-2015 (5), there were still 1.2 million AIDS-related deaths in 2014 
(3), highlighting the need for further research to find more effective antiretroviral 
therapies. 
Knowledge of the molecular virology related to HIV infection is necessary for 
discussions of the development of antiretroviral treatment and accompanying challenges. 
HIV can be grouped into two major types, HIV-type 1 (HIV-1) and HIV-type 2 (HIV-2). 
It is clear that nearly all infections are due to the spread of HIV-1, whereas HIV-2 is 
restricted to West Africa and is less virulent (6). HIV is a lentivirus from the Retroviridae 
family, which has two identical copies of RNA genome enclosed in a capsid and a bi-
layered lipid envelop (Figure 1.1). 
Mature HIV particles have a spherical morphology of 100 nm in diameter, whose 
structure is shown in Figure 1.1 (7). The center of a HIV virion includes two copes of 
identical 9.7kb single stranded viral RNA (8) that encode structural proteins (gag and 
env), enzymes (pol), and other regulatory/accessory proteins (tat, rev, vpr, vpu, vif, and 
nef). The gag gene encodes the structural proteins that form the truncated cone-shaped 
capsid (p24) and the matrix (p17). The pol gene encodes enzymes necessary for viral 
replication, including reverse trancriptase that retrotranscribes the viral RNA genome into 
DNA, integrase that inserts linear double-stranded DNA into the host chromosome 
(provirus integration), and the protease that cleaves the Gag-Pol polyproteins into their 
components (9). The viral genomic RNA and enzymes are packed into the capsid, which 
3	  
	  
is surrounded by a bilayered membrane (or envelope) derived from the host cell’s outer 
surface during the process of budding. The env gene encodes two major viral 
glycoproteins, gp41 and gp120 that are required for viral entry (9). The 
regulatory/accessory genes play key roles in modulating virus replication, whose 
functions are reviewed in (10). 
The replication cycle of HIV (right panel, Figure 1.1) includes 1) virus entry, 
involving CD4 binding, co-receptor (CXCR4 or CCR5) interactions and membrane 
fusion (step 1-3); 2) post-entry events, including reverse transcription that converts viral 
RNA into proviral DNA (detailed in section 1.3), nuclear import, and integration of 
proviral DNA into host genome (step 4-5); 3) gene expression, where the integrated viral 
genome is expressed using the host machinery (step 6); 4) virus particle production, in 
which a Gag precursor polyprotein assists plasma membrane targeting and binding (step 
7) (11), then RNA is encapsidated and final assembly and budding occur (step 8). 5) 
maturation, where protease cuts the precursor polyproteins to generate mature Gag and 





Figure 1.1 (Left) HIV viral proteins and gene structure. (Right) Replication of HIV. 
Reproduced from Chinen and Shearer (7). (Left) HIV gene structure is shown on the top. 
LTR: long terminal repeat. The gag-pol gene encodes two precursor polyproteins that are 
cleaved to generate structural proteins and 3 viral enzymes: reverse transcriptase (RT), 
integrase (IN), and protease (PR). The env gene encodes the gp160 polypeptide precursor 
that contains two glycoproteins, gp 120 and gp41. HIV accessory genes are shown in 
yellow. (Right) HIV infection begins with binding (step 2), then viral core is released into 
the cell (step 3). Viral RNA is then converted to viral cDNA (step 4) that can be inserted 
into host genome (step 5). The viral DNA is transcribed into mRNA (step 6), followed by 
protein synthesis and assembly (step 7). Finally, new mature viruses are released from the 
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1.3 HIV RT FUNCTION IN VIRAL REPLICATION 
The multifunctional reverse transcriptase initiates the process of reverse 
transcription once the viral RNA genomes are released into the cytoplasm of infected 
cells. Although some viral and cellular factors may assist in the process of reverse 
transcription, HIV-1 RT contains all necessary enzymatic functions for the conversion, 
including RNA- and DNA-dependent DNA polymerase and RNase H activities.  
The individual steps for provirus DNA synthesis are illustrated in Figure 1.2. 
There is an 18-nucleotide-long primer binding site (PBS), located approximately 180 
nucleotides from the 5’ end of the viral genome (14). The host tRNAlys3 is base paired to 
the PBS via sequence complementarity and serves as the primer for (-) strand DNA 
synthesis using viral RNA as the template until it stops at the 5’ end of viral genome. The 
resulting DNA/RNA hybrid is a substrate for RNase H that selectively removes the 
copied RNA strand, exposing the newly synthesized DNA strand. Since the viral genome 
has two copies of identical sequence at the 5’ and 3’ ends (R or repeat), the nascent DNA 
is able to anneal with the 3’ end of one of the two genomic RNA strands so that DNA 
synthesis can resume, a process called ‘(-) strand DNA transfer’. As DNA synthesis 
proceeds, RNase H continues to hydrolyze the RNA strand with two exceptions known as 
polypurine tracts (cPPT and 3’ PPT) that are proposed to adopt a special conformation 
(15) and therefore are resistant to RNase H cleavage. The 3’ PPT serves as the primer for 
the initiation of the (+) strand DNA synthesis that will continue until it encounters a 
modified A in the template, which is the 19th base from the 3’ end of the tRNA primer. 
After that, PPT and tRNA primers are removed by RNase H cleavages and the second (or 
6	  
	  
plus) strand transfer occurs based on homology between (-) and (+) strand DNA primer 
binding sites. Then, bidirectional DNA synthesis extends both the (-) and (+) strands to 
the ends of both templates (reviewed in (14, 16-17)). 
The role of RNase H in reverse transcription has been reviewed by Sharon and 
James (18). The polymerization-dependent RNase H is presumably responsible for 
generating nicks on genomic RNA but is not sufficient to completely remove the copied 
RNA template since the polymerization rate is much greater than the cleavage rate of the 
enzyme (19-22). Consequently, the synthesis-independent RNase H cleavages take place 
to remove genomic RNA that remains annealed to the (-) strand DNA (19, 21). 
Polymerization-independent hydrolysis also participates in the generation of PPT primer 
and the removal of extended tRNA and PPT primers (23-24). 
It has been suggested that HIV-1 RT is an error-prone DNA polymerase, which 
accounts for the rapid emergence of mutations to evade the immune system and antiviral 
drugs. Although the fidelity of HIV-1 RT measured in vitro is particularly low (25-26), 
the mutation rates of HIV-1 replication measured in vivo is similar to other retroviruses 
(27-29), and the observed diversity of viral sequences is due to the rapid replication of 
HIV-1 viruses in a large number of infected cells (14). As another component of the viral 
replication cycle, the relative contribution of host DNA-dependent RNA polymerase II 
(RNA pol II) to the overall viral mutation rate is still unknown. Nonetheless, the ability 
of HIV-1 to diverge rapidly via reverse transcription is important for the virus to become 






Figure 1.2 HIV-1 Reverse Transcription Process. Reproduced from Esposito, Corona 
and Tramontano(16). Step 1: Host tRNAlys3 is hybridized to the primer binding site (PBS) 
and initiates (-) strand DNA synthesis. Step 2: RNase H degrades the copied RNA 
segment in a DNA/RNA hybrid and frees the newly synthesized DNA strand. Step 3: The 
first strand transfer occurs since the viral genome has identical sequence (R or repeat) at 
the two ends, after which (-) strand DNA synthesis continues. Step 4: As DNA synthesis 
proceeds, RNase H degrades the RNA strand, leaving two polypurine tracts (PPTs) intact, 
namely, the central PPT (cPPT) and 3’PPT. Step 5: The latter serves as the primer for (+) 
strand DNA synthesis, which stops at a modified A of the 3’-end of the tRNA. Then, 
tRNA is removed by RNase H. Step 6: The second strand transfer occurs based on 
homology between (-) and (+) strand DNA primer binding sites. Then, bidirectional DNA 
synthesis completes DNA synthesis.	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1.4 THE STRUCTURE OF HIV RT 
HIV-1 RT is a heterodimer, consisting of two related chains, p66 and p51. The 
p66 subunit is composed of the polymerase and RNase H domains and fulfills the 
catalytic role, while the p51 subunit is derived from p66 by proteolytic cleavage to 
remove the C-terminal RNase-H domain (30). The polymerase domain shows a 
conserved right hand morphology and consists of the fingers (residues 1-85 and 118-155), 
palm (residues 86-117 and 156-237), thumb (residues 238-318), and connection 
subdomains (residues 319-426) (31-32). The RNase H domain comprises residues 427-
560 (Figure 1.3). On the other hand, p51 adopts a different conformation after a complex 
maturation process (33-34) and is proposed to only provide structural support (31-32) and 
form part of the nucleic acid binding cleft.  
Active Sites         
The polymerase active site was described in detail by Huang et al. (35) and key 
residues involved in nucleotide binding, metal ions coordination, and catalysis have been 
reviewed (36). Notably, three aspartatic acid residues (D110, D185 and D186) form the 
catalytic triad and help to position the two divalent ion cofactors (Mg2+). R72 and K65 of 
the fingers interact with the β- and γ- phosphates of the incoming dNTP, respectively 
(Figure 1.3, bottom left). The importance of R72 in coordinating the phosphate was 
supported by the fact that a R72A mutation significantly impaired the PPi release step 
(37).  Residue Y115 serves as the ‘steric gate’ that contributes to discriminate against the 
ribonucleoside triphosphates. A two metal-ion mechanism is utilized for catalysis (38), in 
which metal ion A coordinates the 3’-hydroxyl group of the primer and lowers its pKa, 
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whereas metal ion B neutralizes the negative charge of the incoming nucleotide and 
stabilizes the transition state. Interestingly, recent structural data obtained using time-
resolved X-ray crystallography have suggested the transient existence of a third Mg2+ on 
the opposite side of the A- and B-site Mg2+ ions. This extra Mg2+ may appear at the active 
site during the process of phosphodiester bond formation, stabilizing the transition state 
(39-40) or arrive after catalysis and promote the pyrophosphorolysis activity (41). 
Notably, the third metal binding site is not formed during incorrect nucleotide insertion, 
which might account for the inability of the polymerase to perform the reverse reaction 
when a mismatched primer terminus was present as shown Chapter 5.  
The RNase H active site is ~60 Å away from the polymerase active site and 
comprises four conserved carboxylates residues (D443, E478, D498, and D549) (18) that 
can coordinate two divalent Mg2+ (Figure 1.4 bottom right). Although both one- (42) and 
two- (38) metal facilitated RNA hydrolysis have been suggested, more recent research 
data have supported the two metal-ion mechanism (43-44). In this mechanism, the first 
metal ion A may assist nucleophilic attack by bringing the nucleophile close to the 
scissile phosphate, whereas the second metal ion B stabilizes the transition state and 
facilitates leaving of the 3’ oxyanion group (43, 45). 
Nucleic Acid Binding Cleft 
In 1992, a structure of HIV-1 RT/DNA complex at 7 Å resolution showed that the 
nucleic acid binds in a cleft on the surface of the enzyme (46).  The cleft was then 
observed in the crystal structure at 3.5 Å resolution of HIV-1 RT complexed with an 
inhibitor, into which a duplex A-form DNA/RNA hybrid can be modeled (31). The 
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nucleic acid binding cleft of HIV-1 RT is formed by the polymerase and RNase H 
domains of the p66 subunit, whereas the floor of the cleft is formed by the thumb and 
connection subdomains of the p51 subunit (36). The cleft runs between the RNase H and 
polymerase active sites, which is able to accommodate 17 to 18 base pairs, depending on 
the nucleic acid substrate (15, 32). Most RT-nucleic acid interactions involve the sugar-
phosphate backbone and therefore are non-specific. There are extensive interactions 
between conserved structural motifs of RT and the primer/template near the polymerase 
active site that play important roles in holding and precisely positioning the nucleic acid 
relative to the polymerase site. These motifs include the ‘template grip’ comprising V75, 
R78, N81, E89, P157, and G93 of the p66 fingers (15, 47), as well as the ‘DNA primer 
grip’ consisting of the β12-β13 hairpin in HIV-1 RT (48). Similarly, the ‘RNase H primer 
grip’ in the p66 connection domain plays a critical role in positioning an RNA-DNA 
hybrid for specific cleavage (49-50). Additional interactions of the RNA template with 
the ‘template grip’ (via 2’-OH) were observed (51), which may account for the higher 
fidelity of RNA-dependent DNA polymerization compared to DNA-dependent DNA 
polymerization by RT (52-53). However, no structural element of RT was found that 
could systematically guide the RNA strand to the RNase H active site (51). 
The geometry of a DNA duplex bound to HIV RT starts with the A-form at the 
polymerase active site, but soon switches to B-form after a ~40° bend adjacent to the p66 
thumb (32). Besides this typical kink near p66 thumb, the DNA/RNA hybrid bound to RT 
showed an additional 20-30° bend when entering the RNase H domain (54), and the 
hybrid structures are mostly in the A form (51, 54), with one exception where the (PPT) 
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RNA/DNA adopts an intermediate between A- and B-form, which was termed the ‘H-
form’ (15). To date, there are only three structures of HIV-1 RT that are in complex with 
a DNA/RNA hybrid, but none of the bound hybrid is captured in the RNase H competent 
mode; therefore, the mechanism by which an RNA template reaches the active site for 
degradation is still unknown (15, 51, 54).    
Conformational Dynamics during DNA Synthesis         
HIV-1 RT undergoes extensive conformational rearrangements during different 
stages of DNA synthesis and crystal structures corresponding to some of the states are 
now available, which has guided the design of biochemical assays to explore these 
structural transitions (36). A large conformational change of the p66 thumb was 
identified by comparing structures of unliganded HIV-1 RT (55-56) and RT/DNA duplex 
(32). The thumb subdomain is in a closed configuration relative to the fingers in 
unliganded RT structures and therefore blocks the nucleic acid binding cleft. However, 
binding of nucleic acid substrate moves the thumb subdomain away from the fingers to 
accommodate the primer/template. At 1998, Huang et al. (35) successfully trapped the 
catalytic complex of HIV-1 RT by chemical cross-linking of the DNA and using a 
dideoxy-terminated primer with the next correct base in order to obtain the structure of 
RT-primer/template-dNTP ternary complex in a closed form. This is the first time an RT 
structure was obtained with DNA bound. Structures in the presence and absence of the 
dNTP then revealed nucleotide-induced conformational changes from an open to a closed 
state. An overlay of RT structures in the open (1J5O (57)) and closed (1RTD (35)) states 
are shown in Figure 1.4 to illustrate the global changes in structure occurring in the 
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enzyme-DNA duplex upon dNTP binding. The fingers domain undergoes the largest 
conformational change (especially the β3-β4 loop), where several positively charged 
amino acids close down on the triphosphate portion of the incoming dNTP to facilitate 
catalysis (58). Results from the MD simulation using Elber’s Milestoning method 
provided molecular details of the conformational transition and helped to explain how 
conformational dynamics of DNA polymerases select correct substrates (58). However, 
there is no direct structural information in HIV-1 RT to illuminate the chemistry and PPi 
release steps during nucleotide incorporation. After PPi dissociation, RT must translocate 
on the nucleic acid substrate to free the occupied nucleotide-binding site (N site), the 
molecular details of which are still unknown. But structures of HIV-1 RT trapped at pre- 
and post-translocation states suggest that the conserved YMDD loop may be involved in 
translocation by ‘acting as a springboard to propel the primer terminus from the N to the 




Figure 1.3 The Crystal Structure of HIV-1 RT in complex with a DNA/RNA Hybrid (PDB: 
4PQU). (Upper panel) The enzyme has two subunits: the p66 (colored) and p51 (gray). 
Structure of the polymerase domain resembles a right hand, consisting of fingers (blue), 
palm (red), thumb (green), and connection (yellow) subdomains. The RNase H domain 
(magenta) is ~60 Å away from the polymerase active site. Mg2+ ions are shown as orange 
spheres. The incoming nucleotide is dATP (green). The DNA primer and RNA template 
are shown in blue and cyan, respectively. The polymerase and RNase H active sites are 
highlighted by red and magenta boxes and zoomed in the bottom. (Bottom left) The 
polymerase active site is located in the middle of palm, fingers, and thumb subdomains. 
The catalytic triad (D110, D185 and D186) are shown in pink. Basic residues (K65 and 
R72) interacting with the phosphates of dATP are shown in blue. (Bottom right) The 
RNase H active site contains the carboxylates residues D443, E478, D498 (D498N 




Figure 1.4 Nucleotide-induced Conformaiton Changes (58). Overlay of HIVRT 
structures 1RTD (35) and 1J5O (57) is present to illustrate the global changes in structure 
occurring in the enzyme-DNA duplex from the open (gray) to closed (blue) states 
(emphasis is put on the polymerase active site). The P51 subunit is not shown for clarity. 
Incoming dNTP substrate (purple-orange) and two Mg2+ ions (yellow) are shown 
together with the primer (palecyan)/template (forest green) duplex. The fingers domain 
undergoes the largest conformational change, where several positively charged amino 
acids come into contact with the triphosphate portion of the incoming dNTP to facilitate 
catalysis. 
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1.5 HIV RT AS A DRUG TARGET 
Six categories of antiretroviral therapies (ARTs) exist, targeting different stages 
during HIV infection lifecycle: nucleoside/nucleotide analogue RT inhibitors (NRTIs), 
non-nucleoside RT inhibitors (NNRTIs), protease inhibitors (PIs), integrase inhibitors 
(IIs), fusion inhibitors (FIs), and viral entry inhibitors (EIs). As mentioned before, HIV-1 
RT plays a central role in viral replication and therefore has been a major target for 
therapeutic treatment of HIV infections (60-61). Among the 26 drugs approved to treat 
HIV-1 infections, 14 are RT inhibitors (14), consisting of two groups of compounds 
(NRTIs and NNRTIs) that function with distinct mechanisms.   
NRTIs and the Drug Resistance  
NRTIs are structurally diverse analogues of natural nucleotides that lack the 3’-
OH group and therefore can serve as chain terminators upon incorporation (Figure 1.5). 
These agents are inactive and must be phosphorylated by cellular kinases to their active 
form, the triphosphate derivatives (62). They inhibit the reverse transcription by the same 
mechanism: the activated triphosphate form of the compounds incorporate into viral 
DNA and prevent the subsequent DNA synthesis due to the lack of 3’-OH group. It is 
important that the eukaryotic DNA polymerases are able to discriminate against these 
compounds to minimize toxic side effects. However, it was found that kinetics of 
incorporation of nucleoside analogues by the human mitochondrial DNA polymerase (Pol 
γ) is correlated with toxic side effects of NRTIs (63). Theoretically, NRTIs should not be 
toxic since human mitochondrial DNA polymerase has a proof-reading activity and 
exhibits moderately high fidelity during DNA replication, whereas RT is an lower fidelity 
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polymerase with less discrimination against these analogues as substrates. However, not 
all NRTIs can be efficiently removed by the proofreading exonuclease of the human 
mitochondrial DNA polymerase (63). A parameter termed the therapeutic index (the ratio 
of the discrimination by RT divided by the discrimination by Pol γ) was introduced to 
assess the effectiveness of NRTIs against their toxicity (64). Notably, two nucleoside 
analogues (ddC and d4T)) exhibiting lowest therapeutic index are no longer used in 
clinics because of their high toxicity (reviewed in (64)). 
 
 
Figure 1.5 Structures of  NRTIs Approved by the FDA. CBV-abacvir, AZT-zidovudine, 
3TC-lamivudine, PMPA (TFV)-tenofovir, d4T-stavudine, ddI-didanosine, ddC-
zalcitabine, and FTC-emtricitabine. PMPA is a nucleotide analogue. TFV and CBV are 






Appearance of drug resistance represents another major limitation for the use of 
NRTIs to treat HIV-1 infections. With the availability of highly active antiretroviral 
therapy (HAART), HIV infection is now controllable as a chronic disease in patients who 
have access to medication and many of whom achieve a sustained viral suppression, but 
this requires long-term medication (66). Prolonged use of NRTIs inevitably results in the 
appearance of viruses resistant to these compounds (67). Some mutations only confer 
resistance to one of the NRTIs, whereas certain combinations of mutations (e.g., the 69 
insertion complex, Q151M complex and thymidine analogue mutations (TAMs)) make 
RT resistant to all or almost all NRTIs approved by the US FDA (Figure 1.6) (68). HIV-1 
RT mutants become resistant to NRTIs by two mechanisms: i) enhanced discrimination 
against NRTIs, which means that RT restricts incorporation of the analogues and 
therefore reduces chain termination; and ii) enhanced excision of chain terminators from 
the 3’-end of the blocked primer, so new DNA synthesis can resume (69). In nucleotide-
dependent excision, ATP reacts with the 3’ terminal base to produce a dinucleotide 
tetraphosphate (Ap4N, where N is the excised base) and a 3’-OH terminated primer 
capable of subsequent extension. This reaction is analogous to the normal reversal of 
chemistry in which pyrophosphate reacts to re-synthesize dNTP, but in this case, ATP 
provides the reactive pyrophosphate portion. In this thesis, both mechanisms of resistance 








Figure 1.6 Mutations in the Reverse Transcriptase Gene Associated with Resistance to 
RT Inhibitors. Reproduced from Johnson et al. (68). (Top) Mutations associated with the 
resistance to NRTIs are shown on the top (pale pink bars), including the 69 insertion 
complex, 151 complex, TAMs, and the mutations associated with drug resistance to a 
specific inhibitor. (Bottom) Mutations associated with the resistance to NNRTIs are 
shown on the botthom (orange bars). Single-letter amino acid codes at the top of colored 
bars represent wild-type residues, whereas those beneath the bars are amino acid 
substitutions conferring resistance. Numbers in the bars are the positions of substituted 
residues. Black triangle denotes the insertion sites. Superscript letters near the compound 






K65R and M184V are two representative mutations for the discrimination 
mechanism. In general this class of mutations are located in close proximity to the 
incoming nucleotide and therefore interfere with its binding. K65R has an enhanced 
interaction with the side chain of R72 and forms a molecular platform that restricts the 
adaptability of the polymerase active site and causes decreased rates for substrate 
incorporation and NRTIs excision (70). This might be the structural basis for the mutual 
phenotypic antagonisms between the K65R and TAMs mutants, which likely accounts for 
the fact that these two kinds of mutations rarely coexist (71). K65R/A substitutions may 
also involve in the enhanced polymerase fidelity of RT by decreasing the dNTP 
misinsertion and mispaired primer extension efficiencies (72). A single mutation of 
residue 184 (M184V/I) is sufficient to confer high levels of resistance to 3TC. 
Comparisons of the structures of HIV-1 RT duplex (with bound DNA) (32) and ternary 
complexes (with bound dNTP) (35) with M184V and M184I mutants (57, 73), together 
with the modeling of the inhibitor into the active site of these structures have suggested a 
steric clash between the sugar moiety of 3TC-TP and the mutation at position 184, which 
might account for the diminished incorporation of 3TC. While in the case of tenofovir 
(TFV) resistance, M184V seems to offset the extent of resistance conferred by K65R (74). 
In addition, it was reported that M184V also played an important role in the excision 
mechanism and was able to severely compromise the removal of chain-terminating 
nucleotides, such as AZTTP (75).  
“Thymidine analogue mutations” (TAMs) comprising M41L, D67N, K70R, 
L210W, T215Y/F and K219E/Q are a well studied example for the excision mechanism. 
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Two questions are important to understand the underlying mechanism for the resistance 
conferred by this complex of mutations: i) how do these mutations enhance the excision, 
and ii) why is the resistance relatively specific for AZT (17)? With regard to the first 
question, all of the mutations have no direct interactions with the AZTTP moiety of 
Ap4AZT (the dinucleotide tetraphosphate product of ATP mediated excision) (76), 
suggesting that AZT resistant mutations may not contribute to the discrimination against 
AZTTP. Indeed, a recent pre-steady-state kinetics study revealed that the TAMs 
mutations led to reduced rate of AZT incorporation, but that was offset by a lower Km, 
yielding only moderate level of discrimination (77). Alternatively, it has been proposed 
that the mutations create a new binding site for ATP (76), where the pyrophosphate 
moiety of ATP is properly positioned, presumably leading to a tighter ATP binding that 
may facilitate the excision. However, there is no evidence to support the enhanced ATP-
binding affinity (78), implying that an alternative mechanism may account for the 
enhanced excision efficiency. As for the second question, steric constraints involving the 
azido group cause the 3’ end of an AZTMP terminated primer to preferentially reside at 
the nucleotide binding site (N site), favoring the excision (79). In fact, unpublished single 
molecule data from this lab have suggested that the DNA primer terminated with 
AZTMP shifts the DNA translocation to favor the pre-translocation complex (at the N 
site) and inhibits the nucleotide-induced isomerization. These two features favored the 
removal of AZTMP by ATP-mediated pyrophosphorolysis. However, these data failed to 
fully address this question since other analogues with azido group exhibited much lower 




Nonnucleoside RT inhibitors (NNRTI) are a group of structurally diverse, small 
hydrophobic agents specifically targeting HIV-1 RT. Transient kinetic studies revealed 
that NNRTIs affected the nucleotide incorporation by allosterically inhibiting the rate of 
the chemical reaction (81). Structural studies of HIV-1 RT have shown that the NNRTI-
binding pocket (NNIBP) only exists on the p66 subunit of the heterodimer upon NNRTI 
binding, which causes a series of short-range and long range distortions of the RT 
structure, including the precise geometry of the polymerase active site, especially the 
‘YMDD’ motif (82), and the structural elements comprising the ‘primer grip’ which are 
involved in the proper positioning of the DNA primer (55). In addition, there are data 
suggesting that the binding of NNRTIs may constrain the mobility of the thumb 
subdomain thus slowing or preventing the primer/template translocation, which in turn 
inhibiting further extension of the nascent DNA strand (31). The combination of all these 
effects may account for the relatively high effectiveness of NNRTIs. However, the 
emergence of NNRTI resistance associated mutations (most of which are found in or 
around the NNIBP) is also the major constraint for their clinic use (Figure 1.6). Recent 
research data indicate that the drug resistance associated mutations are stimulated by 
NNRTIs at the early stages of replication (83).  
The advent of multi-drug combination antiretroviral therapies has saved a lot of 
lives in developed countries. However, the toxicity and development of drug resistance 
are the major limitations of the highly active antiretroviral therapy (HAART). In the 
future, molecular modeling, biochemical, and enzymatic approaches should be combined 
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to explore the structure-function relationship of target enzymes, as well as the 
mechanisms for drug resistance, which would shed light on the development of new 
antiretroviral drugs. 
1.6 KINETIC CHARACTERIZATION OF HIV RT 
Nucleotide-induced Conformational Change and Enzyme Specificity 
A simplified model for polymerization was proposed more than 20 years ago 
(Scheme 1.1) for quantification of polymerase specificity using single-nucleotide 
incorporation kinetic measurements (reviewed in (84)). In this model, the nucleotide 
concentration dependence of incorporation rates defines the apparent dissociation 
constant of dNTP (Kd) and the maximum incorporation rate (kpol). This model is valid 
when nucleotide binding is a rapid equilibrium process and chemistry is the only rate-
limiting step for product formation. The two assumptions are largely valid since PPi 
release and translocation are generally fast. Consequently, the measurements of kpol and 
apparent Kd provided an estimate for the specificity constant, kcat/Km = kpol/Kd. However, 
nucleotide binding is not a simple, one-step process, as structural analyses reveal a large 
conformational change of the fingers domain that forms part of the nucleotide-binding 
pocket (32, 35). As shown in Scheme 1.2, binding of nucleotide involves a weak ground 
state binding (1/K1), followed by an isomerization of the fingers domain from open 
(EDndNTP) to closed (FDndNTP). The role for this change in enzyme specificity, 
however, has been controversial (reviewed in (85)), as least partially, to the lack of a 
proper signal to directly measure the kinetics of the isomerization step. By site-
specifically labeling HIV-1 RT with an environmentally-sensitive fluorophore (7-
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diethylamino-3-((((2-maleimidyl) ethyl) amino) carbonyl) coumarin, or MDCC) on the 
fingers of the polymerase, Kellinger and Johnson (77, 86) were able to measure both the 
rate and the equilibrium constants for the nucleotide-induced conformation change, 
leading to the conclusion that the isomerization step governs specificity and analogue 
discrimination by HIV-1 RT. A similar conclusion was also obtained to explain substrate 
specificity of the T7 DNA polymerase (87). Although the simplified model is still valid 
in most situations and allows adequate quantification of specificity, the complete model 
is far more robust in terms that it is capable of revealing the mechanistic basis for 
specificity. In this dissertation, a comprehensive set of experiments and global data 
analysis were performed to explore the mechanistic basis for the observed discrimination 
against AZT by the 69 insertion complex (Chapter 2). 
 








Role of Pyrophosphate Release 
PPi release is generally assumed to be fast based on the fact that during processive 
DNA synthesis, there is no significant delay after the incorporation of one nucleotide and 
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preceding the binding and incorporation of the next (20, 88). The fast PPi release is 
critical for understanding specificity, but kinetics of PPi dissociation has never been 
measured for HIV-1 RT. There have been a few instances in previous studies of the 
human mitochondrial DNA polymerase (89-91) where PPi release was much slower than 
the chemistry step during the incorporation of modified or mismatched nucleotides, 
leading to altered nucleotide specificity constants. In addition, the slow PPi release was 
proposed to provide a novel type of proofreading mechanism by allowing the reversal of 
chemistry (89-90). Previous measurements of the rates of polymerization and 
pyrophosphate release in single turnover experiments with DNA templates showed that 
pyrophosphate (PPi) dissociation was fast following nucleotide incorporation so that it 
did not contribute to enzyme specificity (kcat/Km) (Chapter 2). Interestingly, for the first 
time it was shown that PPi release was rate-limiting when a RNA template was used 
(Chapter 4). Analysis is presented to show how the slow PPi dissociation alters  
nucleotide selectivity by HIV-1 RT (Chapter 5).   
Coordination Between the Polymerase and RNase H Active Sites 
There has been considerable debate over the presence of a temporal and spatial 
coordination between the two distal active sites of HIV-1 RT, the polymerase and RNase 
H active sites. Several biochemical data have supported the existence of some 
coordination. First, RNA cleavage was observed 18 or 19 nucleotides upstream from the 
3’-OH of the growing DNA primer in the presence of trap that prohibited substrate 
rebinding, indicating the extension and degradation activities were able to be achieved by 
a single binding event (92). A more definitive study showed that DNA polymerization 
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and RNase H hydrolysis occur coincidently on the ms time scale with 18 base-pairs   
between the two sites (20). Then, a more recent biochemical study suggested that HIVRT 
can simultaneously engage its DNA/RNA substrate at both active sites based on the 
observations that small ligands capable of stabilizing the nucleic acid in the polymerase 
active site only affected the pattern but not the efficiency of RNA cleavage under single-
turnover conditions (93). However, structural analyses have suggested that a DNA/RNA 
hybrid is not able to engage the polymerase and RNase H active sites of HIV-1 RT 
simultaneously (15, 51, 54). Alternatively, these structural analyses suggested a ‘toggling’ 
model, where the bound substrate must toggle between the two active sites of HIV-1 RT. 
The ‘toggling’ model was supported by insufficient biochemical analyses. First, the rate 
of primer extension was determined to be 7-fold faster than that of RNA cleavage (20) 
and the template was not degraded processively in RNA dependent extension assays (19). 
Moreover, RNA cleavage tended to occur more efficiently when primer extension paused 
before a hairpin on the RNA template (94) and NNRTIs inhibitory to DNA synthesis 
were able to activate RNA cleavage (95). Therefore, whether the two catalytic centers 
coordinate with each other during the reverse transcription is still elusive and will be 
further explored in this dissertation.          
Single Molecule Studies 
HIV-1 RT is multi-function enzyme that participates in DNA- and RNA-
dependent DNA synthesis (including strand-transfer and strand-displacement synthesis), 
as well as DNA-directed RNA hydrolysis. Crystallographic and ensemble kinetic studies 
have demonstrated certain conformational dynamics of HIV-1 RT during different stages 
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of DNA synthesis. However, how RT recognizes different substrates and performs 
corresponding functions is still unknown. Single-molecule FRET (smFRET) assays 
revealed that RT bound to DNA and RNA primers with opposite orientations, directing 
primer extension or template degradation activities. When a PPT primer was utilized for 
(+) strand DNA synthesis, HIV-1 RT could flip between the two opposite orientations 
and the binding of next correct nucleotide stabilized the polymerization-competent mode 
(96). In addition, a similar smFRET study showed that RT did not directly bind to the 3’ 
terminus of the growing primer. Alternatively, it slided a long range on the nucleic acid 
substrate and found the DNA 3’ end. The sliding and flipping mechanisms may facilitate 
multiple stages of the reverse transcription pathway, especially for the strand-transfer and 
strand-displacement synthesis (97). Ensemble kinetic studies of DNA synthesis on the 
hairpin containing templates revealed the productive and nonproductive binding modes of 
RT to the substrates. If RT binds in a nonproductive mode, it can switch to the productive 
mode by melting the next stem base-pair (98-99). Single-molecule DNA flow-stretching 
assay was performed to address the question how RT replicates through secondary 
structures on RNA template or nacent single-stranded DNA (ssDNA) without the help 
from a motor protein (e.g., a helicase) for unwinding. Their results revealed that the 
strand-displacement synthesis by RT utilized the combination of active (dNTP 
incorporation) and passive (thermal fraying) mechanisms (100). However, these studies 
merely reproduced what had been defined by more comprehensive and quantitative 
ensemble studies a decade earlier (98, 101-102).  Single molecule studies also provided 
kinetic insights on how HIV-1 RT initiates the (-) strand DNA synthesis. In vitro studies 
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showed that the addition of first few nucleotides was slow during the initiation process, 
but then speeded up after the successful insertion of 5-6 nucleotides (103-104). Single-
molecule FRET (smFRET) assays revealed the mechanistic basis for this phenomenon by 
demonstrating that HIV-1 RT transitions between two opposite binding orientations and 
pauses are corresponding to the polymerization-incompetent configuration. 
Destabilization of the stem-loop structure within viral RNA triggers the initiation-to-
elongation transition (105).  
In summary, biochemical and crystallographic studies have led to a better 
understanding of the nucleotide selectivity and drug resistance by HIV-1 Reverse 
Transcriptase in the past 20 years. However, questions remain in this field due to 
inadequate experimental design and flawed kinetic analysis. In addition, the role of 
pyrophosphate release in nucleotide specificity by HIV-1 RT has been overlooked. On 
the other hand, the limited number of structural analyses failed to demonstrate the 
potential coordination between the polymerase and RNase H active sites of HIV-1 RT. 
These questions, however, are explored in this dissertation by pre-steady-state kinetics 
and global data analysis. Data presented in the following chapters provide insights into 
HIV-1 RT nucleotide selectivity, drug resistance and RNase H activities.	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Chapter 2: Mechanistic Basis for AZT Drug Resistance Conferred by 
Dipeptide Insertions in the Fingers of HIV-1 Reverse Transcriptase 
	  
2.1 INTRODUCTION 
HIV-1 reverse transcriptase (HIVRT) is a heterodimer, consisting of two related 
subunits: p66 contains both polymerase and RNase H sites, while p51 is derived from 
p66 by proteolytic removal of the C-terminal RNase H domain (30). The RNA- and 
DNA-dependent polymerase and the RNase-H activities are essential for converting the 
viral RNA genome into dsDNA that can be integrated into the host genome (106-107). 
Due to its vital role at the beginning of the viral life cycle, RT has been an important 
target for antiretroviral therapy (60-61). Two distinct groups of compounds were 
developed targeting HIVRT: nucleoside/nucleotide analog reverse transcriptase inhibitors 
(NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). NRTIs are a 
group of structurally diverse analogues of natural nucleoside/nucleotides, which lack the 
3’-hydroxyl group and therefore can serve as chain terminators after incorporation. 
Among these compounds, AZT was the first approved by the US Food and Drug 
Administration (FDA) in 1987 and has been widely used in the clinic until now.  
Sustained viral suppression requires long term treatment (66), which often results 
in the appearance of viruses resistant to these compounds. Mutational patterns in the RT 
gene associated with drug resistance to every NRTI have been identified and some 
complexes of mutations were found to confer cross-resistance to all (or almost all) NRTIs 
currently approved by the US FDA, such as the Q151M complex, thymidine analog 
mutations (TAMs) and the 69 insertion complex (67). TAMs mutations (M41L, D67N, 
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K70R, L210W, T215F/Y, and K219Q/E) appeared following prolonged treatment with 
AZT and are associated with decreased susceptibility of HIV to AZT (108), as well as all 
other NRTIs (67). Dipeptide insertions between residues 69 and 70 of HIVRT (most 
commonly Ser-Ser/Ser-Gly) were observed in clinic samples of patients receiving 
combination therapy with AZT and other drugs (ddC or ddI) (109-110). These insertions 
generally occurred in the background of AZT resistance mutations (TAMs) and were 
therefore termed the 69 insertion complex (111-113). Among TAMs mutations, D67N 
was rarely found in 69 insertion complex mutations (114-115) but A62V, which is not a 
common mutation for AZT resistance, was frequently found in this complex. Structurally, 
A62V was reported to interact with M41L and thereby affect the positioning of the β3-β4 
loop (116). Fingers insertion in the presence of TAMs have been reported to enhance 
ATP-dependent excision of thymidine analogues, including AZT (117-119), as well as 
cause lower susceptibility to almost all other NRTIs (109, 117, 120-121).   
Two primary mechanisms have been proposed for RT resistance to NRTIs: i) 
enhanced discrimination against NRTI incorporation, and; ii) enhanced removal of chain 
terminators from the 3’-end of the blocked primer, so DNA synthesis can resume (69). In 
nucleotide-dependent excision, ATP reacts with the 3’ terminal base to produce a 
dinucleotide tetraphosphate and a 3’-OH terminated primer capable of subsequent 
extension. TAMs are a well studied example for the excision mechanism (79, 122), which 
has been proposed to facilitate excision of thymidine analogues either by promoting a 
proper orientation of the pyrophosphate donor molecule (115) or by creating a high-
affinity ATP-binding site (76). However, comparable dissociation constants of ATP were 
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obtained from kinetic analysis for WT and AZT resistant mutants (78). A recent single 
turnover kinetic analysis showed that the minimal 2-fold discrimination against AZT 
relative to TTP by TAMs was due to the fact that the slower rate of AZT incorporation by 
TAMs was offset by a lower Km, resulting from the equilibration of the conformational 
change step (77). However, the mechanism by which the 69 insertion complex enhances 
the resistance to AZT and other NRTIs is still controversial.  Some studies showed that 
mutants with fingers insertions can interfere with incorporation of certain drugs, 
especially, 3TCTP (117) while others suggested that these mutations showed no or only 
limited discrimination against incorporation of chain terminators (119, 123). Several 
reports have indicated that the resistance phenotype associated with the fingers insertion 
complex involves ATP-mediated excision (115-117, 119-120, 124), and the role of the 
dipeptide insertion is to destabilize the formation of ternary dead end complex (DEC) 
(117) and thereby reduce the inhibition of ATP-dependent unblocking reaction by the 
next complementary dNTP (119-120). However, some of the published excision data are 
not so convincing because the data were obtained either at a fixed time point under 
various ATP concentrations or at different time points but with fixed ATP concentration. 
Consequently, key information about excision rates (kexc), ATP binding affinity (Km,ATP), 
as well as excision efficiency (kexc/Km,ATP) was unfortunately missed. Meanwhile, some 
other data are hard to interpret because the protein used in these studies were derived 
from clinical isolates harboring complex suites of mutations in addition to fingers 
insertions and AZT resistant mutations.  
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Whether fingers insertion has any effect on discrimination against incorporation 
of NRTIs is not well determined so we have revisited this problem using AZT as an 
example. To address this question, pre-steady-state kinetic analysis was performed with 
recombinant proteins harboring simple set of mutations (T69SSS in the otherwise WT RT 
or in the TAMs mutant). Specificity constants of TTP and AZTTP were compared to 
quantify and examine the mechanistic basis for changes in AZT discrimination afforded 
by the dipeptide insertion.  Also, primer unblocking and extension assays were performed 
by analysis of the concentration dependence and time course of reaction to assess the role 







Figure 2.1 69 Insertion complex mutations of HIV RT. The crystal structure of HIV RT 
(PDB: 1RTD) in complex with a DNA primer/template (green and blue) and TTP (color 
coded by element). The 69 insertion complex has the TAMs backbone (M41L, K70R, 
L210W, T215F/Y, and K219Q/E) , together with A62V, T69S, and a dipeptide insertion 
between residues 69 and 70 of HIVRT (most commonly Ser-Ser/Ser-Gly, not shown in 
the figure). Among TAMs mutations, D67N was rarely found in 69 insertion complex 
mutations, but A62V, which is not a common mutation for AZT resistance, was 
frequently found in this complex and reported to interact with M41L and thereby affect 
the positioning of the β3-β4 loop (116). 










2.2 MATERIALS AND METHODS 
Expression and Purification of MDCC-labeled HIV Reverse Transcriptase   
The T69SSS and TAMs_T69SSSVD HIV-1 RTs were expressed, purified and 
labeled following methods previously described (77, 86). Briefly, the T69SSS mutant 
was produced by introducing the T69S substitution and a two-serine insertion between 
position 69 and 70 (T69SSS) in genes of both subunits using a Quikchange Multi kit 
(Stratagene). Based on genes of the thymidine analogues mutant (TAMs: M41L, D67N, 
K70R, L210W, T215Y and k219E), the TAMs_T69SSSVD mutant was produced by 
introducing T69SSS followed by the introduction of A62V and a reverse mutation of 
N67D (Table 2.1). Two subunits for each mutant were individually expressed in T7 
Express Competent E.coli (New England Biolabs; NEB), mixed in a 1:1 ratio and 
purified by tandem Q-Sepharose and Bio-Rex 70 columns followed by a single-strand 
DNA affinity column. Following MDCC labeling, excess MDCC was removed using a 
Bio-Rex 70 column. The labeled enzymes were assayed by pre-steady-state burst 














Table 2.1 Mutagenic T69SSS and TAMs_T69SSSVD primers 
PRIMER 1: T69S-SS 
5’-TATTTGCCATAAAGAAAAAAGACAGTTCTTCTTCTAAATGGAGAAAATTAGTAGATTTCA-3’ 
PRIMER 2: TAMS-T69S-SS 
5’-TATTTGCCATAAAGAAAAAAAACAGTTCTTCTTCTCGCTGGAGAAAATTAGTAGATTTCA-3’ 
PRIMER 3: TAMS-T69S-SS-A62V-N67D 
5’-CATACAATACTCCAGTATTTGTCATAAAGAAAAAAGACAGTTCTTCTTCTCGCTGGAGAA-3’ 
Mutated codons are shown in bold and underlined. Primers 1 and 2 were used to 
introduce T69S-SS in WT or TAMs backbone. Primer 3 was used to introduce A62V and 
N67D into TAMs-T69S-SS. 
 
DNA Substrates for Kinetic Studies  
The 25mer and 45mer DNA ordered from Integrated DNA Technologies (Table 
2.2) were purified by gel extraction individually. Annealing of the 25mer primer and 
45mer template was carried out by mixing the two oligonucleotides in a 1:1 molar ratio at 
95°C for 5min, followed by slow cooling to room temperature. The primer was 5’ -32P - 
labeled with T4 polynucleotide kinase (NEB) for use in the rapid quench flow kinetic 
assays. Dideoxynucleotide-terminated oligo-primer used in nucleotide off-rate assay 





Table 2.2 DNA substrates for kinetic studies 
25/45-A: 
            25mer: 5’-GCCTCGCAGCCGTCCAACCAACTCA-3’ 
     45mer: 3’-CGGAGCGTCGGCAGGTTGGTTGAGTAGCAGCTAGGTTACGGCAGG-5’ 
25ddA/45-A: 
            25mer: 5’-GCCTCGCAGCCGTCCAACCAACTCAdd-3’ 
             45mer: 3’-CGGAGCGTCGGCAGGTTGGTTGAGTAGCAGCTAGGTTACGGCAGG-5’ 
Quench Flow Kinetic Assays  
The time dependence of nucleotide incorporation was measured by single-
turnover rapid quench flow techniques as described (77) using a KinTek RQF-3 (KinTek 
Corp.).  A preformed enzyme-DNA duplex (150 nM of MDCC-labeled HIV RT and 100 
nM 25/45 DNA) was rapidly mixed with various concentrations of nucleotide using the 
RQF-3 Quench Flow (KinTek).  All reactions were conducted in 50 mM Tris pH7.5, 100 
mM KCl and 10 mM magnesium acetate (all concentrations final) at 37°C and the 
reaction was stopped by the addition of 0.5 M EDTA. Products were separated by 15% 
denaturing PAGE and quantified using a Typhoon scanner in ImageQuant 6.0 (GE). 
Primer block excision and extension was measured by a hand-quench assay. The 
25/45mer template-primer (100 nM) was pre-incubated with either WT or mutant RTs 
(150 nM) at 4°C for 10 min in the same buffer for nucleotide incorporation assays. The 
primer was then extended by adding equal volume of AZTTP (12.5 µM) and incubating 
at 37°C for 5 min to form an AZT-terminated primer. Primer rescue and extension was 
initiated by adding 100 µM TTP and 1 µM dCTP in the presence of various 
concentrations of ATP and 0.6 µM pyrophosphatase. A 10 µL aliquot of the reaction was 
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mixed with 10 µL 0.5 M EDTA and 20 µL loading buffer to stop the reaction for each 
time point. Products were then separated and quantified as described above. The 
experimental setup was similar in assays designed to assess the inhibitory effect of dCTP 
(the next correct nucleotide at the 3’-end of AZT-terminated primer) except that the 
concentration of ATP was fixed at 4.8 mM while various concentrations of dCTP were 
used. 
Stopped Flow Kinetic Assays  
The time dependence of transient MDCC fluorescence changes corresponding to 
nucleotide induced enzyme conformational change was monitored using an Auto SF-
200x (KinTek Corp.). A pre-formed enzyme-DNA duplex (100 nM of MDCC-labeled 
HIV RT and 150 nM 25/45 DNA) was rapidly mixed with various concentrations of 
nucleotide in the stopped flow for 300-500 ms. MDCC fluorescence was excited at 425 
nm and fluorescence was monitored at 475 nm with a 50 nm band width band-pass filter 
(Semrock). To determine the nucleotide dissociation rate, 200 nM enzyme-DNAdd (2’, 3’-
dideoxy-terminated primer) was pre-incubated with 2.5 to 10 µM of nucleotides (TTP or 
AZTTP), depending on their binding affinities. The preformed ternary complex was then 
mixed with unlabeled enzyme-DNA duplex to serve as a trap for free nucleotide. A 
coupled fluorescence assay described elsewhere (125) was used to measure the kinetics 
of pyrophosphate (PPi) release. Briefly, the preformed enzyme-DNA duplex (150 nM of 
HIV RT and 100 nM 25/45 DNA) was rapidly mixed with 25 µM of nucleotide in the 
presence of 0.6 µM of pyrophosphatase (PPase), the Pi “mop” containing 100 µM of 7-
38	  
	  
methylguanosine (7-MEG) and 0.02 IU/mL purine nucleoside phosphorylase (PNPase), 
as well as 1.5 µM of fluorescently labeled E.coli phosphate binding protein (PBP).  
Global Analysis of Kinetic Data   
The kinetic constants governing nucleotide binding and incorporation were 
obtained by a global fitting of the data to a two-step nucleotide binding mechanism 
(Scheme 2.1) using KinTek Explorer software (KinTek Corp.)  Rate constants governing 
DNA binding (kon) and dissociation (koff) were fixed based on previous estimates while 
those governing the isomerization step (k2) were fixed based on estimates from 
temperature dependent assays. 
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Nucleotide dissociation rates were measured by a trap assay and analyzed using a 
previously developed mechanism (Scheme 2.2) (77).  
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Kinetics of PPi release were also included in the global fitting (Scheme 2.3) and 
kinetics of pyrophosphatase, as well as phosphate binding to MDCC-PBP were 
determined to calibrate the kinetics of the sensor. F represents MDCC-PBP, F~P 
represents the phosphate induced high fluorescent state of MDCC-PBP, and G represents 
pyrophosphatase (PPase). Pyrophosphate (PP) released from the reaction is captured by 
the pyrophosphatase (k1) and undergoes two steps of hydrolysis (k2 and k3) to release two 
inorganic phosphates (P). In order to reduce the number of variables, pyrophosphate 
binding and hydrolysis steps are all set to be irreversible. The released phosphates then 
bind to the MDCC-labeled PBP (K1), which isomerizes (K2) to the high-fluorescent state 
(F~P) and yields the signal we measured. 
 
Scheme 2.3 Calibraiton of the kinetics of the fluoresent sensor (MDCC-PBP) 
	  
 
F  + P 
K1⎯ →⎯⎯← ⎯⎯  FP 
K2⎯ →⎯⎯← ⎯⎯  F ~ P  
G + PP k1⎯ →⎯  G.PP k2⎯ →⎯  GP + P;  GP k3⎯ →⎯  G + P
 
         
Excision efficiencies were determined by ATP concentration dependent rescue 
assays while the inhibitory effect of dCTP was examined through similar assays with 
fixed ATP concentration and various nucleotide concentrations. The data were globally 
fit to a model including a translocation step between the nucleotide binding site (N site) 
and  the priming site (P site) (79), as shown in Scheme 4.  
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2.3 RESULTS 
TTP and AZTTP Incorporation by the HIV RT_T69SSS-MDCC  
In order to identify the rate constants governing nucleotide binding and 
incorporation, four sets of experiments (Figure 2.2 and 2.5) were conducted and fit 
simultaneously to a single model as illustrated by Scheme 2.1, 2.2 and 2.3. Figure 2.2A 
shows the time course of fluorescence changes upon nucleotide binding and 
incorporation at various nucleotide concentrations. Figure 2.2B shows time dependence 
of nucleotide incorporation measured by rapid chemical quench flow method at several 
nucleotide concentrations. Figure 2.2C shows the time course of fluorescence increase 
occurring when nucleotide dissociates from the enzyme-DNAdd-TTP ternary complex 
and is then trapped by unlabeled enzyme-DNA duplex. Figure 2.2D shows the time 
dependence of the fluorescence change measured using the stopped flow fluorescence 
coupled assay to monitor pyrophosphate (PPi) release, hydrolysis to Pi and then binding 
of Pi to the fluorescent Pi binding protein sensor. The data were fit globally, as illustrated 





Table 2.3 Kinetic Constants Governing Nucleotide Binding and Incorporation 








TTP 274±2 2140±180 1.5±0.1 1430±150 21.1±0.1 
AZTTP 25±2 590±30 31.8±1.4 18.6±1.3 15.8±0.1 
TAMs_T69SSSVD 
TTP 2840±12 4350±380 1.5±0.1 2900±320 11.6±0.1 
AZTTP 26±2 105±11 48.4±3.7 2.2±0.3 11.0±0.6 
Rate constants were derived from global analysis of the data fitted to Scheme 2.1 
allowing for a nucleotide induced conformational change prior to chemistry. Values for 
k2 were determined by temperature dependence analysis at lower temperatures and the 
rate at 37°C was determined by extrapolation based on Arrhenius analysis to constrain 
the global fit. Global analysis of K1 was performed by locking the initial second-order 
nucleotide on-rate (k1) to a modest estimate for diffusion-limited collision (100 µM-1s-1). 
The reverse rate (k-1) was fit globally. The reported ground-state Kd (1/K1) and 
equilibrium constant of conformational change step (K2) were calculated using the values 





Table 2.4 Nucleotide Binding, Specificity, and Discrimination for WT_T69SSS and TAMs 
_T69SSSVD 









TTP 0.20±0.02 3.1±0.3 20.9±2.5 6.8±0.6  
AZTTP 1.3±0.1 2.0±0.2 14.6±1.1 7.3±0.7 0.93±0.11 
TAMs_T69SSSVD 
TTP 1.0±0.1 8.6±0.8 11.7±1.4 1.4±0.1  
AZTTP 11.8±1.9 9.5±1.2 7.0±0.9 0.7±0.1 2.0±0.3 






Figure 2.2 Global fitting of TTP Binding and Incorporation by MDCC-labeled HIV 
Reverse Transcriptase T69SSS. (A) TTP concentration dependence of MDCC 
fluorescence to monitor nucleotide binding and incorporation. Various concentrations of 
TTP (2.5, 5, 10, 20, 30, 40, 60, 80, and 100 µM) were mixed with a pre-formed enzyme-
DNA complex (150 nM 25/45mer and 100 nM MDCC-labeled HIV RT_T69SSS). (B) 
Rapid quench flow TTP concentration dependence of the rate of product formation. 
Various concentrations of TTP (0.1, 0.25, 0.75, 3, 15 µM) were mixed with a pre-formed 
enzyme-DNA complex (75 nM 25/45mer DNA and 175 nM MDCC-labeled HIV 
RT_T69SSS). (C) The rate of re-opening of the ‘closed’ ternary complex was measured 
by rapidly mixing a pre-formed enzyme-DNAdd-TTP complex (200 nM HIV 
RT_T69SSS-MDCC, 300 nM 25ddA/45mer, 2.5 µM nucleotide) with a nucleotide trap 
consisting of 2.5 µM unlabeled enzyme-DNA complex. (D) Rate of PPi release during 
the incorporation of TTP was monitored by rapidly mixing 25 µM of TTP with a pre-
formed enzyme-DNA complex (100nM 25/45mer DNA and 150 nM MDCC-labeled HIV 
RT_T69SSS) in the presence of 1.5 µM of MDCC-PBP and 0.6 µM of PPase. In each 
panel the smooth lines show the best fit achieved by globally fitting data in panels A-D 
simultaneously. Rate constants are summarized in Table 2.3. 
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Because the maximum rate of conformational change (k2) was too fast to measure 
at  37°C (Figure 2.2A), the experiments were repeated at lower temperatures (5°C, 10°C, 
18°C and 25°C) in order to estimate the maximum rate of nucleotide-induced 
conformational change (k2) by extrapolation to 37°C. Analysis of the TTP concentration 
dependence of the rate of the decrease of fluorescence gave estimates of k2 = 104±6, 
178±4, 353±17, and 749±18 s-1; as well as estimates of Kd = 41±5, 59±3, 126±7, and 
154±7 µM at 5, 10, 18, and 25°C, respectively (Figure 2.3A/B). A maximum rate of 
2140±180 s-1 at 37°C was obtained by extrapolation (Figure 2.3C). This is in agreement 
with the lower and upper limits of k2 (650~5000 s-1) estimated by confidence contour 
analysis while globally fitting the data shown in Figure 2.2. The Kd values can also be 
used in the Van’t Hoff analysis to derive thermodynamic parameters governing 
nucleotide binding, in particular the enthalpy change (Figure 2.3D). To calculate the free 
energy, a standard concentration of nucleotide substrate was set as 100 µM, which is the 
approximate physiological concentrations of nucleotides in living cells.  The data showed 
the free energy of ground state TTP binding is favorable at lower temperatures (5°C and 
10°C, where Kd < 100 µM) but unfavorable at higher temperatures (18°C and 25°C, 
where Kd > 100 µM). The value of k2 at 37°C obtained from Arrhenius analysis was 
fixed and all other rate constants were then derived from the global data fitting. The 
second-order rate constant of TTP binding K1k2 = 7.1±0.3 µM-1s-1 was accurately 
determined from the data obtained at 37°C (dash line, Figure 2.3A). Since k2 = 2140 s-1, 
an estimate of 1/K1 = 300±28 µM can be calculated. This value is comparable to the 
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ground state dissociation constant of 1/K1 = 274±2 µM that was obtained from the global 
data fitting. Therefore, results obtained from conventional data analysis provide an 











Figure 2.3 Temperature Dependence of the HIV RT_T69SSS Conformational Change 
Rate upon TTP Binding. (A) The experiment shown in Figure 2.2A was repeated at 
various temperatures. A pre-incubated complex of 150 nM 25/45mer and 100 nM 
MDCC-labeled HIV RT_T69SSS was rapidly mixed with various concentrations of TTP 
(2.5, 5, 10, 20, 30, 40, 60, 80, and 100 µM) at 5°C (○), 10°C (●), 18°C (□) and 37°C 
(■). (B) A pre-incubated complex of 150 nM 25/45mer and 100 nM MDCC-labeled HIV 
RT_T69SSS was rapidly mixed with various concentrations of TTP (5, 10, 20, 40, 60, 80, 
100, 150, 200 and 300 µM) at 25°C. The concentration dependence of the fast decrease 
of fluorescence (corresponding to conformational closing) was fit to hyperbolic equation 
to obtain the maximum rate of the conformational change (k2) at each temperature 
resulting in rates of 104±6, 178±4, 353±17, and 749±18  s-1; as well as estimates of Kd = 
41±5, 59±3, 126±7, and 154±7 µM at 5, 10, 18, and 25°C, respectively. The data 
corresponding to the concentration dependence of the conformational change rate at 
37°C were fit to a linear equation because rates at higher concentrations of nucleotide 
were not accurately determined due to the dead time limitation of the instrument and the 
fast rate of the reaction. (C) The temperature dependence of k2 was analyzed by 
Arrhenius plot to estimate a maximum rate for k2 of 2140±180 s-1 at 37°C. This value 
was then fixed to constrain data fitting by global analysis. (D) The temperature 
dependence of Kd was analyzed by Van’t Hoff plot to derive estimates of ΔH of -48.4± 
6.3 kJ/mol, ΔS of 0.17±0.02 kJ K-1/mol, as well as ΔG of -2.1±0.3, -1.3±0.1, 0.56±0.1, 







Next, the rate of TTP release from an E-DNAdd-TTP ternary complex was 
measured by mixing the complex with unlabeled enzyme-DNA duplex to trap free TTP. 
3’-dideoxy-terminated primer was used in this assay to block the chemistry step. Since 
the ground state binding of TTP is a fast equilibrium process, the reverse of the 
conformational change is the limiting step for TTP dissociation and was actually 
determined by the assay.  This yielded a k-2 value of 1.5±0.1 s-1, which was well 
constrained in the global fitting according to confidence contour analysis. It is worth 
noting that a three-step binding mechanism was used to fit the biphasic data obtained 
from the competition assay. Specifically, an additional isomerization step (Scheme 2.2) 
was included to account for the slower phase. 
The rate of PPi release was examined using a coupled assay previously developed 
in our lab (125). Briefly, PPi released from the reaction is hydrolyzed by the 
pyrophosphatase (PPase), yielding inorganic phosphates, which then bind to the 
fluorescently labeled E.coli phosphate binding protein (PBP) and give the fluorescence 
signal. The kinetics of PPi hydrolysis and Pi binding to MDCC-PBP are calibrated by 
two sets of experiments (Figure 2.4). Binding of Pi to PBP includes two steps: a weak 
ground state binding (K1 =10 µM) followed by a rapid isomerization to the highly 
fluorescent state (Scheme 2.3). The rate constants obtained by fitting these two 
experiments were then used in the global fitting to derive the rate of PPi release. This 
afforded a PPi release rate of 2360±680 s-1, which unfortunately was not well constrained 
since the rate was too fast to be accurately determined (Figure 2.2D).  The confidence 
contour analysis set a lower limit for the rate as 203 s-1 (i.e., it must be ~10X faster than 
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catalysis); therefore the rate was fixed at 1000 s-1 for simplicity in the global fitting to 
derive the remaining rate constants.  
 
 
Figure 2.4 Calibration of the kinetics of the sensor. (A) Kinetics of Pi binding to 
fluorescent phosphate sensor (MDCC-PBP). Various concentrations of Pi (0.2, 0.5, 1, 2, 
3, and 5 µM) were rapidly mixed with 1.5 µM of MDCC-PBP in the presence of Pi 
“mop”, using a stopped flow instrument. (B) Kinetics of pyrophosphatase (PPase) 
measured using the fluorescent phosphate sensor. Various concentrations of PPi (0.05, 
0.1, 0.2, 0.4, 0.6, and 0.8 µM) were rapidly mixed with 1.5 µM of MDCC-PBP in the 
presence of 0.6 µM of PPase and the Pi “mop”. Panel A and B were fit globally 
according to scheme 2.3. Rate constants obtained from global analysis were then used to 
derive the rate of PPi release in subsequent experiments. 
 
Similar experiments and data analysis were performed to determine kinetics 
governing AZTTP binding and incorporation as shown in Figure 2.5 and summarized in 
Table 2.3. The ground state dissociation constant of AZTTP binding (1/K1) is 10-fold 
lower than that of TTP binding, with value of 25±2 µM, indicating a much tighter 
binding of AZTTP to the active site. In the case of AZTTP incorporation, the rate of 
conformational change decreased to a measurable range (<600 s-1), so Arrhenius analysis 
was not performed and a rate of 590±30 s-1 was derived from the global fitting.  The 
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nucleotide dissociation-rate was fit to a rate of 31.8±1.4 s-1.  The rate of chemistry was 
15.8±0.1 s-1, which is a little bit slower than for of TTP incorporation. This rate was 
defined by the slow second phase of the stopped flow data (Figure 2.5A), the rapid 
chemical quench flow data (Figure 2.5B), as well as the PPi release data (Figure 2.5D). 
Again, PPi release was fast, with a rate of 520±65 s-1 (Figure 2.5D) and a lower limit of 
that rate as 213 s-1, determined by confidence contour analysis. 
TTP and AZTTP Incorporation by MDCC labeled HIVRT TAMs_T69SSSVD  
Four experiments were performed to determine the rate constants governing the 
binding and incorporation of TTP by the TAMs_T69SSSVD mutant. The concentration 
dependence of nucleotide incorporation in the chemical quench flow data and that of 
fluorescence change in the stopped flow data determined the ground state dissociation 
constant as 2840±12 µM (Figure 2.6A/B). Temperature dependence of the 
conformational change rate was studied, yielding rates of 205±3, 332±9 and 770±29 s-1; 
as well as estimates of Kd = 402±2, 600±2, and 980±2 µM for 5, 10, and 18°C (Figure 
2.7A). The temperature dependence of the rates was analyzed on an Arrhenius plot 
(Figure 2.7B) and extrapolation afforded an estimate of a maximum rate of k2 of 
4350±380 s-1 at 37°C. Since K1k2 = 1.54±0.05 µM-1s-1 was accurately determined, an 
estimate of 1/K1 = 2820±260 µM can be calculated. Again, this value is consistent with 
the ground state dissociation constant of 1/K1 = 2840±12 µM that was obtained from the 
global data fitting. Thermodynamic constants were also derived by Van’t Hoff analysis 
(Figure 2.7C), yielding free energy change values (ΔG) of 3.2±0.1, 4.2±0.1, and 5.5±0.1 
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KJ/mol for 5, 10, and 18°C. So the binding of TTP to TAMs_T69SSSVD mutant was 
unfavorable at all temperatures tested. The dissociation rate of TTP (k-2) was 1.5±0.1 s-1, 
as measured by the nucleotide off-rate assay (Figure 2.6C). The rate of chemistry is 
defined by three experiments (Figure 2.6A/B/D), and therefore was well constrained to a 
value of 11.6±0.1 s-1. Measurement of the PPi release was fit to a rate of 340±23 s-1 
(Figure 2.6D), with its lower limit of 90 s-1. 
AZTTP binding and incorporation were also globally fit to a two-step nucleotide 
binding model. The ground state binding of AZTTP is much tighter that than of TTP, 
with a dissociation constant of 26±2 µM (Figure 2.8A/B). Global analysis resulted in a 
value of k2 = 105±11 s-1, governing conformational change from the “open” to “closed” 
state. Since this rate is low enough to be accurately determined at 37°C, Arrhenius 
analysis was no longer required. The reverse rate of the conformational change (k-2) was 
fit to a value of 48.4±3.7 s-1, as measured by the competition assay (Figure 2.8C). And it 
is worth noting that the amplitude dependence of the stopped flow binding experiment 
(Figure 2.8A) provided additional constraint on k-2 since equilibrium was established 
prior to chemistry due to the fact that k-2 was 4-fold larger than k3. The rate of chemistry 
was 11.0±0.6 s-1 (Figure 2.8A/B/D). PPi release assay afforded a rate of 1000±650 s-1, 
with a lower limit of 172 s-1 (Figure 2.8D). Global fitting results for TTP and AZTTP 





Figure 2.5 Global fitting of AZTTP Binding and Incorporation by MDCC-labeled HIV 
RT_T69SSS. (A) AZTTP concentration dependence of nucleotide binding and 
incorporation. Various concentrations of AZTTP (2.5, 5, 10, 20, 30, 40, 60, 80, and 100 
µM) were mixed with a pre-formed enzyme-DNA complex (150 nM 25/45mer and 100 
nM HIVRT_T69SSS-MDCC). (B) Rapid quench flow AZTTP concentration dependence 
of the rate of product formation. Various concentrations of AZTTP (0.1, 0.25, 0.75, 3, 15 
µM) were mixed with a pre-formed enzyme-DNA complex (75 nM 25/45mer DNA and 
175 nM HIVRT_T69SSS-MDCC). (C) The rate of re-opening of the ‘closed’ ternary 
complex was measured by rapidly mixing a pre-formed enzyme-DNAdd-AZTTP complex 
(200 nM HIVRT_T69SSS-MDCC, 300 nM 25ddA/45mer, 2.5 µM nucleotide) with a 
nucleotide trap consisting of 2.5 µM unlabeled enzyme-DNA complex. (D) Rate of PPi 
release during the incorporation of AZTTP was monitored by rapidly mixing 25 µM of 
AZTTP with a pre-formed enzyme-DNA complex (100nM 25/45mer DNA and 150 nM 
HIV RT_T69SSS-MDCC) in the presence of 1.5 µM of MDCC-PBP and 0.6 µM of 
PPase. In each panel the smooth lines show the best fit achieved by globally fitting panels 




Figure 2.6 Global fitting of TTP Binding and Incorporation by MDCC-labeled HIV RT_ 
TAMs_T69SSSVD. (A) TTP concentration dependence of nucleotide binding and 
incorporation. Various concentrations of TTP (2.5, 5, 10, 20, 30, 40, 60, 80, and 100 µM) 
were mixed with a pre-formed enzyme-DNA complex (150 nM 25/45mer and 100 nM 
HIVRT_TAMs_T69SSSVD-MDCC). (B) Rapid quench flow TTP concentration 
dependence of the rate of product formation. Various concentrations of TTP (0.25, 0.75, 
3, 10, 30 µM) were mixed with a pre-formed enzyme-DNA complex (75 nM 25/45mer 
DNA and 175 nM HIVRT_TAMs_T69SSSVD-MDCC). (C) The rate of re-opening of 
the ‘closed’ ternary complex was measured by rapidly mixing a pre-formed enzyme-
DNAdd-TTP complex (200 nM HIVRT_TAMs_T69SSSVD-MDCC, 300 nM 
25ddA/45mer, 9 µM TTP) with a nucleotide trap consisting of 9 µM unlabeled enzyme-
DNA complex. (D) Rate of PPi release during the incorporation of TTP was monitored 
by rapidly mixing 25 µM of TTP with a pre-formed enzyme-DNA complex (100nM 
25/45mer DNA and 150 nM HIVRT_TAMs_T69SSSVD-MDCC) in the presence of 1.5 
µM of MDCC-PBP and 0.6 µM of PPase. In each panel the smooth lines show the best fit 
achieved by globally fitting panels A-D simultaneously. Rate constants are summarized 
in Table 2.3. 
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Figure 2.7 Temperature Dependence of 
the HIVRT TAMs_T69SSSVD 
Conformational Change Rate upon TTP 
Binding. (A) The experiment shown in 
Figure 2.6A was repeated at various 
temperatures. A pre-incubated complex 
of 150 nM 25/45mer and 100 nM 
MDCC-labeled HIVRT TAMs_ 
T69SSSVD was rapidly mixed with 
various concentrations of TTP (20, 50, 
100, 200, 400, 600, 800, 1200, 1600 and 
2000 µM) at 5°C (□), 10°C (●), and 
18°C (○). The concentration 
dependence of the fast decrease of 
fluorescence (corresponding to 
conformational closing) was fit to 
hyperbolic equation to obtain the 
maximum rate of the conformational 
change (k2) at each temperature 
resulting in rates of 205±3, 332±9 and 
770±29 s-1; as well as estimates of Kd = 
402±2, 600±2, and 980±2 µM at 5, 10, 
and 18°C, respectively. (B) The 
temperature dependence of k2 was 
analyzed by Arrhenius plot to estimate a 
maximum rate for k2 of 4350±380 s-1 at 
37°C. The value was then fixed to 
constrain data fitting by global analysis 
of the data in Figure 2.6. (C) The 
temperature dependence of Kd was 
analyzed by Van’t Hoff plot to derive 
estimates of ΔH of -45.9±2.6 kJ/mol, 
ΔS of 0.18±0.01 kJ K-1/mol, as well as 
ΔG of 3.2±0.1, 4.2±0.1, and 5.5±0.1 kJ 
/mol at 5, 10, and 18°C, respectively. 
 
         







Figure 2.8 Global fitting of AZTTP Binding and Incorporation by MDCC-labeled HIV 
RT_TAMs_T69SSSVD. (A) AZTTP concentration dependence of nucleotide binding and 
incorporation. Various concentrations of TTP (2.5, 5, 10, 20, 30, 40, 60, 80, and 100 µM) 
were mixed with a pre-formed enzyme-DNA complex (300 nM 25/45mer and 200 nM 
HIVRT_TAMs_T69SSSVD-MDCC). (B) Rapid quench flow AZTTP concentration 
dependence of the rate of product formation. Various concentrations of AZTTP (0.5, 1.5, 
6, 20, 60 µM) were mixed with a pre-formed enzyme-DNA complex (75 nM 25/45mer 
DNA and 175 nM HIVRT_TAMs_T69SSSVD-MDCC). (C) The rate of re-opening of 
the ‘closed’ ternary complex was measured by rapidly mixing a pre-formed enzyme-
DNAdd-AZTTP complex (200 nM HIVRT_TAMs_T69SSSVD-MDCC, 300 nM 
25ddA/45mer, 10 µM AZTTP) with a nucleotide trap consisting of 10 µM unlabeled 
enzyme-DNA complex. (D) Rate of PPi release during the incorporation of AZTTP was 
monitored by rapidly mixing 25 µM of AZTTP with a pre-formed enzyme-DNA complex 
(100nM 25/45mer DNA and 150 nM HIVRT_TAMs_T69SSSVD-MDCC) in the 
presence of 1.5 µM of MDCC-PBP and 0.6 µM of PPase. In each panel the smooth lines 
show the best fit achieved by globally fitting panels A-D simultaneously. Rate constants 
are summarized in Table 2.3. 
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Determination of Specificity Constants Governing TTP and AZTTP Binding and 
Incorporation to T69SSS and TAMs_T69SSSVD HIVRTs  
The specificity constant (kcat/Km) was calculated as kcat/Km = k1k2k3/ (k2k3+k-1(k-2 
+k3)) for each combination of nucleotide and enzyme. The specificity constants defining 
TTP and AZTTP incorporation by the HIVRT_T69SSS mutant were 6.8±0.6 and 7.3±0.7 
µM-1s-1, respectively. Based on these values a net discrimination (D = 
[kcat/Km]TTP/[kcat/Km]AZTTP) of 0.93±0.11 was derived (Table 2.4). The net Kd values for 
the two-step nucleotides binding (Kd,net = 1/(K1(1+K2))) were 0.20±0.02 and 1.3±0.1 µM, 
respectively. 
The specificity constants defining TTP and AZTTP incorporation by the 
HIVRT_TAMs_T69SSSVD mutant were 1.4±0.1 and 0.7±0.1 µM-1s-1, respectively. 
These values defined the AZTTP discrimination by the TAMs_T69SSSVD mutant of 
2.0±0.3, a modest increase from the T69SSS mutant. Except for reduced specificity 
constants for TTP and AZTTP, introduction of fingers insertion into the TAMs 
background also resulted in weaker net nucleotide binding affinities of 1.0±0.1 and 
11.8±1.9 µM, respectively. The reduction in the overall nucleotide binding interaction for 
the TAMs_T69SSSVD mutant was 5~9 fold. This mutant also showed a reduction of 5-
fold in enzyme efficiency, as defined by kcat/Km values. 
Effect of Fingers Insertion on AZTMP Excision and the Binding of the Next Correct 
Nucleotide  
ATP dependent excision of AZT-monophosphate (AZTMP) from the 3’ end of 
the blocked primer has been identified as a significant source of resistance to AZT (122). 
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In this study, ATP concentration dependent excision and extension assays were 
conducted to determine efficiencies (kexc/Km,ATP) of the RTs (WT/T69SSS/TAMs/TAMs_ 
T69SSSVD) to rescue AZTMP-terminated primer (Figure 2.9A-D). Since AZTMP-
terminated primer rescue can be specifically inhibited by the next complementary 
nucleotide (126-127), dCTP (the next correct nucleotide) concentration dependence of 
excision rates by various RTs were determined to explore if the fingers insertion have any 
effect on the inhibitory effect of dCTP (Figure 2.10A-D). Global analyses were 
performed independently for WT (Figure 2.9A/2.10A), T69SSS (Figure 2.9B/2.10B), 
TAMs (Figure 2.9C/2.10C), and TAMs_T69SSSVD (Figure 2.9D/2.10D), according to 
Scheme 2.4, as illustrated by the smooth curves in each figure, in order to derive the rate 
constants that were used to calculate the excision efficiencies (kexc/Km,ATP) and the 
apparent binding affinities of dCTP (Kd,dCTP), as summarized in Table 2.5. 
 
Table 2.5 Excision Efficiencies of AZTMP and Apparent Dissociation Constants for the 
Binding of the Next Correct Nucleotide 
Enzyme kexc/Km,ATP (M-1s-1)	   Fold Effect Kd,dCTP (µM)c Fold Effect 
WT 0.40±0.13 a  273±35  
T69SSS 0.67±0.17 a 1.7X 370±35 1.3X 
TAMs 1.95±0.05 b 4.9X 720±90 2.6X 
TAMs_T69SSSVD 0.74±0.16 b 1.8X 1380±170 5.0X 
akexc/Km,ATP values for WT and T69SSS RTs were calculated based on kexc and Km,ATP 
values derived from global analysis according to scheme 2.4 using Km,ATP values 
obtained from the conventional fitting as starting estimates. 
bkexc/Km,ATP values for those two mutants were derived from global analysis of the data 
fitted to Scheme 2.4 allowing for a one-step excision. 
cThe apparent Kd as a result of a reverse translocation step prior to dCTP binding was 





Figure 2.9 ATP concentration dependent excision of AZTMP by various RTs. ATP 
concentration dependence of AZTMP excision was measured by manual chemical 
quench flow method. A pre-formed enzyme-DNAAZTMP complex (150 nM WT RT (A) or 
T69SSS (B), 100nM 25/45mer, 12.5 µM AZTTP) was rapidly mixed with 100 µM TTP 
and 1 µM dCTP in the presence of various concentrations of ATP (0.8, 1.6, 3.2, and 4.8 
mM). Similarly, a pre-formed enzyme-DNAAZTMP complex (150 nM TAMs (C) or 
TAMs_T69SSSVD (D), 100 nM 25/45mer, 12.5 µM AZTTP) was rapidly mixed with 
100 µM TTP and 1 µM dCTP in the presence of various concentrations of ATP (1.0, 2.0, 






Figure 2.10 dCTP concentration dependent excision of AZTMP by various RTs. dCTP 
concentration dependence of AZTMP excision was measured by manual chemical 
quench flow method. A pre-formed enzyme-DNAAZTMP complex (150 nM WT (A), or 
T69SSS (B), 100 nM 25/45mer, 12.5 µM AZTTP) was rapidly mixed with 100 µM TTP 
and 4.8 mM ATP in the presence of various concentrations of dCTP (100, 200, 500, and 
1000 µM). Similarly, a pre-formed enzyme-DNAAZTMP complex (150nM TAMs (C), or 
TAMs_T69SSSVD (D), 100 nM 25/45mer, 12.5 µM AZTTP) was rapidly mixed with 
100 µM TTP and 4.8 mM ATP in the presence of various concentrations of dCTP (10, 50, 
100, 200, 500, and 1000 µM). Global analysis were performed independently for WT 
(Figure 2.9A/2.10A), T69SSS (Figure 2.9B/2.10B), TAMs (Figure 2.9C/2.10C), and 
TAMs_T69SSSVD (Figure 2.9D/2.10D), according to Scheme 2.4. Excision efficiencies 
(kexc/Km,ATP) and apparent binding affinities of dCTP (Kd,dCTP) resulting from global 




Conventional data analysis of ATP concentration dependence of excision rates of 
WT RT afforded a Km,ATP value of 5250±2130 µM. In addition, our unpublished data 
shown that ~86% of the AZTMP blocked primers reside at the N site, from which an 
equilibrium constant (K0) of 6 was obtained. These values were set as the starting 
estimates in the global fitting to derive other rate constants. The rate of excision (kexc) 
was 0.0024±0.0008 s-1, based on which a kexc/Km,ATP of 0.40±0.13 M-1s-1 were derived 
(Figure 2.9A). Global analysis resulted in a value of 39±5 µM (Kd,1) governing the 
ground-state binding of dCTP to RT locating at the P site. Equilibrium constant of the 
reverse translocation between the P site and N site (K0) was fixed at a value of 6, as 
mentioned above. These values produced an apparent Kd (Kd,1(1+K0)) of dCTP binding 
as 273±35 µM (Figure 2.10A). Similar experiments and data analysis were performed to 
determine kinetics governing AZTMP excision by and dCTP binding to the T69SSS 
mutant. Estimate of Km for ATP as 4000±2160 µM was derived from the conventional 
fitting, and were then locked in the global data analysis, resulting in a kexc value of 
0.0028±0.0007 s-1, which produced a kexc/Km,ATP of 0.67±0.17 M-1s-1 (Figure 2.9B). Data 
contained within the families of curves for dCTP and ATP concentration dependence of 
excision rates were used to constrain a dCTP binding constant (Kd,1) of 53±5 µM. The 
binding of dCTP to T69SSS was 1.4-fold weaker than to WT RT, with apparent Kd of 
370±35 µM (Figure 2.10B). 
In cases of TAMs and TAMs_T69SSSVD, estimates of Km values for ATP were 
not available since binding of ATP to these mutants was very weak and therefore the 
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maximum concentration of 5 mM ATP was too low to even partially saturate the reaction. 
Consequently, a one-step excision mechanism was used to derive the kexc/Km,ATP (keff) 
values directly, which afforded 1.95±0.05 and 0.74±0.16 M-1s-1 for the TAMs and 
TAMs_T69SSSVD mutants, respectively (Figure 2.9C/D). Similarly, equilibrium 
constant governing the reverse translocation between the P site and N site (K0) was fixed 
at 6. The apparent binding affinity (Kd,dCTP) of dCTP to the TAMs mutant was 720±90 
µM, as calculated from the ground-state Kd (Kd,1) of 103±13 µM and the equilibrium 
constant (K0) of 6 (Figure 2.10C). Binding of dCTP to TAMs_T69SSSVD mutant was 
1.9-fold weaker than to TAMs RT, with an apparent Kd of 1380±170 µM, derived from a 
Kd,1 of 197±24 µM and a K0 of 6 (Figure 2.10D). 
MDCC Labeling Does Not Affect the Excision Activity of HIV RT 
Because mutants with fingers insertion were MDCC labeled control experiments 
were performed to test if this labeling has any effect on the excision reaction (Figure 
2.11). WT and WT-MDCC were tested at 3.2 mM of ATP, yielding comparable excision 
rates as 0.0012±0.00005 and 0.0013±0.00004 s-1, respectively, implying that the labeling 
did not affect enzyme activity. Previous data also showed identical kinetics of 




Figure 2.11 Excision Activities of 
WT and WT-MDCC HIVRT 
Proteins. The excision activities by 
WT (open circle) and WT-MDCC 
(solid square) HIVRT are compared 
at 3.2 mM of ATP. A pre-formed 
enzyme-DNAAZTMP complex (150 
nM WT RT or WT-MDCC, 100nM 
25/45mer, 12.5 µM AZTTP) was 
rapidly mixed with 100 µM TTP 
and 1 µM ddCTP in the presence of 
3.2 mM ATP. Excision data were fit 
to a single exponential equation. 
Excision rates obtained with WT 
and WT-MDCC HIVRT proteins 
are 0.0012±0.00005 and 




The effects of fingers insertion of HIVRT on nucleotide specificity and ATP 
mediated excision of AZT have been examined. Previous studies suggested that fingers 
insertions might have only limited effect on discrimination against NRTIs. However, 
structural modeling showed that insertions reside in the vicinity of and therefore can 
affect the dNTP-binding pocket (109). Meanwhile, single dNTP exclusion assays 
confirmed that insertions in combination of AZT resistant mutations could reduce 
misincorporation efficiencies to a large extent (128). Our data also showed that a Ser-Ser 
insertion alone can reduce misincorporation efficiencies by 10~15 fold, indicating that 
insertions might have some influence on nucleotide binding and/or incorporation (An Li, 
unpublished data). Given those considerations, the problem was revisited in this research 
by pre-steady-state experiments and global analysis of the data to a comprehensive model 
61	  
	  
shown in Scheme 2.1, 2.2 and 2.3. In addition we have examined the role of the 
conformational change in nucleotide discrimination. It has already been shown that fitting 
data based upon numerical integration of the rate equations with no simplifying 
assumptions is far more robust and demanding than fitting to equations derived from a 
simplified form of the model because it requires that the model account for both the rate 
and amplitude of all reactions simultaneously (77, 86). In the previous studies, no 
information existed to define the rate of pyrophosphate release (k4). Although available 
evidence indicates that pyrophosphate (PPi) release is usually fast, it was not known if 
fingers insertion would affect PPi release. The first three experiments (e.g., Figure 2.2A-
C) did not provide enough information to distinguish between two alternative 
mechanisms: either slow PPi release (18 s-1) with faster chemistry (33 s-1, data not shown) 
or fast PPi release (>200 s-1) with slower chemistry (21 s-1). To address this question, the 
rate of PPi release was directly measured using a coupled fluorescence assay previously 
developed in our lab, which at last supported the fast PPi release model, indicating that 
fingers insertion mutations did not affect PPi release. Notably, a more accurate estimation 
of rate of chemistry could be obtained since additional information from this assay could 
provide more constrains in fitting the data globally.  
Discrimination factors for WT RT (1.02±0.08) and TAMs mutant (2.4±0.05) were 
obtained in our previously studies (77). The comparisons (WT vs. T69SSS and TAMs vs. 
TAMs_T69SSSVD) indicate that a Ser-Ser insertion did not improve discrimination 
against AZT either in an otherwise WT RT or in the TAMs mutant. As reported 
previously, the small 2-fold improvement in discrimination may not be enough to provide 
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the clinically observed high level of AZT resistance conferred by the 69 insertion 
complex. Although certain published data have shown similar trends (119, 124), the 
steady-state kinetic analysis failed to provide the mechanistic basis for this absence of 
discrimination. Results shown in the current study, however, provided information to 
address this question. For the T69SSS insertion mutants, the ground-state binding of TTP 
(1/K1, Table 2.3) was much weaker (10-100 fold) than that for AZT. The same pattern 
was also observed in our previous studies conducted with WT and TAMs proteins, but 
only by a factor of 3, indicating that the Ser-Ser insertion improved the ground state 
binding of AZTTP to a much larger extent than the TAMs mutant. Although ground-state 
binding is reduced, TTP still binds 6~12 folds tighter than AZTTP (Table 2.4, Kd,net) as a 
result of contributions from the much more favorable conformational change step. It’s 
worth noting that the insertion greatly reduced the equilibrium constants (K2) of the 
isomerization induced by AZTTP. In the case of TAMs_T69SSSVD, a K2 value around 
2.2 was obtained. This small equilibrium constant might account for the small amplitudes 
of fluorescent signals observed in Figure 2.8A. Arrhenius analysis to determine the 
maximum rate of the conformational change (k2) at 37°C was performed only for the 
binding of TTP because rates of AZTTP resided in the detectable range of the instrument. 
The negative ΔH values between 45.9 and 48.4 kJ/mol indicate initial “ground-state” 
binding of TTP is an exothermic process (Figure 2.3 and 2.7). 
We have shown the role of induced-fit in determining enzyme specificity to 
nucleotides in the cases of T7 DNA polymerase (87) as well as HIV RT (77, 86). Briefly, 
the relative rates of chemistry (k3) and the reverse of the conformational change (k-2) 
63	  
	  
determines if the equilibrium is established prior to chemistry or not. Based on different 
kinetic partitioning, different simplified derivations of kcat/Km (K1k2 or K1K2k3) could be 
obtained. However, the data in this paper did not follow this simple trend because 
observed differences in these rates (k-2 vs k3) are not significant enough to make the 
simplifications. We observe that kcat/Km values for T69SSS incorporation of TTP and 
AZTTP are equal in spite of the weaker ground-state binding of TTP (Kd,TTP >> Kd,AZTTP), 
because it is offset by a more favorable conformational change for TTP (K2,TTP >> 
K2,AZTTP), while the rates of chemistry are comparable. A similar analysis of 
TAMs_T69SSSVD provides the mechanistic basis for the modest increase in 
discrimination in spite of weaker ground-state binding of TTP to the mutant enzyme than 
AZTTP. Although TTP binds much more weakly to the mutant enzyme (>100 folds 
weaker), the conformational change to the “closed” state is more highly favored 
compared to AZTTP induced isomerization (K2,TTP = 2900±320, K2,AZTTP = 2.2±0.3), 
while the rates of chemistry are equal. Consequently, the whole process is similar to that 
of T69SSS but the changes in ground-state Kd and equilibrium of the conformational 
change are more profound. This can also be seen in the free energy profiles for binding 
and incorporation of nucleotides (Figure 2.12). It is notable that in the cases of AZTTP 
incorporation by either T69SSS or TAMs_T69SSSVD, the reverse conformational 
change rates are higher than rates of chemistry (k-2 > k3). This allows the two-step 
binding mechanism to come to equilibrium, leading to reduced Km values, which reflect 
the true Kd,net (Table 2.4). Consequently, these reduced Km values contribute to the 
absence of significant discrimination against AZTTP. This absence of discrimination 
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against AZT is likely due to the high degree of structural homology between the inhibitor 
and TTP. It was reported that human mitochondrial DNA polymerase discriminates 
against AZT by slowing the rate of PPi release after incorporation (90) while our data 
clearly showed that fingers insertion did not affect PPi release. 
 
 
Figure 2.12 Free-energy profiles for HIV-1 RT mutants. (A) Free-energy diagram for 
TTP and AZT nucleotide binding and incorporation reactions by T69SSS mutant. The 
free energy was calculated as ΔG = RT[ln(kT/h)-ln(kobs)] kcal/mol using rate constants 
from Table 2.3. The constant k is the Boltzmann constant, T is 310K, h is Planck’s 
constant and kobs is the first-order rate constant. The nucleotide concentration was set as 
100 µM. (B) Free-energy diagram for TTP and AZT nucleotide incorporation reactions 




Several findings have demonstrated that drug resistance associated with the 69 
insertion complex also involves ATP-mediated excision reactions and suggested that the 
fingers insertion enhances this reaction by reducing inhibition from the next correct 
nucleotide (116-117, 119-120, 124). ATP concentration dependent primer rescue and 
extension assays were performed to monitor effects of fingers insertion on ATP binding 
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during excision reaction. Meanwhile, the 50% inhibitory concentration (IC50) analysis 
widely used in many studies is not an accurate measurement of the binding affinity of the 
next cognate nucleotide due to the complexity of the system. Therefore, dCTP (the next 
complementary nucleotide in this experimental set up) concentration dependent excision 
assays were also performed and globally fit to a comprehensive model shown in Scheme 
2.4. There is a crucial translocation step (between N site and P site) in this model, the 
equilibrium of which determines fates of the blocked primer: either dead end complex 
(DEC) formation or rescue and extension. Our single molecule analysis of pulse width 
lifetime (nucleotide bound state) and interpulse duration (nucleotide unbound state) 
demonstrated that only 14% of AZTMP terminated primers reside at P site that are 
capable of nucleotide binding, from which an equilibrium constant (K0)  of 6 was 
obtained for WT RT (unpublished data). This number was used as a first estimation of K0 
in global fitting, which was then fixed for better constrain on other parameters. 
Unfortunately, we did not have any information regarding K0 for RT mutants. Site-
specific hydroxyl foot-printing was thought to be an ideal method to assess subtle 
structural differences at single nucleotide resolution (72, 129-130). In order to explore the 
equilibrium of the translocation of AZTMP terminated primers, foot-printing assays were 
conducted using WT RT, TAMs and TAMs_T69SSSVD mutants.  As expected, all 
AZTMP-terminated primers predominantly resided at the N site no matter WT or mutant 
proteins were used (data not shown). However, this method is hardly an ideal one for 
accurate determination of the translocational equilibrium for two reasons:  1) the reaction 
is too slow compared to rapid equilibration, and 2) different reducing reagents (ascorbate 
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or DTT) yield various results, which suggests this method is not accurate. In studies of 
fluorescence changes induced by the binding of dCTP to ddTMP or d4TMP terminated 
primers, we found that the ratio of the fraction of fast conformational change to that of 
the slower isomerization provided sufficient information to define the equilibrium 
constant. The results suggested that the TAMs mutations shifted the equilibrium to favor 
the residence of DNA at the N site by 5-20 fold (Chapter 3). However, no signal was 
observed in similar experiments conducted with AZTMP-terminated primers, probably 
because both azido group and TAMs mutations facilitate the primers to reside at N site 
where the incoming nucleotide cannot bind.  Based on these observations, it is known K0 
has a lower limit of 6 which was used in global fitting for all RTs used in this study. On 
the other hand, the apparent dissociation constants for dCTP (Kd,dCTP) were determined 
by the product of Kd,1(1+K0), which was well defined in spite of uncertainties in Kd,1 and 
K0. An estimation of K0 as 6 is acceptable which can then be fixed in the global analysis 
so that well constrained parameters governing dCTP binding and AZTMP excision were 
obtained (Table 2.5).  
Fingers insertion promoted excision efficiency modestly when introduced into 
WT RT. To our surprise, the presence of Ser-Ser insertion in combination with TAMs 
mutations decreased the excision efficiency by a factor of ~2.5. Others proposed that 
fingers insertions enhanced ATP-dependent excision because it reduced inhibition from 
the next cognate nucleotide. However, Kd,dCTP derived for TAMs and TAMs_T69SSSVD 
are 720±90 and 1380±170 µM, respectively. This weak binding shouldn’t make any 
significant difference under physiological concentrations of nucleotides which are in the 
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5-40 µM range (131). Also the previously reported IC50 values for WT (9 µM) and 
T69SSS (12 µM) RTs (119) are underestimated since most of AZTMP terminated primers 
locate at the N site (no matter WT or mutant proteins were used) where the next 
complementary nucleotide cannot bind, which would make the apparent binding much 
weaker.  Other groups reported higher IC50 values of 80±13 (132), 110±40 (122) or > 500 
µM (78) for WT protein, which are more close to our Kd values. Also, fixed time point 
analysis is not convincing to draw the conclusion that fingers insertion can enhance ATP-
mediate excision. Others did observe an increase of excision rate but failed to consider 
effects on ATP binding affinity. Although we do not have enough information to define 
ATP binding affinities to AZTMP terminated primer for the two mutants containing 
TAMs mutations since the highest concentration we could reach is 5 mM, above which 
excision rate would decrease. Nonetheless, our data refute claims of increased ATP 
binding affinity for the TAMs mutants. One possible scenario is that the Ser-Ser insertion 
increases maximum excision rate but makes ATP binding weaker and the combination of 
these two effects gives a smaller kexc/Km,ATP value. Actually, fingers insertion weakened 
the binding of ATP by 1.4-2.4 fold in experiments studying the excision of ddTMP and 
d4TMP (Chapter 3).  
Notably, the TAMs mutations enhanced the excision efficiency only by a factor of 
5, which is smaller than some previously published values. However, excision 
efficiencies of our mutants (e.g., 2 M-1 s-1 for TAMs) are comparable to previously 
reported ones, but the keff of our WT RT is much higher than those in the literature (e.g., 
only ~10% completion within 30 min (116)). One possible explanation is that the 
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untagged RT proteins we made are much more efficient than those his-tagged ones, and 
therefore harboring faster polymerization (7 vs. 0.5 µM-1 s-1 (119)), as well as excision. 
Also, some other groups reported  5-fold increase of excision efficiency by the TAMs 
mutant, for example, 0.33 vs. 0.066 M-1s-1 (132) and 0.39 vs. 0.08 M-1s-1 (122). 
In conclusion, our data suggested that the 69 insertion complex exhibited only 
moderate discrimination against AZT incorporation, as well as modest increase in ATP-
mediate excision, a finding that is not consistent with a widely accepted proposal that 
ATP-dependent phosphorolytic activity plays a predominant role in AZT resistance. The 
fingers insertions may increase the maximum excision rate but weaken ATP binding to a 
larger extent. Although binding of the next cognate nucleotide to an AZTMP terminated 
primer is also weaker for the 69 insertion complex, the binding is too weak to make any 
significant contribution to excision activities at physiological conditions.  Consequently, 
the two mechanisms seem to be equally important and work together during DNA-
dependent DNA synthesis or probably, during the RNA-dependent DNA synthesis also.  
Given the size of the viral genome, the two mechanisms can take place at multiple sites, 
which might explain why the relatively modest changes can result in high level of drug 
resistance. Further studies of effects of fingers insertions during other stages of reverse 
transcription, e.g., strand transfer (133) and strand displacement synthesis, or their 
influence in viral fitness may provide a more detailed basis for evolving advantages of 
the 69 insertion complex. 
69	  
	  
Chapter 3: Effects of AZT Resistance Mutations and Dipeptide 
Insertions in Fingers of HIV-1 Reverse Transcriptase on ATP-
Dependent Excision of Thymidine Analogs 
 
3.1 INTRODUCTION 
HIV-1 reverse transcriptase (HIVRT) replicates the viral RNA genome through its 
RNA and DNA-dependent DNA polymerization and RNase H degradation activities at 
the early stage of the viral cycle (134-135). Consequently, HIVRT has been a major 
target for the development of antiretroviral therapies (60-61). Nucleoside/nucleotide RT 
inhibitors (NRTIs) and nonnucleoside RT inhibitors (NNRTIs) are two distinct classes of 
compounds targeting HIVRT, the former are a group of structurally diverse analogs of 
the natural substrates for DNA synthesis, which lack the 3’-OH and thereby act as chain 
terminators after incorporation by RT. Among these compounds, AZT (zidovudine) and 
d4T (stavudine) are thymidine analogs, the former was the first approved by the US Food 
and Drug Administration (FDA) in 1987 and has been widely used until now while d4T 
is no longer used in therapies due to toxic side effects (63-64, 136). 
Drug resistance is a major challenge in HIV therapies since sustained viral 
suppression requires prolonged usage of medications (66). Resistance mutations for all 
approved NRTIs have been identified and certain combinations of mutations were found 
to confer cross-resistance to all (or nearly all) NRTIs (67). TAMs mutations (M41L, 
D67N, K70R, L210W, T215F/Y, and K219Q/E) confer high levels of resistance to AZT, 
as well as lower levels of resistance to all other NRTIs (67, 108, 137-138), and therefore 
are an example of multi-NRTI resistance. Several studies were performed to explore the 
molecular mechanism of AZT resistance conferred by TAMs mutations and the most 
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accurate evidence indicates that TAMs mutations confer only a twofold change in 
specificity relative to incorporation of TTP (77, 139-140). Rather, these mutations 
provide an enhanced ATP-mediated removal of chain terminators from the 3’ end of the 
blocked primer (79, 122, 126). However, our previous studies reported that the TAMs 
mutations enhanced the excision efficiency only by a factor of 5 (Chapter 2), but also 
reduce the binding of the next correct nucleotide which would otherwise block the ATP-
mediated excision, and a recent single turnover kinetic analysis showed that 
discrimination against AZTTP incorporation was increased by 2.4-fold (77). Therefore, 
contrary to prior reports, the clinically observed 200-fold resistance to AZT appears to 
result from the combined exclusion and excision mechanisms operating over multiple 
sites during replication. 
Boyer et al. proposed a model of ATP-mediated NRTI excision and its inhibition 
by the next correct nucleotide based on both biochemical and structural evidences (79). 
Central to this model is the finding that the 3’ end of the primer is in dynamic equilibrium 
between the nucleotide-binding site (N site) and the priming site (P site). For the excision 
reaction to be carried out, the chain terminator must reside in the N site where 
nucleophilic attack by ATP can occur. When the 3’ end of a primer resides in the P site, 
the N site is open for the binding of the next cognate nucleotide. In this situation, a 
“dead-end complex” (DEC) forms so ATP has no access to remove chain terminators 
(127) (Figure 3.1). This model answered some important questions but failed to solve 
other questions. For example, why does the TAMs mutant selectively excise AZTMP 
with a much higher rate than other NRTIs? A possible explanation is that the steric 
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hindrance from azido group interferes with the binding of the next complementary 
nucleotide, which alleviates its inhibitory effect and allows an AZTMP terminated primer 
to more readily access the N site (59). However, not all 3’-azido analogs are good 
substrates for excision (80) and excision efficiencies of many other NRTIs are still lower 
than that of AZTMP even without the inhibition from an incoming nucleotide (141), 
which suggests that other components of NRTIs, such as bases, also contribute to the 
selectivity of excision. How the TAMs mutations confer enhanced excision is another 
unresolved question. Although some studies claimed that the main role of the TAMs was 
to increase the ability of RT to bind ATP (76, 115), kinetic analyses reported comparable 
binding affinities of ATP in the presence of TAMs mutations (78). Since the equilibrium 
of translocation between N site and P site is the key point of the Boyer model, it’s worth 
exploring if the TAMs mutations have any direct influence on the translocation status of 
HIVRT. 
 
Figure 3.1 Competition between DEC Formation and Excision. The RT structure is 
shown as grey surface. Primer/template is shown as blue sticks. The red ellipse denotes 
the incoming nucleotide binding site (N site). (A) Structure of HIVRT with a dead-end-
complex (DEC) formed at the active site, where the N site is occupied by the next correct 
nucleotide (dCTP) so that ATP has no access for excision. (B) AZT terminated 
primer/template resides in the P site, allowing dCTP to bind to the N site. (C) AZT 
terminated primer/template occupies N site blocking nucleotide binding. (D) ATP binds 
and is ready to initiate the unblocking of the AZT-terminated primer. Drawn using Pymol 




An additional T69S mutation and a nearby dipeptide insertion (usually SS, SA or 
SG) in the TAMs backbone give rise to enhanced breadth and efficiency of NRTI 
excision (117-121). The fingers insertion can destabilize the formation of ternary dead-
end complexes so that inhibition against the excision of these NRTIs would be reduced in 
the presence of physiological concentrations of dNTPs (115, 117, 120). However, our 
previous studies showed that introduction of a Ser-Ser insertion into the TAMs 
background actually decreased the excision efficiency of AZTMP by ~2.5-fold while 
weakening the binding of the next correct nucleotide (dCTP) by 2-fold  (Chapter 2). 
Unfortunately, the binding of dCTP is too weak to allow the 2-fold change to make any 
significant contribution to excision rates at physiological conditions.  
In this chapter, studies are continued to explore the excision of another two 
thymidine analogs, d4T and ddT, by TAMs and 69 insertion complex mutants to explore 
how fingers insertions would broaden excision specificity. To address this question, 
primer unblocking and extension assays were performed to explore the concentration 
dependence of the reaction time course. Stopped flow and equilibrium titration assays 
were also conducted to accurately define the relevant kinetic parameters including the 
binding affinity for the next cognate nucleotide. In addition, comparisons of the excision 
of the three thymidine analogs by RT mutants shed some light on how drug components 
contribute to excision selectivity. 
Although the reactions contributing to NRTI resistance have been described 
previously, there has been no accurate quantitative analysis to provide rigorous 
assessment of the relative contributions of each reaction to the net resistance. Assays for 
73	  
	  
rescue of an analog-terminated primer are complex in that they are dependent on five 
reactions: translocation of the primer to the N-site on the polymerase, ATP binding and 
excision of the analog-terminated primer, elongation of the primer by the addition of TTP 
and then again by dCTP, but the process is also inhibited by the binding of dCTP to the 
analog-terminated primer to form a dead-end complex when it is in the P site. The 
interplay between the various competing reactions and their additive effects on the net 
observable parameters is difficult to resolve by conventional analysis. Here we resolve 
this complexity by taking advantage of global data fitting to reveal the intrinsic rate and 
equilibrium constants governing each step leading to resistance to chain terminators. 
3.2 MATERIALS AND METHODS 
Expression and Purification of Proteins Used in This Study  
The method for the preparation of MDCC-HIVRT used in this study was 
described previously (77, 86). Briefly, the thymidine analogues mutant (TAMs) was 
produced by introducing six mutations (M41L, D67N, K70R, L210W, T215Y and k219E) 
in genes of both subunits using a Quikchange Multi kit (Stratagene). Based on genes of 
the TAMs mutant, the TAMs_T69SSSVD mutant was produced by introducing T69SSS 
followed by the introduction of A62V and a reverse mutation of N67D (Table 2.1). Both 
subunits for each mutant were individually expressed in T7 Express Competent E.coli 
(New England Biolabs; NEB), mixed in a 1:1 ratio and purified by tandem Q-Sepharose 
and Bio-Rex 70 columns followed by a single-strand DNA affinity column. Following 
MDCC labeling, excess MDCC was removed using a Bio-Rex 70 column. The labeled 
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enzymes were assayed by pre-steady-state burst experiments to determine the active site 
concentrations, divided into aliquots, and stored at -80°C. 
DNA Substrates for Kinetic Studies  
Primer DNA terminated with ddTMP or d4TMP was made through enzymatic 
primer extension using RT (Table 3.1), as described in Chapter 2. Following the synthetic 
reactions, terminated 26mer primers (26ddTMP or 26d4TMP) were purified by gel 
extraction. Annealing of the 26mer primers and 45mer template was carried out by 
mixing the two oligonucleotides in a 1:1 molar ratio at 95°C for 5min, followed by slow 
cooling to room temperature. Primers used in quench flow assays were 5’-32P-labeled 
using T4 polynucleotide kinase (NEB).  
 
 
Table 3.1 DNA substrates for excision assays 
26ddT/45-A: 
            25mer: 5’-GCCTCGCAGCCGTCCAACCAACTCATdd-3’ 
     45mer: 3’-CGGAGCGTCGGCAGGTTGGTTGAGTAGCAGCTAGGTTACGGCAGG-5’ 
26d4T/45-A: 
            25mer: 5’-GCCTCGCAGCCGTCCAACCAACTCAT4-3’ 
             45mer: 3’-CGGAGCGTCGGCAGGTTGGTTGAGTAGCAGCTAGGTTACGGCAGG-5’ 
 
	  
Quench Flow Kinetic Assays  
Excision of ddTMP or d4TMP from the 3’ end of blocked primers and 
concomitant primer extension were measured using a hand-quench assay. The 26/45mer 
primer-template (100 nM) was pre-incubated with either TAMs or TAMs_T69SSSVD 
mutants (150 nM) at 4°C for 10 min in a buffer containing 50 mM Tris pH7.5, 100 mM 
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KCl and 10 mM Magnesium acetate (all concentrations final).  Primer rescue and 
extension were initiated by adding 100 µM TTP and 1 µM dCTP in the presence of 
various concentrations of ATP and 0.6 µM pyrophosphatase. A 10 µL reaction aliquot 
was mixed with 10  µL 0.5 M EDTA and 20  µL loading buffer to stop the reaction for 
each time point. Products were separated by 15% denaturing PAGE and quantified using 
a Typhoon scanner in ImageQuant 6.0 (GE). The experimental setup was similar for 
assays designed to assess the inhibitory effect of dCTP (the next correct nucleotide 
binding to the 3’end of a ddTMP or d4TMP-terminated primer) except that the 
concentration of ATP was fixed at 4.8 mM while various concentrations of dCTP were 
used.    
Stopped Flow Kinetic Assays  
Binding affinities of dCTP to ddTMP or d4TMP terminated primers were 
measured by fluorescence stopped-flow and equilibrium titration assays using MDCC-
labeled RT (77, 86). The time dependence of MDCC fluorescence changes corresponding 
to dCTP-induced enzyme conformational change was monitored using an Auto SF-200x 
(www.kintekcorp.com). A pre-formed enzyme-DNA duplex (100 nM of MDCC-labeled 
HIV RT mutants and 150 nM 26ddTMP or 26d4TMP/45mer DNA) was rapidly mixed 
with various concentrations of dCTP in the stopped flow for 10 or 60 s, depending on the 
rate the reaction. Time was shown in logarithmic scale to illustrate the fast and the slower 
phases. MDCC fluorescence was excited at 425 nm and fluorescence was monitored at 
475 nm with a 50 nm band-pass filter (Semrock). To get more information of dCTP 
binding to thymidine analog-terminated primers, equilibrium titration assays were also 
76	  
	  
performed using a KinTek TMX titration module (www.kintekcorp.com) (87). Briefly, 
the preformed enzyme-DNA duplexes (100 nM of MDCC-labeled HIV RT mutants and 
150 nM 26ddTMP or 26d4TMP/45mer DNA) were continuously mixed with increasing 
concentrations of dCTP while recording the fluorescent intensities at equilibrium. 
Different final concentrations (15-400 µM) were chosen based on varying binding 
affinities of dCTP to the enzyme-DNA duplexes. 
Data Analysis   
A representative data set (data obtained from the TAMs/26ddTMP duplex) were 
analyzed by both conventional and global fitting to demonstrate how the combination of 
the two measurements allows resolution of binding and dissociation rates: on the one 
hand, conventional fitting provide numbers we could use as first estimations in the global 
analysis and they provide a the rationale for the models used in the more accurate global 
fitting. On the other hand, conventional fitting analyzes data separately and can ignore 
valuable linkage among experiments while global analysis treats the data as a whole and 
fits them to a single model, and therefore yields more accurate results and can reveal 
additional kinetic details.  
Conventional Data Fitting  
The time course of reactions were fit to single (Figure 3.2A and C) or double 
(Figure 3.2E) exponential functions using GraFit 5 (Erithacus Software Limited) (86). 
The ATP concentration dependence of the observed rates (Figure 3.2B) was fit to a 




k  =  
kexc  [ATP]
Km  +  [ATP]
 	  	  	  	  	  	  	  	  	  	  	  	  (Equation 3.1)      
Similarly, dCTP concentration dependence of its inhibitory effect was fit to 
Equation 3.2 to derive the apparent Kd of dCTP, where v0 is the initial excision rate 
without any inhibition from dCTP (Figure 3.2D). 
 
v =  v0 × (1−
[dCTP]
Kd ,app  +  [dCTP]
 ) 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  (Equation 3.2) 
Apparent binding affinity of dCTP was also determined from the hyperbolic 
analysis (Equation 3.3) of dCTP concentration dependence of amplitude changes in 
stopped flow assays (Figure 3.2F), where Amax represents the maximum amplitude of 




 =  [dCTP]
Kd ,app  +  [dCTP]
                 (Equation 3.3)                
Equilibrium binding data were also fitted to a hyperbola (Equation 3.4), where F0 
is the starting fluorescence and ΔF is the change. 
 
F =  F0  + ΔF
[dCTP]
Kd ,app  +  [dCTP]
             (Equation 3.4) 
Global Data Fitting  
In order to derive kinetic constants governing the competition between chain 
terminator removal and dead-end complex formation, the data were first globally fit to a 
model containing a three-step nucleotide binding mechanism, and a key translocation step 
between N site and P site. As shown in Scheme 3.1, ED25ddT represents an enzyme-DNA 
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complex with DNA terminated by ddT, FD and GD represent closed enzyme states with 
altered fluorescence, XD represents the enzyme state with DNA bound to the N site and 
Ap4ddT is the dinucleotide tetraphosphate product of the excision reaction.            
 





 +  dCTP 
K 1⎯ →⎯⎯← ⎯⎯  ED25ddT.dCTP 
K 2⎯ →⎯⎯← ⎯⎯  FD25ddT.dCTP 
K 3⎯ →⎯⎯← ⎯⎯  GD25ddT.dCTP
     K0                                                                                                                
XD25ddT
N  site
 + ATP 
Km⎯ →⎯⎯← ⎯⎯  XD25ddT.ATP 
kexc⎯ →⎯⎯← ⎯⎯  ED25  + Ap4ddT    
 
 
Excision efficiencies were determined by examining the ATP concentration 
dependence of the rate of rescue while the inhibitory effect of dCTP was quantified 
through similar assays with a fixed ATP concentration and various dCTP concentrations. 
The stopped flow data further defined the binding affinity of dCTP to the 3’ end of 
analog-terminated primers in the absence of ATP. The smooth curves in each figure panel 
represent the best fit of all of the data according to the model (Figure 3.3). In order to 
better understand the apparent tighter binding of dCTP defined by the quench flow data, 
the same set of data were also fit to an improved model (Scheme 3.2), in which ATP can 
also bind to the GD25ddT.dCTP (or GD25d4T.dCTP) species to explain the observed 
tighter apparent dCTP binding in the presence of ATP (Figure 3.5).  
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 +  dCTP K 1⎯ →⎯⎯← ⎯⎯  ED25ddT.dCTP 
K 2⎯ →⎯⎯← ⎯⎯  FD25ddT.dCTP 
K 3⎯ →⎯⎯← ⎯⎯  GD25ddT.dCTP
     K0                                                                                                               Kd, ATP  ATP
XD25ddT
N  site
 + ATP 
Km⎯ →⎯⎯← ⎯⎯  XD25ddT.ATP 
kexc⎯ →⎯⎯← ⎯⎯  ED25  + Ap4ddT            GD25ddT.dCTP.ATP
 
      
The remaining data sets (Figure 3.6-3.8) were also fit to this improved model 
since it described the reactions more accurately. Parameters derived from global fitting 
are summarized in Table 3.2 and 3.3. In Table 3.3, the net dissociation constant of dCTP 
in the absence of ATP (Kd,dCTP) is given by the formula: Kd,dCTP  = 1 / (K1 × (1 + K2 + 
K2K3)), where K1, K2 and K3 are equilibrium constants governing the ground-state 
binding of dCTP, and two dCTP-induced conformational change steps (Scheme 3.2).  
ATP binding (Kd,ATP) induced an additional conformational change and resulted in the 
apparently tighter binding of dCTP (KdCTP,app), which is defined by equation KdCTP,app = 
Kd,dCTP  / (1 + [ATP]/Kd,ATP), where Kd,dCTP  was just defined and Kd,ATP is the dissociation 
constant governing the binding of ATP to the GD25ddT.dCTP species. The equilibrium 
constant for the translocation step (K0, defined in the reverse direction of translocation 
during processive polymerization) and binding affinity of ATP to XD25ddT (Km,ATP) 
together determined the fraction of E-DNAdd duplex residing at the P site that is able to 
bind dCTP and therefore should also be included when calculating the overall apparent 
Kd of dCTP (Kd,app): Kd,app = KdCTP,app × (1 + K0 × (1 + [ATP]/Km,ATP)).  The complete 
derivations of these formulas can be found below. In the absence of ATP, the overall 
apparent Kd of dCTP can be easily determined as Kd,dCTP  × (1 + K0).  
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 ,    [ED25ddT.dCTP] = K1 × [ED25ddT]× [dCTP]
K2  = 
[FD25ddT.dCTP]
[ED25ddT.dCTP]
 ,        [FD25ddT.dCTP] = K2 × [ED25ddT.dCTP] =  K1 × K2 × [ED25ddT]× [dCTP]
K3  = 
[GD25ddT.dCTP]
[FD25ddT.dCTP]
 ,       [GD25ddT.dCTP] = K3 × [FD25ddT.dCTP] = K1 × K2 × K3 × [ED25ddT]× [dCTP]
θ = 
[ED25ddT.dCTP] + [FD25ddT.dCTP] + [GD25ddT.dCTP]
[ED25ddT] + [ED25ddT.dCTP] + [FD25ddT.dCTP] + [GD25ddT.dCTP]
 
   = 
K1 × [ED25ddT]× [dCTP]× (1 + K2 + K2 × K3)
[ED25ddT] + K1 × [ED25ddT]× [dCTP]× (1 + K2 + K2 × K3) 
   = 
K1 × [dCTP]× (1 + K2 + K2 × K3)
1 + K1 × [dCTP]× (1 + K2 + K2 × K3) 
  =  [dCTP]
1
K1 × (1 + K2 + K2 × K3)
 + [dCTP] 
 = [dCTP]
1
K1 × (1 + K2 × (1 + K3))





Derivation of KdCTP,app: 
To make the derivation process simpler and more clear, we simplify the steps 
before ATP binding to only one step, which includes ground state binding and two 
conformational change steps (showing in Scheme 3.2) and which are governed by the net 
dissociation constant of dCTP, that is, Kd,dCTP. 
So we have: 
 
Kd,dCTP  = 
[ED25ddT]× [dCTP]
[GD25ddT.dCTP]
 ,      [GD25ddT.dCTP] = 
[ED25ddT]× [dCTP]
Kd,dCTP
Kd,ATP  = 
[GD25ddT.dCTP]× [ATP]
[GD25ddT.dCTP.ATP]









[ED25ddT] + [GD25ddT.dCTP] + [GD25ddT.dCTP.ATP]



















 + [dCTP]× [ATP]
Kd,dCTP × Kd,ATP
  =  
[dCTP]
Kd,dCTP





 ×  (1 + [ATP]
Kd,ATP
)










Derivation of Kd,app: 
To make the derivation more concise and straightforward, we again consider the 
binding of dCTP to E-DNAdd duplex before ATP binding as one step which is governed 
by Kd,dCTP. With this in mind, we have: 
 
K0  = 
[XD25ddT]
[ED25ddT]
,       [XD25ddT] = K0 × [ED25ddT]
Kd,dCTP  = 
[ED25ddT]× [dCTP]
[GD25ddT.dCTP]
 ,      [GD25ddT.dCTP] = 
[ED25ddT]× [dCTP]
Kd,dCTP
Kd,ATP  = 
[GD25ddT.dCTP]× [ATP]
[GD25ddT.dCTP.ATP]








Since the excision rate is extremely slow relative to that of ATP dissociation, the 
binding of ATP comes to equilibrium so that Km,ATP reflects the true Kd of ATP. In this 
case, we have: 
 
Km  = 
[XD25ddT]× [ATP]
[XD25ddT.ATP]




K0 × [ED25ddT]× [ATP]
Km
,  so 
 
θ = 
  [GD25ddT.dCTP] + [GD25ddT.dCTP.ATP]
[ED25ddT] + [GD25ddT.dCTP] + [GD25ddT.dCTP.ATP] + [XD25ddT] + [XD25ddT.ATP] 













 +  K0 × [ED25ddT] + 
K0 × [ED25ddT]× [ATP]
Km
  =  
 [dCTP]
Kd,dCTP





× (1 + [ATP]
Kd,ATP


















× (1 + [ATP]
Kd,ATP




 = 0.5 ,  




× (1 + [ATP]
Kd,ATP




Finally, we have: 
 
[dCTP]50  = 

























Excision of ddTMP by the HIVRT_TAMs-MDCC 
ATP dependent excision of AZTMP from the 3’end of the blocked primer has 
been identified as a significant source of resistance to AZT (122). In this study, the ATP 
concentration dependence of excision and extension were examined to determine 
excision efficiencies (kexc/Km,ATP) of two thymidine analogs (ddT and d4T) by TAMs 
mutants with or without the T69SSS fingers insertion. Since AZTMP-terminated primer 
rescue can be specifically inhibited by the next complementary nucleotide (126-127), 
dCTP (in our studies) concentration dependence of the excision rates of ddTMP or 
d4TMP by the RT mutants was determined to explore whether the fingers insertion has 
any effect on the ability of dCTP to inhibit excision. Stopped flow and equilibrium 
titration assays were also performed to further determine affinities for dCTP binding to 
analog-terminated primers. 
ATP concentration dependent excision assays were first performed to determine 
the excision efficiency of ddTMP by the HIVRT_TAMs-MDCC (Figure 3.2A).  The data 
were fit to a single exponential function at each ATP concentration and the concentration 
dependence of the observed rates was then fit to a hyperbola (Equation 1) to define the 
maximum excision rate, 0.0052 ± 0.0004 s-1, and Km of ATP, 2.8 ± 0.4 mM, based on 
which, an excision efficiency of 1.9 ± 0.3 M-1s-1 was obtained (Figure 3.2B). Excision 
assays were also performed with a fixed concentration of ATP (4.8 mM) and various 
concentrations of dCTP (Figure 3.2C). Observed rates obtained by fitting the data to a 
single exponential function were fit to Equation 3.2, which yielded the apparent 
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dissociation constant of dCTP as 8.6 ± 0.6 µM (Figure 3.2D). Figure 3.2E shows the time 
dependence of the fluorescence changes measured by stopped flow methods during dCTP 
binding at several nucleotide concentrations. Since the fluorescence decreases were 
biphasic, the data were fit to a double exponential function. Amplitudes of the fluorescent 
signals were fit to Equation 3.3, from which an apparent Kd of 41 ± 2 µM was obtained 
(Figure 3.2F). Figure 3.2G shows the measurement of the binding affinity of dCTP by the 
equilibrium titration assay, where the black line represents the hyperbolic analysis 
(Equation 3.4) of the data, which defines an apparent dissociation constant of 35 ± 0.1 
µM. It is worth noting that Kd values of dCTP obtained from fluorescence measurements 
are in good agreement with each other, which, however, are 4~5 fold higher than the 




Figure 3.2 (A-D) Conventional fitting of ATP and dCTP concentration dependence of 
ddTMP excision by MDCC-labeled HIV RT_TAMs, as well as binding affinity of dCTP to 
preformed TAMs-E.DNAdd duplex (A-D). ATP (A) and dCTP (C) concentration 
dependence of ddTMP excision and rescue as monitored by the formation of elongated 
product. A preformed TAMs/26ddTMP complex (150 nM MDCC-labeled HIVRT_ 
TAMs and 100 nM of 26ddTMP/45mer) was rapidly mixed with 100 µM TTP and 1 µM 
dCTP in the presence of various concentrations of ATP (0.4, 0.8, 1.6, 3.2, and 4.8 mM). 
Rates were obtained by nonlinear regression to single exponential function (A) and the 
concentration dependence of the observed rates was then fit to a hyperbola (Equation 3.1) 
to define the maximum excision rate (kexc = 0.005 ± 0.0004 s-1),  Km of ATP (2.8 ± 0.4 
mM), and the specificity constant (kexc/Km,ATP) as 1.8 ± 0.3 M-1s-1 (B). (C) As to dCTP 
concentration dependent assays, the preformed enzyme-DNA duplex (150 nM MDCC-
labeled HIVRT_TAMs and 100 nM of 26ddTMP/45mer) was rapidly mixed with 100 
µM TTP and 4.8 mM ATP in the presence of various concentrations of dCTP (1, 5, 10, 
20, 50 and 100 µM).  Similarly, the concentration dependence of inhibition by dCTP was 
fit to a hyperbola (Equation 3.2) to define the apparent Kd of dCTP as 8.6 ± 0.6 µM (D). 
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Figure 3.2 (E-G) Conventional fitting of 
ATP and dCTP concentration 
dependence of ddTMP excision by 
MDCC-labeled HIV RT_TAMs, as well 
as binding affinity of dCTP to preformed 
TAMs-E.DNAdd duplex (E-G). Binding 
affinity of dCTP to enzyme-DNA 
complex terminated with ddTMP was 
measured by stopped flow (E), as well 
as equilibrium titration assays (G). (E) A 
preformed TAMs/ 26ddTMP complex 
(100 nM TAMs and 150 nM of 
26ddTMP/45mer) was rapidly mixed 
with various concentrations of dCTP (20, 
40, 60, 80, 100 and 200 µM). 
Fluorescence was observed by 
excitation of MDCC at 425 nm and 
monitoring emission with a 475 nm 
band-pass filter with a 50 nm bandwidth 
for 60 s (time was showed in 
logarithmic scale). Stopped flow data 
were fit to a double exponential function 
at each nucleotide concentration and the 
concentration dependence of the derived 
amplitudes (A1+A2) was then fit to a 
hyperbola (Equation 3.3) to define an 
apparent dissociation constant of dCTP 
as 41 ± 2 µM (F). (G) In the titration 
assay, the preformed TAMs/26ddTMP 
complex (100 nM TAMs and 150 nM of 
26ddTMP/45mer) was continuously 
mixed with increasing concentrations of 
dCTP (0-100 µM) while recording 
fluorescence. Data were fit by nonlinear 
regression to a hyperbolic equation 
(Equation 3.4) to define an apparent 
dissociation constant of 35 ± 0.1 µM.           





Global analysis was also performed for the four experiments, according to 
Scheme 3.1, as illustrated in materials and methods (Figure 3.3). This analysis 
demonstrates the simultaneous fitting of chemical quench flow data to monitor the rate of 
excision in the presence of various concentrations of ATP (Figure 3.3A), or dCTP 
(Figure 3.3B), the fluorescence data to monitor dCTP-induced conformational changes 
(Figure 3.3C), and the equilibrium binding affinity of dCTP (Figure 3.3D). The 
maximum excision rate and Km of ATP obtained from conventional fitting were set as 
starting estimates in the global fitting to derive other rate constants. However, fitting 
curves in Figure 3.3B were significantly discrepant from the real data, suggesting that the 
data cannot be accurately fit to the minimal model shown in Scheme 3.1. This was not so 
surprising since conventional fitting already showed the discrepancies among Kd values 
of dCTP measured by quench flow and stopped flow methods, and this irreconcilable 




Figure 3.3 Global fitting of ddTMP excision and dCTP binding assays by MDCC-labeled 
HIVRT_TAMs. ATP (A) and dCTP (B) concentration dependent excision/rescue assays, 
as well as dCTP binding (C) and equilibrium titration (D) assays shown in Figure 3.2 
were also analyzed by global fitting of all the data to a single model (Scheme 3.1) using 
KinTek Explorer. Reaction time in panel C is shown in logarithmic scale. In each figure, 
the smooth lines show the best fit to the model. The fitting curves in panel B are 
significantly off from the real data since the discrepancies among binding affinities of 
dCTP derived from quench-flow data (B) and stopped-flow data (C/D) are significant, 
suggesting that important step(s) may be missing in the model. 
 
Since the major difference between quench flow and stopped flow experiments is 
that binding affinity of dCTP was measured under the influence of high concentration of 
ATP (4.8 mM) in chemical quench assays, it is reasonable to speculate that ATP can bind 
90	  
	  
to the enzyme-DNAdd-dCTP triplex and make the binding of dCTP tighter. This 
hypothesis was tested by mixing a pre-formed ternary complex either with buffer (Figure 
3.4A) or in the presence of 4.8 mM ATP (Figure 3.4B) while recording the fluorescence. 
As was expected, when mixed with buffer, an increase of fluorescence was observed 
since dCTP dissociated from the ternary complex during the dilution and a new 
equilibrium was established. The rate was 2.1±0.1 s-1, which is comparable to the 
dissociation rates of nucleotides from a closed ternary complex we previously measured 
(77, 86).  Notably, in the presence of ATP, a decrease of fluorescence was observed with 
a rate of 0.45±0.01 s-1, suggesting a slow conformational change after the binding of ATP. 
 
  
Figure 3.4 ATP makes the binding of dCTP tighter by inducing an additional 
isomerization step. A pre-formed E-DNAdd-dCTP ternary complex (100 nM MDCC-
labeled HIVRT_TAMs, 150 nM of 26ddTMP/45mer, and 200 µM dCTP) was mixed 
with the reaction buffer (A) or 4.8 mM of ATP (B). Fluorescence was observed by 
excitation of MDCC at 425 nm and monitoring emission with a 475 nm band-pass filter 
with a 50 nm bandwidth for 1 (A) or 30 (B) s (time was showed in logarithmic scale). 
Stopped flow data were fit to a single exponential function. The rate of fluorescence 
increase (A) due to dCTP dissociation is 2.1±0.1 s-1. While the rate of fluorescence 




Theoretically, ATP can bind to the triplex during any stage of the binding event, 
either the ground-state binding (ED25ddT.dCTP), or any one of the two conformational 
changes (FD25ddT.dCTP or GD25ddT.dCTP). In order to make the model as simple as 
possible, it was assumed that ATP only binds to the GD25ddT.dCTP species. With this 
consideration in mind, the data were then globally fit to a modified model (Scheme 3.2) 
to derive rate constants that were used to calculate kinetic parameters governing the 
excision efficiency and binding of dCTP (Figure 3.5), as summarized in Table 3.2 and 3.3. 
The excision rate (kexc) was 0.0047 ± 0.0003 s-1, the Km of ATP was 2.6 ± 0.05 mM, 
yielding a kexc/Km,ATP of 1.8 ± 0.1 M-1s-1 (Table 3.2), all of which agree with values for 
kexc, Km,ATP and kexc/Km,ATP obtained from conventional fitting. Global analysis resulted 
in a value of 3.3 ± 0.7 µM (Kd,dCTP  = 1/(K1×(1 + K2 +K2K3))) governing the binding of 
dCTP to RTs locating at the P site in the absence of ATP. However, binding of ATP to 
GD25ddT.dCTP (Kd,ATP = 0.06 ± 0.003 mM) made the binding tighter by ~80 fold and 
defined the apparent Kd of dCTP as 0.04 ± 0.007 µM (KdCTP,app = Kd,dCTP /(1 + 
[ATP]/Kd,ATP)). The ratio of the fluorescent amplitude for the fast phase to that of the 
slower phase defines an equilibrium constant (K0) governing the reverse translocation 
between P site and N site (Figure 3.5C and Figure 3.10) of 12 ± 1. These values produced 
overall Kd values for dCTP binding with (Kd,app = KdCTP,app × (1 + K0 × (1 + 
[ATP]/Km,ATP))) or without (Kd,app = Kd,dCTP × (1 + K0)) ATP as 1.3 ± 0.3 and 41 ± 10 µM, 
respectively. The former is smaller than the Kd of 8.6 ± 0.6 µM obtained from the 
conventional fitting of quench flow data (Figure 3.2D and Table 3.4) but the latter agrees 
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with Kd values (41 ± 2 or 35 ± 0.1 µM) derived from fluorescence measurements (Figure 
3.2F and G). 
 
Table 3.2 Kinetic Parameters Governing Thymidine Analog Excision Efficiencies 







Excision Rates ×1000 
(s-1, 50 µM dCTP) 
TAMs / 26ddT 0.0047±0.0003 2.6±0.05 1.8±0.1 0.5±0.02 
TAMs_T69SSSVD / 
26ddT 0.0032±0.0002 6.3±0.06 0.5±0.03 0.7±0.03 
TAMs / 26d4T 0.022±0.0001 2.7±0.2 8.1±0.6 0.6±0.07 
TAMs_T69SSSVD / 




Table 3.3 Kinetic Parameters Governing the Binding of Next Correct Nucleotide  









TAMs / 26ddT 3.3±0.7 0.06±0.003 0.04±0.007 12±1 1.3±0.3 
TAMs_T69SSSVD / 26ddT 7.1±1.5 0.32±0.01 0.45±0.09 12±1 9.9±2.5 
TAMs / 26d4T 0.6±0.05 0.27±0.01 0.03±0.003 2.8±0.1 0.26±0.04 
TAMs_T69SSSVD / 26d4T 0.7±0.1 1.6±0.2 0.18±0.04 5.6±0.3 2.5±0.6 
a Net dissociation constant of dCTP (Kd,dCTP) is defined by the product of equilibrium 
constants up to the catalytic step (in the absence of ATP):  Kd,dCTP  = 1/(K1×(1+K2+K2K3)). 
b Kd,ATP is the dissociation constant governing the binding of ATP to the GD25ddT.dCTP. 
c Apparent dissociation constant of dCTP in the presence of ATP is defined by the 
formula: KdCTP,app = Kd,dCTP  / (1 + [ATP] / Kd,ATP). 
d Apparent dissociation constant is the product of the apparent dissociation constant of 
dCTP and the equilibrium constant of the translocation step from P site to N site: Kd,app = 






Figure 3.5 Global fitting of ddTMP excision and dCTP binding assays by MDCC-labeled 
HIVRT_TAMs to an improved model. The same set of data were fit to an improved model 
shown in Scheme 3.2, in which binding of ATP onto the ternary complex “G-DNAdd-
dCTP” can induce the tighter binding of dCTP observed in the quench-flow data. All 
curves represent the best fit to get the rate constants shown in Table 3.2 and 3.3. 
 
Excision of ddTMP by the HIVRT_TAMs_T69SSSVD-MDCC 
Similar experiments and data analyses were performed to determine the kinetics 
governing ddTMP excision by and dCTP binding to the TAMs_T69SSSVD mutant, as 
shown in Figure 3.6 and summarized in Table 3.2 and 3.3. The rate of excision was 
0.0032 ± 0.0002 s-1, and the Km for ATP was 6.3 ± 0.06 mM, as defined by the chemical 
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quench flow data (Figure 3.6A). The fingers insertion reduced the excision efficiency by 
3.6-fold, with a specificity constant of 0.5 ± 0.03 M-1s-1 (Table 3.2). The net dissociation 
constant of dCTP (Kd,dCTP) was 7.1 ± 1.5 µM. However, fingers insertion weakened the 
binding of ATP to GD25ddT.dCTP by 5-fold (Kd,ATP = 0.32 ± 0.01 mM), which finally 
made the binding of dCTP in the presence of ATP weaker by 11 fold (KdCTP,app =  0.45 ± 
0.09 µM). Measurements of the equilibrium constant governing translocation (K0 = N/P 
ratio of DNA binding) were fit to a value of 12 ± 1, suggesting that this mutant favors the 
binding of DNA at the N site where the drug is positioned to be excised efficiently. 
Taken these values altogether, the overall apparent Kd for dCTP was determined as 9.9 ± 
2.5 µM (Table 3.3), so the binding of dCTP to TAMs_T69SSSVD/26ddTMP was 7-fold 
weaker than to the TAMs/26ddTMP duplex, suggesting that the excision of ddTMP by 
the mutant with fingers insertion might be more resistant to the inhibition by dCTP 
binding to form the dead end complex. 
Excision of d4TMP by the HIVRT_TAMs-MDCC and HIVRT_TAMs_T69SSSVD-
MDCC 
	  
ATP concentration dependence of the rates of excision of d4TMP by the TAMs 
mutant defined a maximum rate of excision of 0.022 ± 0.0001 s-1, a Km for ATP of 2.7 ± 
0.2 mM, the excision efficiency was then calculated as kexc/Km,ATP = 8.1 ± 0.6 M-1s-1, 
which is 4.5-fold higher than that observed for the excision of ddTMP (Figure 3.7A and 
Table 3.2). Data contained within the titration curve and families of curves for the dCTP 
concentration dependence of excision rates and fluorescence changes (Figure 3.7B-D) 
were used to define a net dissociation constant of dCTP (Kd,dCTP) as 0.6 ± 0.05 µM, a 
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dissociation constant governing the binding of ATP to the triplex (Kd,ATP) as 0.27 ± 0.01 
mM, which leads to an apparent dissociation constant of dCTP (KdCTP,app) of 0.03±0.003 
µM (Table 3.3). The global analysis resulted in a K0 of 2.8±0.1, suggesting that the 
TAMs mutant still favor binding the d4TMP-terminated primer/template at the N site, but 
with less than the ddTMP-terminated primer/template. In the presence of ATP, the 
binding of dCTP to TAMs/26d4TMP was 5-fold tighter than to the TAMs/26ddTMP 
duplex, with an overall apparent Kd (Kd,app) of 0.26 ± 0.04 µM, suggesting that the 
excision of d4TMP by TAMs might be more susceptible to the inhibition by the next 
correct nucleotide (Table 3.3). 
Excision of d4TMP by the TAMs_T69SSSVD mutant and the binding of dCTP to 
the E-DNAd4T duplex (Figure 3.8) were also globally fit to the four-step nucleotide 
binding model (Scheme 3.2). To determine the maximum rate of excision and Km for 
ATP, the concentration dependence was examined (Figure 3.8A) to obtain a rate of 0.014 
± 0.0007 s-1, and a Km,ATP of 3.7 ± 0.4 mM, and the excision efficiency was determined to 
be 3.8 ± 0.4 M-1s-1, indicating that the fingers insertion decreased the excision efficiency 
by 2.2-fold (Table 3.2). Rate constants obtained from global analysis afforded a Kd,dCTP = 
0.7 ± 0.1 µM governing the binding of dCTP to the E.DNAd4T duplex located at the P site. 
Then the fingers insertion made the binding of ATP to the GD25d4T.dCTP complex 6-
fold weaker, with a Kd,ATP value of 1.6 ± 0.2 mM. The apparent Kd for dCTP in the 
presence of ATP (KdCTP,app) was then determined as 0.18 ± 0.04 µM. The equilibrium 
constant governing translocation (K0) was 5.6 ± 0.3 and the overall apparent Kd for dCTP 
(Kd,app) was then calculated as 2.5 ± 0.6 µM, which is 10-fold larger than the value 
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obtained for the TAMs mutant (0.26 ± 0.04 µM). Again, our data supported that the 
fingers insertion weakened the binding of dCTP to a thymidine analog terminated primer 
and therefore might reduce its inhibition towards the excision. Global fitting results for 
ddTMP and d4TMP excision by TAMs and TAMs_T69SSSVD mutants are summarized 







Figure 3.6 Global fitting of ddTMP excision and dCTP binding assays by MDCC-labeled 
HIVRT_TAMs_T69SSSVD. ATP (A) and dCTP (B) concentration dependence of ddTMP 
excision and rescue as monitored by the formation of elongated product. (A) A preformed 
TAMs_T69SSSVD/26ddTMP complex (150 nM MDCC-labeled mutant and 100 nM of 
26ddT/45mer) was mixed with 100 µM TTP and 1 µM dCTP in the presence of various 
concentrations of ATP (0.4, 0.8, 1.6, 3.2, and 4.8 mM). (B) A preformed enzyme-DNA 
duplex (150 nM MDCC-labeled RT mutant and 100nM of 26ddT/45mer) was mixed with 
100 µM TTP and 4.8 mM ATP in the presence of various concentrations of dCTP (1, 5, 
10, 20, 50, 100 and 200µM). Binding affinity of dCTP to enzyme-DNA complex 
terminated with ddTMP was measured by stopped-flow fluorescence (C), as well as 
equilibrium fluorescence titration assays (D). (C) A preformed TAMs_T69SSSVD 
/26ddTMP complex (100 nM mutant and 150 nM of 26ddT/45mer) was rapidly mixed 
with various concentrations of dCTP (10, 20, 40, 80, 100, 200, 400 and 600 µM). 
Fluorescence was observed for 60 s (time is showed on a logarithmic scale). (D) In the 
titration assay, the preformed TAMs_T69SSSVD/26ddTMP complex (100 nM mutant 
and 150nM of 26ddT/45mer) was continuously mixed with increasing concentrations of 
dCTP (0-400 µM) while recording fluorescence. All curves represent the best global fit to 




Figure 3.7 Global fitting of d4TMP excision and dCTP binding assays by MDCC-labeled 
HIVRT_TAMs. ATP (A) and dCTP (B) concentration dependence of d4TMP excision and 
rescue as monitored by the formation of elongated product. (A) A preformed 
TAMs/26ddTMP complex (150 nM MDCC-labeled RT mutant and 100 nM of 
26d4T/45mer) was rapidly mixed with 100 µM TTP and 1 µM dCTP in the presence of 
various concentrations of ATP (0.4, 0.8, 1.6, and 3.2 mM). (B) A preformed enzyme-
DNA duplex (150 nM MDCC-labeled RT mutant and 100 nM of 26d4T/45mer) was 
rapidly mixed with 100 µM TTP and 4.8 mM ATP in the presence of various 
concentrations of dCTP (2, 5, 10, 20, 50, and 100 µM). Binding affinity of dCTP to 
enzyme-DNA complex terminated with d4TMP was measured by ensemble stopped-flow 
(C), as well as equilibrium titration assays (D). (C) A preformed TAMs/26d4TMP 
complex (100 nM TAMs and 150 nM of 26d4T/45mer) was rapidly mixed with various 
concentrations of dCTP (1, 2, 5, 10, 20, 40 and 100 µM). Fluorescence was observed for 
10 s (time was showed in logarithmic scale). (D) In the titration assay, the preformed 
TAMs/26d4TMP complex (100 nM TAMs and 150 nM of 26d4T/45mer) was 
continuously mixed with increasing concentrations of dCTP (0-15 µM) while recording 





Figure 3.8 Global fitting of d4TMP excision and dCTP binding assays by MDCC-labeled 
HIVRT_TAMs_T69SSSVD. ATP (A) and dCTP (B) concentration dependence of d4TMP 
excision and rescue as monitored by the formation of elongated product. (A) A preformed 
TAMs_T69SSSVD/26d4T complex (150 nM MDCC-labeled RT mutant and 100 nM of 
26d4T/45mer) was rapidly mixed with 100 µM TTP and 1 µM dCTP in the presence of 
various concentrations of ATP (0.4, 0.8, 1.6, and 3.2 mM). (B) A preformed enzyme-
DNA duplex (150 nM MDCC-labeled mutant and 100 nM of 26d4T/45mer) was rapidly 
mixed with 100 µM TTP and 4.8 mM ATP in the presence of various concentrations of 
dCTP (5, 10, 50, 100 and 200 µM). Binding affinity of dCTP to enzyme-DNA complex 
terminated with d4TMP was measured by ensemble stopped-flow (C), as well as 
equilibrium titration assays (D). (C) A preformed TAMs_T69SSSVD/26d4TMP complex 
(100 nM mutant and 150 nM of 26d4T/45mer) was rapidly mixed with various 
concentrations of dCTP (2, 5, 10, 20, 40, 60, 80 and 100 µM). Fluorescence was observed 
for 10 s (time was showed in logarithmic scale). (D) In the titration assay, the preformed 
TAMs_T69SSSVD/26d4TMP complex (100 nM mutant and 150 nM of 26d4T/45mer) 
was continuously mixed with increasing concentrations of dCTP (0-20 µM) while 
recording fluorescence. Smooth lines represent the best fit to get the rate constants shown 
in Table 3.2 and 3.3. 
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Fingers Insertion Broadened Excision Specificity by Alleviating Inhibition from the 
Next Correct Nucleotide 
	  
Previous studies have shown that fingers insertion enhanced ATP dependent 
excision of NRTIs in the presence of one or more TAMs mutations (117, 124). However, 
our data suggested that introduction of a Ser-Ser dipeptide in the fingers domain 
decreased excision efficiencies of ddTMP and d4TMP by 2~4 fold if one only considers 
kexc/Km,ATP (Table 3.2). However, the fingers insertion also made the binding of dCTP 
weaker by 7~10 fold (Table 3.3), which therefore results in less inhibition against the 
excision of thymidine analogs (Figure 3.9 and Table 3.2). As shown in Table 3.2, the 
mutant containing a dipeptide insertion showed higher excision rates in the presence of 
50 µM of dCTP, which is close to its physiological concentration of approximately 30 
µM (131).  To demonstrate this trend more clearly, excision rates of ddTMP and d4TMP 
by TAMs and TAMs_T69SSSVD mutants were plotted versus dCTP concentrations 
shown in logarithmic scale (Figure 3.9). Excision rates of the TAMs_T69SSSVD mutant 
decreased less significantly with increasing concentrations of dCTP, either in the case of 
ddTMP (Figure 3.9A) or d4TMP (Figure 3.9B) excision. The data were fit to a hyperbola 
function (Equation 3.2), and apparent Kd values obtained were 8.6 ± 0.6 (for TAMs/ddT), 
50 ± 4 (for TAMs_T69SSSVD/ddT), 1.1 ± 0.3 (for TAMs/d4T), and 5 ± 0.2 µM (for 







Figure 3.9 Fingers insertion alleviates inhibitory effect of dCTP on the excision of both 
ddTMP (A) and d4TMP (B) by TAMs and TAMs_T69SSSVD mutants. Excision rates of 
ddTMP (A) and d4TMP (B) by TAMs and TAMs_T69SSSVD mutants were plotted 
against dCTP concentration shown on a logarithmic scale. Smooth lines in each panel 
represent conventional fitting of the concentration dependence of inhibition by dCTP to a 
hyperbola (Equation 3.2), which defines the apparent binding affinities of dCTP 
(apparent Kd) to TAMs/26ddTMP, TAMs_T69SSSVD/26ddTMP, TAMs/26d4TMP, and 
TAMs_T69SSSVD /26d4TMP complexes as 8.6 ± 0.6, 50 ± 4, 1.1 ± 0.3, and 5 ± 0.2 µM, 
respectively. The apparent weaker binding of dCTP onto TAMs_T69SSSVD/26ddTMP 
or 26d4TMP duplexes results in less inhibition at the physiological concentration of 
dCTP (~ 30 µM). 
 




We have studied the effects of T69SSS fingers insertion of HIVRT on ATP 
mediated excision of thymidine analogs and the binding of next correct nucleotide (dCTP) 
onto the 3’ end of thymidine analog-terminated primers. Previous studies have shown 
that fingers insertion in the backbone of TAMs could broaden the excision specificity by 
destabilizing the formation of dead-end complex (115, 117, 120). However, accurate 
measurements and comparisons of the excision efficiencies (kexc/Km,ATP) by different 
mutants are still missing since none of these studies explored the ATP concentration 
dependence of the reaction. Also, the binding affinities of next correct nucleotides were 
usually determined by gel mobility shift assays, which unfortunately, is not a reliable 
method due to the rapid dissociation of dCTP from the enzyme. We now revisit this 
problem and carefully determine the excision efficiencies, as well as apparent binding 
affinities of dCTP by measuring the concentration dependence of the reactions followed 
by robust global data analysis. Our data show that a Ser-Ser insertion decreased excision 
efficiencies of all thymidine analogs tested by 2-4 fold while weakened the binding of 
dCTP by 7-10 fold, which resulted in the enhanced excision ability by “69 insertion 
complex” observed under physiological conditions by a factor of ~1.5. 
Fitting data based upon numerical integration of the rate equations with no 
simplifying assumptions is far more robust and demanding than fitting to equations 
derived from a simplified form of the model because it requires that the model account 
for both the rate and amplitude of all reactions simultaneously (77, 86). To address this, 
our data were analyzed by both conventional (Figure 3.2) and global fitting methods 
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(Figure 3.3-3.4), as detailed in Materials and Methods. Figure 3.2A & C show the ATP 
or dCTP concentration dependent rescue and extension assays, in which a purified 
ddTMP terminated primer was used. The excised chain terminators can interfere with the 
excision and extension reactions since the dinucleoside tetraphosphate product is a good 
substrate for the reaction to restore the analog (142-143). However, a purified substrate 
minimized the interference when the drug was removed due to its relatively low 
concentration (100 nM) yielding a small concentration of the dinucleoside tetraphosphate 
compared to that of TTP (100 µΜ) , so re-formation of terminated primer was negligible. 
Also, the excision is the rate-limiting step, followed by a very fast extension of 2 
nucleotides, which drives the net reaction to completion. The design of the assays ensures 
that we can obtain reliable data for further analysis. Hyperbolic analysis (Figure 3.2B and 
D) yields key parameters, such as kexc, Km,ATP, excision efficiency (kexc/Km,ATP), and the 
apparent binding affinity of dCTP, which can be used as first estimations in global 
analysis and to double check values obtained from global fitting. The two stopped flow 
assays (Figure 3.2E and G) provided more information about dCTP binding from other 
aspects. The amplitude changes of dCTP induced fluorescent signals are proportional to 
the fraction of bound dCTP, from which apparent binding affinity of dCTP could be 
obtained (Figure 3.2F). Surprisingly, the apparent Kd values obtained from stopped flow 
assays are not consistent with the value obtained from quench flow assays which is ~5 
fold tighter. This trend is more obvious when we globally fit the data set to a three-step 
binding model (Scheme 3.1), as shown in Figure 3.3. The scheme was derived based on 
the Boyer model (79), where the competition between drug removal and DEC formation 
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was governed by the equilibrium constant (K0) of the reverse translocation between P site 
and N site. The failure of global fitting of the data inspired us to re-evaluate our model 
and ask if we miss certain important factors. The first possibility we examined is that 
maybe the inhibition by dCTP is not specific and the apparent tighter binding of dCTP is 
due to additional inhibition from other nucleotides in the reaction. This possibility was 
ruled out quickly since our data clearly showed that only dCTP could inhibit the reaction 
(data not shown), which is also consistent with results published by other groups (127). 
Then we carefully examined the differences between chemical quench and stopped flow 
assays and realized that there was no ATP in fluorescent measurements but the 
concentration was high in quench assays (4.8 mM). So a hypothesis was formulated that 
the apparent tighter binding of dCTP observed in quench flow assays is due to an 
additional conformational change induced by the binding of ATP to the E-DNAdd-dCTP 
ternary complex. This hypothesis was supported by the fact that a decrease of 
fluorescence was observed with a rate of ~0.5 s-1, when a pre-formed ternary complex 
was mixed with 4.8 mM of ATP (Figure 3.4B). As was expected, when mixed with 
buffer, an increase of fluorescence was observed (Figure 3.4A) since a new equilibrium 
was established after the dilution, suggesting that the binding of ATP induced an 
additional conformational change.  
Based on these observations, a new model was derived, as shown in Scheme 3.2, 
in which ATP can bind to the GD25ddT.dCTP triplex and lead to the apparent tighter 
binding of dCTP in the chemical quench assays. Theoretically, ATP can bind to the 
ternary complex at any stage of the binding (either ground state binding or 
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conformational changes). In this circumstance only binding to the GD25ddT.dCTP triplex 
is allowed to propose the minimal model to account for the data when the global fitting is 
performed. As shown in Figure 3.5, this model matches the data set very well, from 
which parameters governing excision efficiencies and binding affinities of dCTP were 
determined, as summarized in Tables 3.2 and 3.3. For ddTMP excision by the TAMs 
mutant, the kexc, Km,ATP and kexc/Km,ATP values obtained from global fitting are consistent 
with corresponding values determined from conventional fitting (Figure 3.2B). This 
analysis shows how data global fitting provide more kinetic details and the inspiration as 
well as the means to solve contradictions observed in conventional data fitting.  
Similar assays and data analysis were performed (Figure 3.6-3.8) to derive kinetic 
parameters governing excision efficiencies of thymidine analogs, as summarized in Table 
3.2. A Ser-Ser insertion decreased the maximum excision rates and weakened the binding 
of ATP, which resulted in lower excision efficiencies. Usually, Km involves both binding 
and chemistry and therefore is not a pure parameter to describe binding affinity. Here 
Km,ATP was used as an estimation of the binding affinity of ATP since the excision is 
extremely slow (the highest rate is only 0.02 s-1) so it is reasonable to presume that the 
binding of ATP reaches equilibrium before the chemistry occurs; thus, in this case the 
Km,ATP approximates the true Kd of ATP (77, 86-87). 
Extensive efforts were expended to derive the binding affinity of dCTP since the 
derivation is really a challenge in such a complex model. First, the translocation step and 
influence of ATP was put aside to derive the net dissociation constant of dCTP (Kd,dCTP = 
1/(K1 × (1 + K2 +K2K3))). As mentioned above, the high concentration of ATP makes the 
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binding of dCTP tighter in the quench flow assays since it induces an additional 
isomerization (governed by Kd,ATP).  Then the apparent dissociation constant of dCTP in 
the presence of ATP can be determined as KdCTP,app = Kd,dCTP  / (1 + [ATP] / Kd,ATP). 
Finally, all the steps are taken into consideration since the equilibrium of the reverse 
translocation from the P site to the N site and the concomitant binding of ATP affect the 
fraction of E-DNAdd duplexes residing in the P site that are capable of the binding of 
dCTP. So the overall apparent dissociation constant of dCTP is Kd,app = KdCTP,app × (1 + 
K0 × (1 + [ATP] /Km,ATP)). Here an example of how to derive the dissociation constant 
from a complex model was shown step by step and all the parameters were summarized 
in Table 3.3. Details of the derivation can be found in the Materials and Methods. But the 
formula can be much simpler in the case of the stopped flow assay since no ATP was 
added (Kd,app = Kd,dCTP × (1+K0)). The overall Kd,app values for the binding of dCTP to the 
TAMs/26ddT duplex derived by this method are 1.3 ± 0.3 µM in the presence of ATP 
and 41 ± 10 µM in the absence of ATP, respectively. The former is 6-fold smaller than 
the number obtained from conventional fitting while the latter agrees very well with 
values determined from conventional analysis (with ATP, 8.6 ± 0.6 µM; without ATP, 41 
± 2 or 35 ± 0.1 µM [Figure 3.2 and Table 3.4]). Further analysis showed that, in the 
absence of ATP, the overall Kd,app values derived from global fitting are consistent with 
corresponding numbers obtained from conventional fitting of the stopped flow data, 
justifying the effectiveness of global fitting. In contrast, Kd,app values derived from 
global fitting are 2-6 fold smaller than the numbers obtained from conventional fitting of 
chemical quench data (Table 3.4).  
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Table 3.4 Kd,app values obtained by conventional and global fitting  
 Kd,app With ATP (µM) Kd,app Without ATP (µM) 
 CFa GFb CF (SFc) CF (ETd) GFb 
TAMs / 26ddT 8.6±0.6 1.3±0.3 41±2 35±0.1 41±10 
TAMs_T69SSSVD / 26ddT 50±4 9.9±2.5 80±6 50±0.2 90±20 
TAMs / 26d4T 1.1±0.3 0.26±0.04 3.4±0.3 2.7±0.1 2.3±0.3 
TAMs_T69SSSVD / 26d4T 5±0.2 2.5±0.6 3.9±0.1 4.6±0.2 4.6±0.8 
a Conventional Fitting ;  b Global Fitting; c Stopped Flow; d Equilibrium Titration. 
 
This inconsistency of Kd,app values demonstrated a potential drawback of the 
“IC50 analysis” which has been widely used to determine apparent binding affinities of 
small inhibitors. This issue is more prominent in our cases first because dCTP is the 
substrate and inhibitor at the same time. More important is that the Kd values to be 
determined are small numbers so it is almost impossible to achieve a dCTP concentration 
that is low enough to accurately determine Kd,app while maintain high extension 
efficiency. For example, another group reported IC50 values of 0.5±0.07 and 2.6±0.2 µM 
governing the inhibition against the rescue of d4TMP or ddTMP terminated primers 
(144). These numbers are 2-fold larger than what we obtained mainly because there are 
not enough reliable data points at low concentrations. Another issue of this research is 
that they separated excision from extension while ignoring the fact that the excision 
product is a good substrate for re-termination. In this situation, parameters obtained from 
global analysis are more reliable since the information contained in the data set defines a 
model, from which unknown information can be derived.  
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Our data show that the Ser-Ser insertion weakens the binding of dCTP by 2-fold 
in the absence of ATP. In quench assays, the dipeptide insertion can reduce the dCTP 
binding affinities by 7-10 fold, which leads to less extent of inhibition and therefore 
higher excision rates by the “69 insertion complex” under physiological conditions 
(Table 3.2 and Figure 3.9). Curves in Figure 3.9 demonstrate how lower excision 
efficiencies finally yield higher excision rates around the physiological concentration of 
dCTP. This trend is more obvious in the case of ddTMP excision by the 
TAMs_T69SSSVD because the apparent Kd (9.9 ± 2.5 µM) is closer to the physiological 
concentration of dCTP (~30 µM).  
The reverse translocation between P site and N site is a crucial step in our 
excision model, which determines the fate of a blocked primer – either DEC formation or 
rescue and extension. Site-specific foot-printing technique has been developed to study 
the translocation status of HIVRT in some studies to determine positions of cleavages (72, 
129-130). However, the foot-printing reaction usually requires 2-5 minutes, which is too 
slow to accurately measure the rapid translocational equilibrium that can establish in less 
that 0.4 s (20). This method is not so convincing also because it was found that different 
reducing reagents (e.g., ascorbate or DTT) yielded different results (data not shown). On 
the other hand, the stopped flow data in this chapter provided sufficient information to 
define the equilibrium constant (K0), as shown in Figure 3.10. We noticed that the 
fraction of fast conformational change was smaller when dCTP binds to the TAMs-
E.DNAd4T duplex (Figure 3.10, red data points) than to the WT-E.DNAd4T complex 
(Figure 3.10, red solid line). This is because the TAMs mutations make RT cause the 
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DNA to shift more toward the N site so only a small fraction of protein-DNA complexes 
reside at the P site where nucleotides can bind directly. In our studies, we observed a 
slower reaction phase that represents the translocation from the N site to the P site. 
Therefore the ratio of the fraction of fast conformational change to that of the slower 
isomerization that is limited by the translocation step defines the equilibrium constant K0. 
Previous single molecule studies performed in this lab showed that ~63% of ddTMP or 
d4TMP terminated primers locate at the P site of WT proteins, yielding a K0 value of 0.6 
(unpublished data). As summarized in Table 3.3, K0 values obtained from these mutants 
are ranging from 3 to 12, suggesting that the TAMs mutations increased the fraction of 
DNA residing at the N site by 5-20 fold. Whether TAMs mutations enhance the excision 
of thymidine analogs by increasing the binding affinity of ATP or not is still controversial. 
However, the results presented here supported a new mechanism by which the TAMs 
mutations enhance the excision. Interestingly, an additional conformational change was 
also observed with extremely low rates (~0.05 s-1) and very small amplitudes, suggesting 
that the binding of nucleotides to a analog-blocked primer can be different from their 





Figure 3.10 Representative data demonstrating the amplitude of the fast phase of 
fluorescence change defines the equilibrium of translocation between P site (Post-
translocation) and N site (Pre-translocation). The data were obtained by rapidly mixing a 
preformed TAMs/26d4TMP complex (100 nM TAMs and 150 nM of 26d4TMP/45mer) 
with 100 µM dCTP (green data points in Figure 3.7C) and shown in semi-logarithmic 
scale. The smooth line represents the fluorescence change upon mixing WT/26d4TMP 
duplex (100 nM WT RT and 150 nM of 26d4TMP/45mer) with 100 µM dCTP, which 
was generated with KinTek Explorer using previously published rate constants. The rate 
constants were kept unchanged but the scaling factors were adjusted to overlay the net 
reaction amplitude of the simulated curve with the real data. The fraction of the signal for 
the fast reaction phase provides an estimate of the equilibrium constant for the 




It has been proposed that the relatively high excision efficiency of AZT by the 
TAMs mutant is due to a fact that the long azido group can interfere with appropriate 
binding of the incoming nucleotide, so blocked primers have better access to the N site 
(79). However, another study indicated that the 3’-azido group alone could not confer 
high level of resistance and therefore is not the primary determinant responsible for its 
clinically observed high level of resistance (80). Our data showed that the TAMs mutant 
excises thymidine analogs with comparable efficiencies, 1.95 ± 0.05 M-1s-1 for AZT, 1.8 
± 0.1 M-1s-1 for ddT, and 8.1 ± 0.6 M-1s-1 for d4T, which are at least 10-fold higher than 
that of ddG (0.17 ± 0.06 M-1s-1, data not shown). The results clearly demonstrate that 
base components of nucleotide analogs determine the “original” excision efficiencies in 
the absence of inhibition. It seems that the TAMs mutations have evolved for the excision 
of thymidine analogs, which was supported by the fact that 3’-azido-guanosine (AZG) 
led to a different set of mutations during in vitro selection experiments, including L74V, 
F77L, L214F, K476N and V518I (145-146). On the other hand, azido group determines 
the extent to which the excision is resistant to the inhibition from the next correct 
nucleotide, which in turn determines the excision rates under physiological conditions. 
Our previous single molecule studies showed that only 14% of AZTMP terminated 
primers reside at P site, from which a K0 value of 6 was derived (unpublished data). So 
the azido group shifts the equilibrium of translocation to favor the residence of an AZT-
terminated primer at the N site by 10-fold. The TAMs mutations also facilitate a 
primer/template to locate at N site by 5-20 fold, varying with different chain terminators. 
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Consequently, the combination of these two factors resulted in the high level of excision 
of AZT by the TAMs mutant. 
In this chapter, our data show that a Ser-Ser dipeptide insertion in the TAMs 
background decreased excision efficiencies of thymidine analogs and weakened the 
binding of next correct nucleotide. This weaker binding led to less extent of inhibition 
and therefore higher excision capacity at physiological concentrations of nucleotides. Our 
data also supported that the TAMs mutations facilitate the 3’ end of a blocked primer 
binding in the N site, which is a novel mechanism by which these mutations result in 
enhanced excision. It was also found that the 3’-azido group was not the primary 
determinant for TAMs mediated excision and base components also played an important 
role to determine the excision specificity. Questions remain regarding the mechanistic 
basis for the >10-fold higher excision efficiencies of thymidine analogs by the TAMs 
mutant. An advanced understanding of how drug resistance mutations determine the 
excision selectivity could be used in the design of the next generation of NRTIs to 
overcome the evolution of resistance. 
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Chapter 4: The Polymerase and RNase H Active Sites of HIV-1 Reverse 
Transcriptase Work Simultaneously and Independently 
	  
4.1 INTRODUCTION 
HIVRT is a heterodimer, consisting of two related subunits: the catalytic p66 
subunit, and a smaller p51 subunit that is proposed to play a structural role. The p66 
subunit has two active sites, namely the N-terminal polymerase active site and the C-
terminal RNase H active site, which perform different enzymatic functions: DNA-/RNA-
dependent polymerization and RNase H cleavage, respectively. The two active sites are 
~60 Å away from each other, flanking the nucleic acid binding cleft that spans 18 base 
pairs of a DNA/RNA hybrid (15). Despite the long distance, the process of reverse 
transcription requires a close coordination between the two catalytic centers, e.g., during 
minus-strand DNA synthesis, the polymerase active site copies the viral genome, while 
the RNase H site degrades the copied RNA segments to free the nascent DNA strand that 
serves as the template for plus-strand DNA synthesis. The fact that three activities of 
HIVRT evolved to be present in a single protein and that their coupled activities are 
required during reverse transcription suggested a possible spatial and temporal 
coordination between the two active sites. This hypothesis has been supported by several 
lines of evidence. First, RNase H is able to function as an independent enzyme, however, 
the isolated RNase H domain of HIV-1 RT was inactive, although its nuclease activity 
was able to be partially restored by adding various N- or C-terminal extensions (147-152), 
indicating other parts of RT were also required for the substrate binding and/or activity of 
RNase H. Secondly, the first RNA cleavage event occurs 18 base pairs from the 3’-OH 
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and seven-fold slower than DNA synthesis (20), suggesting a possible coupling between 
the two active sites. Subsequent RNase H cleavage events result in shorter products, but 
in the presence of a trap to inhibit substrate rebinding, only the 18-19 base products were 
observed, suggesting that sequential RNase H cleavage events are slow relative to 
dissociation of the DNA/RNA duplex from the enzyme (92). Finally, a more recent 
biochemical study suggested that HIVRT can simultaneously engage its DNA/RNA 
substrate at both active sites based on the observations that small ligands capable of 
stabilizing the nucleic acid in the polymerase active site only affected the pattern but not 
the efficiency of RNA cleavage under single-turnover conditions (93). 
Despite the abundance of HIV-1 RT structures, only three of them were in 
complex with a DNA/RNA hybrid and none of them were in an RNase H competent 
mode (15, 51, 54). Therefore, the structural basis for the mechanism by which the two 
catalytic centers might coordinate with each other is still elusive. One study suggested 
that by positioning the DNA primer strand the ‘RNase H primer grip’ might also help to 
determine the trajectory of the hybrid substrate around the RNase H active site and 
thereby play an important role in coupling the two active sites (15). A later biochemical 
study then revealed that the cleavage specificity by RNase H could be modified by 
altering the RNase H primer grip (50). 
Whether the two active sites of HIV-1 RT are able to act simultaneously is still 
under debate since structural and biochemical data suggested that primer extension and 
template degradation may be mutually exclusive and might occur sequentially. The 
DNA/RNA hybrids cocrystallized with HIV-1 RT were all in the polymerization mode 
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and did not reach the RNase H site (15, 51, 54). Meanwhile, the attempt to model a 
DNA/RNA hybrid into the RNase H active site of HIV-1 RT revealed that even with a 
severe bending, the substrate was not able to simultaneously occupy the two catalytic 
centers (153). These structural analyses suggested a ‘toggling’ model, where the bound 
substrate must toggle between the two active sites of HIV-1 RT, probably through 
conformational changes. As for the biochemical data, the rate of primer extension was 
determined to be 7-fold faster than that of RNA cleavage monitored simultaneously on a 
millisecond time scale (20) and the template was not degraded processively in RNA 
dependent extension assays (19), all of which were inconsistent with the tight temporal 
coupling between the two active sites. Moreover, RNA cleavage tended to occur more 
efficiently when primer extension paused before a hairpin on the RNA template (94). 
NNRTIs inhibitory to DNA synthesis were able to activate RNA cleavage, presumably 
through increasing the accessibility of the DNA/RNA hybrid substrate to the RNase H 
site (95). Based on these observations, it has been proposed that the nucleic acid substrate 
could only engage one active site at one time, but the data are not compelling.  
In the present chapter, whether a DNA/RNA hybrid can simultaneously engage 
both active sites was further explored by examining single nucleotide incorporation and 
RNase H cleavage using pre-steady-state kinetics together with global data analysis. The 
data quantitatively demonstrated the existence of a spatial and temporal coordination 
between the two active sites. RNase H activities were also measured under the processive 
nucleotide incorporation condition and a model was proposed suggesting that the 
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polymerization activity of HIVRT was limited by the slow PPi release and therefore was 
able to act simultaneously with the RNase H activity at comparable rates. 
4.2 MATERIALS AND METHODS 
Expression and Purification of Proteins Used in This Study  
WT and mutant HIVRT proteins were expressed, purified and labeled following 
methods previously described (77, 86). Briefly, single mutations (W71A, W71D and 
R72A) were introduced in genes of both subunits using a Quikchange Multi kit 
(Stratagene). The method for the preparation of MDCC-labeled PBP used in this study 
was described previously (154) and its active-site concentration was determined by 
fluorescent titration with various concentrations of inorganic Pi. 
Nucleic Acid Substrates for Kinetic Studies 
All DNA/RNA hybrids were designed to have a DNA primer recessed at the 3’-
end on a RNA template to monitor the primary polymerase-dependent cleavage events 
(Table 4.1). The 45mer RNA templates with random sequence (r45rd) or a string of Gs 
covering the RNase H cleavage site (r45) were purchased from Integrated DNA 
Technologies (IDT) with RNase free HPLC purification. The 25mer DNA primers 










Table 4.1 DNA/RNA Hybrids for Kinetic Assays 
d25rd/r45rd: 
            d25rd: 5’-GCCTCGCAGCCGTCCAACCAACTCA-3’ 
     r45rd: 3’-CGGAGCGUCGGCAGGUUGGUUGAGUAGCAGCUAGGUUACGGCAGG-5’ 
d25/r45: 
            d25: 5’-GCCTCCCCCCCCCCCAACCAACTCA-3’ 
             r45: 3’-CGGAGGGGGGGGGGGUUGGUUGAGUAGCAGCUAGGUUACGGCAGG-5’ 
 
A series of primers with various lengths (Figure 4.8B) were designed to study the 
minimum number of ribonucleotides downstream of the cutting site that are required for 
efficient cleavage. Shortening the primer by one nucleotide will shift the cutting site by 
one nucleotide towards the 3’-end of the RNA template in the DNA 3’-end directed 
cleavage mode. DNA primers terminated with ddAMP or ddTMP were made through 
enzymatic synthesis with RT. Following the biosynthetic reactions, terminated 25 or 
26mer primers (25ddA or 26ddT) were purified by gel extraction. Primers and templates 
used in quench flow assays were 5’ -32P - labeled with T4 polynucleotide kinase (New 
England Biolabs). Annealing of DNA primers and RNA templates was carried out by 
mixing the two oligonucleotides at a 1:1 molar ratio and incubating at 67°C for 8 min, 
followed by slow cooling to room temperature.   
RNA Cleavage Assays 
Time courses of RNA cleavage were measured by rapid quench flow techniques 
using a KinTek RQF-3 (KinTek Corp.).  5’-labeled RNA template was annealed to the 
DNA primer as described above and diluted to a final concentration of 75 nM, pre-
incubated with 175 nM of HIVRT and then rapidly mixed with 10 mM of Mg2+ to initiate 
the cleavage. Effects of small-molecule ligands on polymerase-dependent RNase H 
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cleavage were studied by performing RNA cleavage assays in the presence of PFA (1 
mM) or the next cognate nucleotides (500 µM, with dideoxy-terminated primers). To 
explore the potential coordination between the two active sites, incorporation and RNase 
H activities were measured simultaneously by pre-incubating 175 nM of HIVRT with 75 
nM of double-labeled DNA/RNA hybrids and mixing with 100 µM TTP or ddTTP. All 
reactions were conducted in 50 mM Tris pH 7.5, 100 mM KCl (all concentrations final) 
at 37°C and were stopped by the addition of 0.5 M EDTA at various time points within 
10 s. Products were separated by 15% denaturing PAGE and quantified using a Typhoon 
scanner in Imagine Quant 8.1 (GE). The incorporation and cleavage data were biphasic 
and fit with a double exponential equation to estimate the observed rates (conventional 
fitting).  
RNase H activities were also explored under the processive nucleotide 
incorporation condition, in which all four nucleotides were added at 100 µM so the 
25mer primer would be fully extended to the 45mer. In order to avoid the overlap of 
bands for extension and cleavage products, the two activities were assayed in parallel 
under the same conditions with the same enzyme by attaching the radioactivity only to 
one strand of the hybrid at one time, e.g., 32P was only labeled to the 5’-end of the primer 
when the incorporation activity was assayed and vice versa. Other procedures were the 
same except that data were collected for 20 s to allow full extension and multiple rounds 
of cleavage to occur. 
	    
119	  
	  
Global Data Analysis  
The inherent relationship between the rates and amplitudes of incorporation and 
cleavage reactions are crucial for the exploration of any potential coordination between 
the two active sites. However, this critical information can be lost in conventional fitting; 
therefore simultaneous fitting of all data within a given set is the preferred method. In the 
case of RNA cleavage during single nucleotide incorporation (TTP or ddTTP), the data 
were globally fit with two control experiments calibrating the RNase H activity of 
HIVRT against substrates before or after primer extension. The whole set of data were fit 
globally to a comprehensive mechanism showed in Scheme 4.1 using KinTek Explorer 
software (KinTek Corp.) (155-156). Three different RT-DNA/RNA complexes were 
identified and included in the model: XD25R45 (inactive), YD25R45 (polymerase active 
only), and ED25R45 (polymerase and RNase H both active), which underwent slow but 
reversible interconversions. Amplitudes of substrate depletion in primer extension 
(Figure 4.3A, red curve) and template degradation (Figure 4.3B, red curve) assays 
defined the equilibrium constants governing the exchanges between different species. 
Both YD25R45 and ED25R45 could extend the 25mer substrate to the 27mer product (with 
one mismatch extension), rates of which were derived from the nucleotide incorporation 
data (Figure 4.3A). RNA cleavage was able to occur before (ED25R45) or after (ED26R45) 
primer extension, yielding products with various lengths ranging from 35mer to 38mer. 
In globally fitting the data, cleavage rates were defined by the cleavage data obtained 
with (Figure 4.3B) or without (Figure 4.3C-D) the addition of an incoming nucleotide so 
that the cleavage pattern observed during polymerization was modeled based upon the 
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patterns seen with RNA/DNA duplex before and after elongation. In order to describe the 
complicated process as complete as possible, secondary cuts (e.g., ED25R38 to ED25R37) 
and nucleotide incorporation after template degradation (e.g., ED25R38 to ED26R38) were 
also included in the model. The simulation of RNA cleavage during ddTTP incorporation 
was similar except that the mismatch extension was prohibited and not included in the 
model (Scheme 4.2). The smooth curves in each figure panel represented the best 
simultaneous fit of all the data to the model and the rate constants were summarized in 
Scheme 4.1 (TTP) and 4.2 (ddTTP).  Results of confidence contour analysis of these 
parameters were listed in Table 4.2. 
Simulation of RNA cleavage during processive nucleotide incorporation was 
performed in an alternative way due to the complexity of reactions occurred in the 
process. First, the incorporation data were fit to a minimal model including sequential 
nucleotide incorporation events followed by possible product dissociation after each 
round of incorporation to account for the retention of a fraction of intermediates at long 
reaction times as attributed to their dissociation from the enzyme (Scheme 4.3 and Figure 
4.9B). Global fitting of primer extension and RNA cleavage data was achieved by using 
rate constants obtained from the analysis of polymerization to constrain the simulation of 
RNA degradation data (Scheme 4.4 and Figure 4.9C). At the beginning, RT-DNA/RNA 
complexes were equilibrating between the RNase H active form (ED25R45) and inactive 
forms (X(Y)D25R45). Then, the ED25R45 complex underwent RNA cleavage (vertical 
arrows) before or after TTP incorporation (horizontal arrows) while the cleaved 
substrates were still extended. After the incorporation of multiple nucleotides, the second 
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round of RNA cleavage occurred, yielding shorter products. Then, another two rounds of 
RNA cleavage would occur until the primer was extended to full length and no more 
space was available for the polymerase-dependent RNA cleavage. In order to simplify the 
model, multiple incorporation events between different rounds of RNA cleavage were 
expressed as ‘one’ step kinetically, e.g., ‘+N8’ represented the incorporation of 8 
nucleotides in a row (ED26R45 to ED34R45). This simplification was appropriate and 
required because of the absence of intermediates.  The cleavage products listed for each 
round (e.g., ED25R38 and ED26R38 for the first round) represented the sum of all cleavage 
products with various lengths and were expressed in that way for simplification. Rate 
constants derived from the simulation were summarized in Scheme 4.4 and Table 4.3. 
4.3 RESULTS 
Kinetics of Nucleotide Incorporation and RNase H Cleavage.  
In order to measure nucleotide incorporation and polymerase-dependent RNase H 
cleavage activities simultaneously, a double-labeled DNA/RNA substrate with a 25mer 
primer recessed at the 3’-end on a 45mer RNA template was designed (d25/r45, Table 4.1 
and Figure 4.1A). Since sequence preferences have been observed for DNA 3’-end-
directed cleavage (157), a string of Gs covering the cleavage window was placed in the 
template to avoid effects due to nucleotide preferences. Primer extension and template 
degradation were then studied simultaneously by rapid quench flow method under pre-
steady-state conditions and both activities were observed to occur within the same time 
frame (Figure 4.1B). During TTP incorporation, RNA cleavage products mainly 
accumulated at positions -18 and -17, with minor bands formed at positions -16 and -15. 
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It was reported that the high-resolution site-specific footprinting was indicative of the 
translocational status of HIVRT(129), so we initially thought that the cleavage pattern 
observed here may have also reflected translocation stages of HIVRT on the DNA/RNA 
hybrid before and after nucleotide incorporation. However, control experiments 
performed in the absence of nucleotides revealed that the DNA 3’-end-directed RNA 
cleavage failed to strictly follow the translocation status of RT (Figure 4.2A). Biased 
cleavage to position -18 was observed for substrate d25/r45. When 26mer primers were 
used, cleavage products accumulated at 4 distinct positions instead of two that were 
characteristic of the pre- and post-translocation stages. Product formation was plotted 
versus time and both the incorporation and cleavage data were biphasic (Figure 4.1C and 
D). So rates of TTP incorporation and concomitant RNA degradation were determined by 
fitting the data to a double-exponential equation. The results showed that TTP was 
incorporated at a rate of  107 ± 11 s-1, which was 6~7-fold faster than the template 
degradation that was 17 ± 2 s-1. This difference was consistent with our previous data 
(20). Cleavage rates measured in the absence of nucleotides were determined as 7.7 ± 1.7 
s-1 and 10.2 ± 1.9 s-1 for the 25mer and 26mer primers, which were a little bit slower than 
the cleavage during TTP incorporation (Figure 4.1D and 4.2B). Rates for the slower 
phase were around 0.5 s-1, which were comparable in rate to DNA/RNA dissociation and 
rebinding to the enzyme. 
Incorporation and cleavage activities were observed simultaneously but this 
observation did not exclude a sequential polymerization - hydrolysis model, because 
incorporation was faster and therefore could have been completed prior to the RNA 
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cleavage. In order to test this scenario, the rate of nucleotide incorporation was slowed by 
using a TTP analog (ddTTP) while exploring the RNA cleavage activity during ddTTP 
incorporation. A similar cleavage pattern was observed, with the major or minor products 
accumulated at positions -18 and -17, or -16 and -15, respectively (Figure 4.1B, right 
panel). The rate of ddTTP incorporation (5 ± 0.3 s-1) was determined to be much slower 
than TTP incorporation (107 ± 11 s-1), but was slightly slower than the RNA cleavage (12 
± 0.7 s-1). Concomitant polymerase and RNase H activities were still observed even if 
they had comparable rates, suggesting that the two active sites were able to function 
simultaneously and independently. Moreover, in the single turnover experiment, if the 
two reactions occurred sequentially, one would expect to see a lag in the second reaction 









Figure 4.1  
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Figure 4.1 Kinetics of Nucleotide Incorporation and RNase H Cleavage. (A) The ‘static’ 
nomenclature for naming the cleavage sites are shown in the cartoon. The sequence of the 
double-labeled DNA/RNA hybrid is shown. The blue oval represents HIVRT, where 
POL and RNH denote the polymerase and RNase H active sites, respectively. Positions 
of cleavage sites are counting from the 3’-terminus of the DNA primer, e.g., -18 means 
the cleavage site is 18 nucleotides upstream of the 3’-end of the DNA primer. (B) To 
explore the potential coordination between the two active sites, polymerase (lower panel) 
and RNase H (upper panel) activities were measured simultaneously by pre-incubating 
175 nM of HIVRT with 75 nM of double-labeled DNA/RNA hybrid and then mixing 
with 100 µM of TTP or ddTTP, in the presence of 10 mM Mg2+. Reactions were stopped 
by adding 0.5 M EDTA at various time points up to 10 s. The 45mer RNA template and 
RNase H cleavages at positions -18 to -15 are marked. Positions of the 25mer primer and 
extended products are marked as well. Incorporation (C) and cleavage (D) data were 
analyzed by conventional fitting. The insets better display data points within 1 s. 
Nucleotide incorporation was fit to the double-exponential equation to derive rates of 
TTP or ddTTP incorporation as 107 ± 11 s-1 and 5 ± 0.3 s-1 for the fast phase, and  2 ± 0.8 
s-1 and 0.5 ± 0.1 s-1 for the slower phase, respectively. Similarly, rates of RNA cleavage 
during TTP or ddTTP incorporation were determined to be 17 ± 2 s-1 and 12 ± 0.7 s-1 for 





Figure 4.2 RNA Cleavage of Substrates before or after primer extension. (A) The 45mer 
RNA template (r45) was annealed to 25mer, 26mer, or 26ddT primers to mimic 
substrates before or after nucleotides (TTP or ddTTP) incorporation. RNA cleavage assay 
of each substrate was performed as mentioned in Figure 4.3 and 4.4. The 45mer RNA 
template and RNase H cleavages at positions -18 to -15 are marked. (B) The Data of 
RNA cleavage against various DNA/RNA hybrids were analyzed by conventional fitting 
and the inset better display data points less than 1 s. Cleavage data were fit to the double-
exponential equation to derive rates measured with d25/r45, d26/r45, and 26ddT/r45 as 
7.7 ± 1.7 s-1, 10.2 ± 1.9 s-1, and 12 ± 3 s-1 for the fast phase, and 0.3 ± 0.1 s-1,0.4 ± 0.1 s-1, 




Global Data Fitting of Nucleotide Incorporation and RNase H Cleavage 
Conventional fitting of above data provided some evidence that the two catalytic 
centers of HIVRT work independently. However, conventional analyses were unable to 
rule out the possibility that the simultaneous activities observed previously were due to 
mixed enzyme states where one enzyme catalyzes polymerization while another catalyzes 
RNase H hydrolysis. Information to distinguish whether a single enzyme species 
catalyzes both reactions simultaneously lies in analysis of the amplitudes of the reactions.   
The inherent relationships between the rates and amplitudes of the incorporation and 
cleavage reactions provide more information to determine with both reactions are 
occurring simultaneously and this can be accomplished using global data fitting. Global 
data analysis was first performed for the 4 experiments measuring TTP incorporation 
(Figure 4.1B, upper left), concomitant RNA cleavage (Figure 4.1B, bottom left), and 
RNase H activities of RT against substrates before or after (Figure 4.2A) primer 
extension.  
Data were fit using a minimal model shown in Scheme 4.1, as described in 
materials and methods. Distinct from the conventional data fitting where the amount of 
products with various lengths were summed to define the net reaction rate, for global 
fitting each band was quantified and analyzed individually. Figure 4.3A shows the time 
course of primer extension during TTP incorporation, while Figure 4.3B shows the 
simultaneous accumulation of RNase H cleavage products. Figures 4.3C and D show the 
time course of RNase H cleavage before and after primer extension, respectively. The 
smooth lines represent the global fit to the entire data set according to Scheme 4.1. 
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The comprehensive mechanism showed in Scheme 4.1 was derived as a minimal 
model to account for the data. First, neither the 25mer primer (Figure 4.3A, red curve) 
nor the 45mer RNA template (Figure 4.3B, red curve) were decayed with a single fast 
rate, suggesting the existence of a nonproductive form of RT-DNA/RNA complexes 
(XD25R45). Second, the amplitude of the fast phase of 25mer consumption (from 
polymerization) was approximately the same as the sum of amplitudes of the fast and 
slower phases of 45mer depletion (RNase H), suggesting that a fraction of polymerase-
competent RT-DNA/RNA complexes were not active for RNase H cleavage (YD25R45) 
and the slower phase of 45mer consumption was due to the delayed switch from the 
inactive form (YD25R45) to the active form (ED25R45). Our data also clearly supported the 
existence of the bifunctional form of RT-DNA/RNA complexes that could perform both 
activities simultaneously (ED25R45). Equilibrium between the three species were 
determined by the ratios of the amplitudes: the ratio of amplitudes of fast and slower 
phases of TTP incorporation determined the equilibrium between the polymerase active 
and inactive forms (YD25R45 + ED25R45, 70%; XD25R45, 30%), whereas the ratio of 
amplitudes of fast and slower phases of RNA cleavage determined the equilibrium 
between the bifunctional and polymerase-only forms (ED25R45, 43% ; YD25R45, 27%). 
Rates of conversions among those species were listed in Scheme 4.1 and Table 4.2. The 
results showed that conversions between the active and inactive forms were very slow, 
with the forward and reverse rates of ~0.014 and ~0.012 s-1, respectively. The 
polymerase-only form (YD25R45) switched to the bifunctional form (ED25R45) at a rate of 
0.5 s-1, which was in good agreement with the rate of slower phase (0.5 ± 0.1 s-1) 
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obtained from the conventional fitting of the cleavage data (Figure 4.1D). Incorporation 
rates were determined as 105 s-1 for correct base pairing and 1.4 s-1 for formation of a 
mismatch (27mer). Rates of RNA cleavage before primer extension were 20 s-1 at 
position -18 and 3 s-1 at position -17, consistent with the strong bias towards -18 cleavage 
observed in the control experiment (Figure 4.2). Rates of RNA cleavage after primer 
extension were 5, 4, 2.5, and 1.5 s-1 for cleavages at positions -18 to -15, respectively. 
The sum of all rates in a branched pathway yielded rates of RNA cleavage before and 
after primer extension as 23 and 13 s-1, respectively. Therefore, the observed rate of 17 ± 
2 s-1 determined from the conventional fitting (Figure 4.1D) appears to be a composite 
rate combining these two reactions. Secondary cuts also occurred since cleavage products 
corresponding to position -18 increased with time at the beginning but eventually 
decreased (Figure 4.3B and D, green curves), the rate of which, however, was much 





Scheme 4.1 Simultaneous TTP Incorporation and RNA Cleavage.  
A minimal model for simultaneous TTP incorporation and RNA cleavage is shown above. 
Three different RT-DNA/RNA complexes were identified and included in the model: 
XD25R45 (inactive), YD25R45 (polymerase active only), and ED25R45 (polymerase and 
RNase H both active). These three species underwent slow but reversible inter-
conversion. Both YD25R45 and ED25R45 could extend the 25mer substrate to the 27mer 
product (including one mismatch incorporation). RNA cleavage was able to occur before 
(ED25R45) or after (ED26R45) primer extension, yielding products with various lengths 
ranging from 35mer to 38mer. In order to describe the complicated process as completely 
as possible, secondary cuts (e.g., ED25R38 to ED25R37) and nucleotide incorporation after 
template degradation (e.g., ED25R38 to ED26R38) were also included in the model. Rate 





Similar data analysis was performed for RNA cleavage during ddTTP 
incorporation (Figure 4.4), in order to explore the effect of a slower polymerization rate 
on the RNase H activity. Rate constants governing the equilibrium between various RT-
DNA/RNA complexes, nucleotide incorporation, and RNA cleavage were derived from 
the global data fitting and summarized in Scheme 4.2 and Table 4.2. Similar to our 
analysis of TTP incorporation, the nonproductive (37%), polymerase-competent only 
(22%), and bifunctional species (41%) of RT-DNA/RNA complexes were also identified. 
The rate of ddTTP incorporation was determined as 5 s-1, which was consistent with the 
number obtained from conventional fitting (5 ± 0.3 s-1). The rate of RNA cleavage prior 
to ddTTP incorporation was 11.8 s-1, equal to the sum of 9.6 and 2.2 s-1 to form -18 and -
17 cleavages, respectively. A net rate of 8.4 s-1 was determined for RNA cleavage after 
primer extension, with comparable rates derived for cleavages at various positions (-18: 
1.8 s-1, -17: 2.4 s-1, -16: 2 s-1, and -15: 2.2 s-1). The cleavage rates were also consistent 
with the number (12 ± 0.7 s-1) derived from the conventional fitting (Figure 4.1D). Again, 
the secondary cuts occurred at very slow rates of ~0.01 and 0.05  s-1, respectively.  
Our global data analysis demonstrated that nucleotide incorporation and RNA 
cleavage occur simultaneously under single-turnover conditions, and we have defined the 
fraction of RT-DNA/RNA complexes that had the substrate engaged at both active sites. 
Also, RNA cleavage could take place at the same time as nucleotide incorporation even if 
rates of the two activities were comparable, which disproved the sequential model where 
one active center acted faster and therefore could have accomplished its tasks prior to the 
second catalytic center. Moreover, we show the coincident appearance of multiple 
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cleavage bands, providing evidence for some plasticity in the location of the cleavage site. 
For example during incorporation of either TTP or ddTTP, we see the nearly equal 
formation of -18 and -17 cleavage products, but see no evidence for the cleavage at 
position -18 before and at -17 after nucleotide incorporation (Figure 4.1B). Note that our 
nomenclature for naming the cleavage site is static (Figure 4.1A), so that after primer 
extension, cleavage 18 base-pairs from the new primer terminus results in a -17 product, 
numbered based upon the starting material. This nomenclature was chosen so that a given 
band is consistently named even when we do not know the primer length during a given 





Scheme 4.2 Simultaneous ddTTP Incorporation and RNA Cleavage. 
The minimal model for simultaneous ddTTP incorporation and RNA cleavage is shown 
above. Three different RT-DNA/RNA complexes were identified and included in the 
model: XD25R45 (inactive), YD25R45 (polymerase active only), and ED25R45 (polymerase 
and RNase H both active), which underwent slow but reversible inter-conversion. Both 
YD25R45 and ED25R45 could extend the 25mer substrate to the dideoxy-terminated 26mer 
product (mismatch extension was blocked). RNA cleavage was able to occur before 
(ED25R45) or after primer extension (ED26ddR45), yielding products with various lengths 
ranging from 35mer to 38mer. In order to describe the complicated process as completely 
as possible, secondary cuts (e.g., ED25R38 to ED25R37) and nucleotide incorporation after 
template degradation (e.g., ED25R38 to ED26ddR38) were also included in the model. Rate 






Figure 4.3 Global Data Fitting of TTP Incorporation and RNase H Cleavage. Data for 
TTP incorporation (A) and concomitant RNase H cleavage (B) were analyzed by global 
data fitting. Two control experiments were performed to measure the RNase H activities 
of HIVRT against substrates before (C) or after (D) primer extension. Briefly, pre-formed 
RT-DNA/RNA complexes (175 nM of HIVRT and 75 nM of d25/r45 (C) or d26/r45 (D) ) 
were rapidly mixed with 10 mM Mg2+, in the absence of any nucleotides. All the data 
were fit to a single model using KinTek Explorer to derive the rate constants summarized 
in Scheme 4.1 and Table 4.2. Smooth lines in each panel represent the best fit to the 
model. Each band was quantified individually so more information can be derived from 
the global fitting. Color codes: (A) 25mer primer, red; 26mer product, green; and 27mer 
product, blue. (B-D) 45mer RNA template, red; cleavage at position -18 (38mer), green; 
cleavage at position -17 (37mer), blue; cleavage at position -16 (36mer), yellow; and 




Figure 4.4 Global Data Fitting of ddTTP Incorporation and RNase H Cleavage. Data of 
ddTTP incorporation (A) and concomitant RNase H cleavage (B) were analyzed by 
global data fitting. Two control experiments were performed to measure the RNase H 
activities of HIVRT against substrates before (C) or after (D) primer extension. Briefly, 
pre-formed RT-DNA/RNA complexes (175 nM of HIVRT and 75 nM of d25/r45 (C) or 
d26ddT/r45 (D) were rapidly mixed with 10 mM Mg2+, in the absence of any nucleotides. 
All the data were fit to a single model using KinTek Explorer to derive rate constants 
summarized in Scheme 4.2 and Table 4.2. Smooth lines in each panel represent the best 
fit to the model. Each band was quantified individually so more information can be 







Table 4.2 Kinetic Parameters Governing Nucleotide Incorporation and RNase H 
Cleavagea 




























































a The lower and upper limits of each rate constant derived from confidence contour 
analysis of the simulation were included in the parenthesis. The nomenclature of rate 
constants was illustrated in Scheme 4.1 and 4.2. 
b Individual rate constant was not well defined by the data, as illustrated by the relatively 
wide range. The ratio of the two (the equilibrium constant), however, was well 
constrained. 
c Rate constants governing those slow reactions were not well defined by the data. 
Therefore, either a wide range or an upper limit is specified. 
 
Effects of Small Ligands on Polymerase-dependent RNase H Cleavage 
Previous structural analyses have suggested a ‘toggling’ model, where the bound 
substrate must toggle between two active sites of HIVRT, probably through 
conformational changes (15, 51, 54, 153). However, a recent biochemical study provided 
data to argue against this mechanism based on observations that small molecule ligands 
capable of stabilizing the nucleic acid in the polymerase active site only affected the 
pattern but not the efficiency of RNA cleavage under single-turnover conditions (93). 
This issue was revisited here since a quantitative analysis of the previously published 
cleavage data was missing. In addition, a study performed with the substrate without 
sequence bias can be more definitive.  
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The pyrophosphate analogue PFA and next correct nucleotide (with dideoxy-
terminated primers) were previously reported to be able to stabilize the pre- or post-
translocated RT-DNA complexes (129, 158) and presumably could lock the nucleic acid 
substrate in the DNA polymerase active site. Effects of these ligands on polymerase-
dependent RNase H activities were explored with various DNA/RNA hybrids containing 
25mer or 26mer primers, in the absence or presence of ligands (Figure 4.5A and B). 
When 25mer primers were examined, predominant cleavage products accumulated at 
position -18 in the absence of a ligand, whereas PFA shifted more than half of the 
cleavages towards position -19, and saturating concentration of TTP biased the cleavage 
toward position -18, with minor products formed at position -17 (Figure 4.5A). Despite 
different cleavage patterns, the cleavage efficiencies remained almost unchanged by the 
ligands (Figure 4.5C). Rates of cleavage in the absence of ligands, in the presence of PFA, 
or using ddAMP-terminated primer with TTP were determined as 11.3 ± 1.4 s-1, 9.4 ± 0.8   
s-1, and 13.4 ± 3.5 s-1 for the fast phase, and 0.4 ± 0.07 s-1, 0.4 ± 0.06 s-1, and 0.6 ± 0.2 s-1 
for the slower phase. The data clearly disagreed with the toggling mechanism postulating 
that the engagement of the substrate at the polymerase active site will lead to the 
exclusive cleavage at a single position in the RNase H site. Rather multiple cleavage 
bands appeared which also differed in comparing 25 and 26 nt primers. We also noted 
secondary, slower cleavage events which we attributed to the conversion of YD25R45 to 
ED25R45 (Scheme 4.1 and 4.2), the rate of which also remained the same, suggesting that 
ligands binding to the polymerase site did not affect the rates of conversion from 
nonproductive to productive states. 
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Similar conclusions can be drawn from the data obtained with DNA/RNA hybrids 
containing 26mer primers although different cleavage patterns were observed (Figure 
4.5B and D). The DNA 3’-end-directed RNA cleavage failed to strictly follow the 
translocation status of RT when 26mer primers were used: in the absence of ligands, 
cleavage products accumulated at 4 distinct positions (from -18 to -15) instead of two that 
are characteristic of the pre- and post-translocation stages. In the presence of PFA, 
positions of cuts reduced to 2, namely, -18 and -17. Whereas the next cognate nucleotide 
(dCTP) was unable to lock RT-DNA/RNA complexes at the post-translocation stage and 
yielded two major bands at positions -17 and -16. Consequently, RNA cleavage assays 
were not an ideal method to study translocational dynamics of RT on DNA/RNA hybrids 
even if sequence biases are avoided as in this study. Similarly, rates of RNA cleavage 
were not affected by the ligands, which were 10.2 ± 1.9 s-1, 8.8 ± 0.7 s-1, and 10.3 ± 1.9  
s-1 for the fast phase, as well as 0.4 ± 0.13 s-1, 0.3 ± 0.08 s-1, and 0.5 ± 0.13 s-1 for the 












Figure 4.5 Effects of Small Ligands on Polymerase-dependent RNase H Activity. RNA 
cleavage assays were performed by mixing preformed RT-DNA/RNA complexes (175 
nM of HIVRT and 75 nM of d25(ddA)/r45 (A) or d26(ddT)/r45 (B)) with 10 mM Mg2+, 
with or without small ligands. (A) RNase H activities were studied in the absence of any 
ligands, in the presence of 1 mM PFA, or using ddAMP-terminated primer with next 
correct nucleotide (0.5 mM TTP). Reactions were stopped by adding of 0.5 M EDTA at 
various time points up to 10 s. The 45mer RNA template and RNase H cleavages at 
positions -19 to -17 are indicated. (B) Similar experiments using 26mer primers were 
performed in the absence of any ligands, in the presence of 1 mM PFA, or using ddTMP-
terminated primer with next correct nucleotide (0.5 mM dCTP). The 45mer RNA 
template and RNase H cleavages at positions -18 to -15 are indicated as well. Cleavage 
data obtained with d25(ddA)/r45 (C) or d26(ddT)/r45 (D) hybrids were analyzed by 
conventional data fitting. The insets better display data points up to 1 s. (C) Cleavage 
data were fit to the double-exponential equation to derive cutting rates measured in the 
absence of ligands, in the presence of PFA, or using 25ddA with TTP as 11.3 ± 1.4 s-1, 
9.4 ± 0.8 s-1, and 13.4 ± 3.5 s-1 for the fast phase, as well as 0.4 ± 0.07 s-1, 0.4 ± 0.06 s-1, 
and 0.6 ± 0.2 s-1 for the slower phase. (D) Similarly, rates of RNA cleavage using 26mer 
primers were determined as 10.2 ± 1.9 s-1, 8.8 ± 0.7 s-1, and 10.3 ± 1.9 s-1 for the fast 
phase, as well as 0.4 ± 0.13 s-1, 0.3 ± 0.08 s-1, and 0.5 ± 0.13 s-1 for the slower phase. 
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Effects of Mutations Causing Impaired TTP Induced Conformational Change on 
RNase H Activity 
	  
Previous studies of HIVRT revealed that the binding of the correct nucleotide 
could induce large conformational changes in structure from an open to a closed complex 
(35, 47), which was later shown to govern the specificity by HIVRT (86). However, 
whether this crucial conformational change at the polymerase domain affects RNase H 
activity and/or specificity remains unknown. Here, the activity and specificity of RNA 
cleavage were examined using three RT mutants (W71A, W71D, and R72A) that were 
characterized to be able to impair the nucleotide induced isomerization step. The kinetic 
characterization of the R72A mutant is shown in Chapter 6. Briefly, the kinetic pathway 
of nucleotide incorporation was quantified by pre-steady-state kinetics together with 
global data analysis. Then, the extent to which each mutation affected the conformational 
change step was determined by evaluating the change of the equilibrium constant 
governing the isomerization step (K2 = k2/k-2). The results revealed that the R72A 
mutation had the most adverse effect and impaired the isomerization step by 170-fold. 
Similarly, W71A and W71D mutations were revealed to disfavor the conformational 
change step by 12 and 35-fold, respectively (Jiawen Li, unpublished results).  
Despite the notable influences on the nucleotide induced conformational change, 
those mutations had modest or no effect on the activity and specificity of RNA cleavage 
(Figure 4.6). Similar to the WT protein, all the mutants yielded one major band 
corresponding to the cutting at position -18 (Figure 4.6A). However, observable cleavage 
products also accumulated at various positions, including -19, -17, -16 and -15. This was 
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more evident for W71A and W71D mutants, indicating these two RT mutants were 
probably less rigidly locked on the DNA/RNA hybrid. In our quantitative analysis, the 
W71A and W71D mutants showed nearly unchanged cleavage activities compared to the 
WT protein, with cleavage rates determined as 7.7 ± 1.3 s-1, and 8.1 ± 0.9 s-1 for the faster 
phase, as well as 0.2 ± 0.07 s-1, and 0.3 ± 0.04 s-1 for the slower phase (Figure 4.6B). The 
rate of the faster phase for R72A mutant was slightly reduced at 6.3 ± 1.2 s-1. Although 
the rate of the slower phase remained the same (0.3 ± 0.1 s-1), its amplitude decreased 
significantly. As analyzed above (Scheme 4.1 and 4.2), the second slower phase was 
corresponding to a conversion from an RNase H inactive form (YD25R45) to the active 
form (ED25R45), so R72A mutant might impair this process but did not affect the RNase 
H activity directly. Consequently, the nucleotide induced conformational change might 
play a role in structural rearrangements involved in conversions between the ‘poly-only’ 
and bifunctional species of RT-DNA/RNA complexes but did not directly affect the 
RNase H activity. These results further supported our ‘working simultaneously’ model 
and denied the competing model, in which the two active sites compete with each other to 
engage substrates and therefore impaired polymerization activity should have led to 





Figure 4.6 Effects of Mutations Causing Impaired TTP Induced Conformational Change 
on RNase H Activity. (A) RNA cleavage assays were performed by rapidly mixing 
preformed RT-DNA/RNA complexes (175 nM of HIVRT_W71A, W71D or R72A 
mutants and 75 nM of d25/r45 hybrid) with 10 mM Mg2+. Reactions were stopped by 
addition of 0.5 M EDTA at various time points in 10 s. The 45mer RNA template and 
RNase H cleavages at positions -18 to -15 were marked. (B) The Data of RNA cleavage 
by various RT mutants were analyzed by conventional fitting. The insets better display 
data points within 1 s. Cleavage data were fit to the double-exponential equation to derive 
rates of RNA cleavage by W71A, W71D or R72A mutants as 7.7 ± 1.3 s-1, 8.1 ± 0.9 s-1, 
and 6.3 ± 1.2 s-1 for the fast phase, as well as 0.2 ± 0.07 s-1, 0.3 ± 0.04 s-1, and 0.3 ± 0.1   






Efficient RNase H Cleavage Requires at least 4 Nucleotides downstream of  the 
Cutting Site 
	  
How can the two active sites of HIVRT work simultaneously with different 
speeds was then examined. Previous studies have suggested that the RNase H activity of 
HIV RT acted as an endonuclease with partial 3’-5’ processivity (159-160), which was 
consistent with our observations that the secondary cuts (38 to 37mer, ~0.05 s-1) were 30- 
to 380-fold slower than the primary cuts (1.5 to 20 s-1, Scheme 4.1). Based on these 
results, a hypothesis was proposed that a minimum length of RNA strand extending from 
the 3’-end to the cutting site was required for efficient DNA 3’-end-directed RNA 
cleavages, probably ensuring a proper alignment of the hybrid substrate near the RNase H 
active site. Under this scenario, the processive RNA cleavage was largely prohibited and 
a next round of cleavage would occur only when the cutting site shifted towards the 5’ 
end of the RNA strand along with multiple nucleotide incorporation events that could 
regenerate a downstream RNA strand long enough for the proper alignment of substrates. 
In order to test this hypothesis, a series of DNA/RNA hybrids were made by 
annealing primers with various lengths onto a radioactive-labeled 45mer RNA template 
with random sequence (Figure 4.7B). RNA cleavage assays were then performed with 
these hybrids. When the d25rd/r45rd hybrid was examined, two major cleavage products 
were noticed at position +7 and +8. A new nomenclature of cutting positions were 
applied here to better illustrate the number of nucleotides extending from the 3’ end of 
the RNA strand to the cleavage site. Theoretically, shortening the primer by one 
nucleotide will shift the cleavage site accordingly by one nucleotide towards the 3’ end of 
145	  
	  
the RNA strand. The real data, however, did not follow this rule strictly (Figure 4.7A and 
B). Shortening the primer by 1 to 3 nucleotides all resulted in cleavages at positions +4 
and +5, but with different biases. For the d24rd/r45rd hybrid, cleavages products 
accumulated almost exclusively at position +5, whereas experiments performed with 
d23rd/r45rd and d22rd/r45rd hybrids showed a strong bias towards +4 cleavage. Further 
shortening the primer by 1 or 2 nucleotides (21 or 20mer) nearly eliminated the cleavage 
activity, yielding faint bands at positions +4 and +5, as well as almost negligible bands at 
position +2. These data supported the idea that at least 4 nucleotides downstream of the 
cutting site (towards the 3’ end of the RNA strand ) were necessary for efficient RNA 
cleavage to occur. As shown in Figure 4.7C, cleavage data were fit to the single-
exponential equation to derive cleavage rates as 5±0.4 s-1, 8.8±1.7 s-1, 22.8±3.8 s-1, 
26.7±2.5 s-1, 13.4±0.7 s-1, and 15.3±2.4 s-1 for DNA/RNA hybrids with lengthening 
primers. Corresponding reaction amplitudes were determined as 16.2±0.4, 18.5±1, 
33.5±1.1, 40±1, 33±0.4, and 31.7±1.2, respectively. The quantitative analysis of the 
cleavage data also revealed that both cleavage rates and amplitudes reduced significantly 
when the number of nucleotides extending from the 3’ end of the RNA strand to the 
cutting site was less than 4. Consequently, a next round of RNA cleavage would not 
occur until the incorporation of at least 4 nucleotides, which might account for the fact 
that the processive template degradation was not observed in previously performed RNA 













Figure 4.7 Efficient RNase H Cleavage Required at least 4 Ribonucleotides downstream 
of the Cutting Site. (A) RNA cleavage assays were performed by rapidly mixing 
preformed RT-DNA/RNA complexes (175 nM of HIVRT and 75 nM of DNA/RNA 
hybrids (the 45mer RNA template was annealed with primers of lengths ranging from 20-
25 nucleotides) with 10 mM Mg2+. Reactions were stopped by adding 0.5 M EDTA at 
various time points up to 1 s. The position of the uncleaved 45mer RNA template was 
marked as 0. Different from the nomenclature previously used in this chapter, positions 
of RNA cleavage products were marked as positive numbers here by counting the 
number of ribonucleotides from the 3’-end the RNA template to the cutting site. As 
shown in panel A and B, cleavage sites shifted from +8/+7 to +5/+4 when lengths of 
primers decreased from 25 to 20 nucleotides. Negligible bands were observed at position 
+2 in cases of 20 and 21mer. (B) The cleavage sites were illustrated in a cartoon, where 
thick or light arrows represented cutting sites for major or minor cleavage products, 
respectively. Short and light arrows indicated the site where negligible cleavage occurred. 
(D) Cleavage data were fit to the single-exponential equation to derive cleavage rates as 5 
± 0.4 s-1, 8.8 ± 1.7 s-1, 22.8 ± 3.8 s-1, 26.7 ± 2.5 s-1, 13.4 ± 0.7 s-1, and 15.3 ± 2.4 s-1 for 
DNA/RNA hybrids with lengthening primers. Corresponding reaction amplitudes were 
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RNase H Cleavage during Processive Nucleotide Incorporation 
RNase H activities during processive nucleotide incorporation were also explored 
to further examine the mechanism by which the two catalytic sites of HIVRT were able 
to work simultaneously but at different rates. As shown in the left panel of Figure 4.8A, 
the 25mer primer was extended continuously to the full-length 45 nt product, with 
markers to indicate intermediates with one nucleotide increments. Whereas 
polymerization is a continuous process at a nearly constant rate, the RNA cleavage 
activity appears to be discontinuous, supporting our previous hypothesis that at least 4 
nucleotides downstream of the cutting site were necessary for efficient RNA cleavage. As 
we expected, the first round of template degradation started at position +7 with minor 
bands spreading to position +10 (corresponding to positions -18 to -15 in our previous 
nomenclature). Incorporation of 9 nucleotides shifted the cutting site accordingly by 9 
nucleotides towards the 5’ end of the RNA strand, which triggered the second round of 
RNA cleavage at position +16, with only negligible bands formed between the two 
rounds of cleavage. Similarly, after the incorporation of 4 and 5 nucleotides, the third and 
fourth rounds of RNA cleavage started at positions +20 and +25, respectively. On 
average, the RNA cleavage occurred repeatedly each time after ~6 nucleotides were 
incorporated. 
The incorporation and cleavage data were then fit globally, but in an alternative 
way due to the complexity of the data, as described in the materials and methods. Briefly, 
the incorporation data were first analyzed according to Scheme 4.3 (Figure 4.8B) to 
derive the rate constants governing the incorporation of each nucleotide: 94±6, 19±1, 
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33±3, 30±4, 19±2, 35±8, 36±10, 43±15, 27±6, 29±8, 20±5, 23±7, 36±18, 21±7, 26±12, 
21±10, 29±20, 36±34, 20±13, and 10±5 s-1, respectively. The average incorporation rate 
of the 2nd to 9th nucleotides was 27.2±2.7 s-1. When the eight-step incorporation was 
simplified kinetically to a one step process as we did in Scheme 4.4 (+N8), its apparent 
net incorporation rate was approximately determined by (27.2±2.7)/8 =3.4±0.3 s-1. 
Similarly, apparent incorporation rates for ‘+N4’ and ‘+N5’ were determined as 6.3±1.3 
and 5±1.7 s-1, respectively.  
 
Scheme 4.3 Processive Nucleotides Incorporation 
	  
 
           
These rates were then applied to constrain the simulation of RNA degradation 
data according to Scheme 4.4 (Figure 4.8C). The comprehensive model shown in Scheme 
4.4 was derived based on the data and our rule of deriving a minimal model. At the 
beginning, RT-DNA/RNA complexes were equilibrating between the RNase H active 
form (ED25R45) and inactive forms (X(Y)D25R45), with the forward and reverse rates as 
0.05 and 0.03 s-1. Then, the ED25R45 complex underwent RNA cleavage before or after 
TTP incorporation to yield the 38mer products while the cleaved substrates were still 
extended. Rates of TTP incorporation (105 s-1) and RNA cleavage prior to primer 
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extension (23 s-1) were determined previously (Figure 4.3) and fixed in the simulation to 
reduce the number of variable parameters. After TTP incorporation, the ED26R45 species 
faced a kinetic partitioning between the RNA cleavage (ED26R38) and multiple nucleotide 
incorporation (ED34R45). In order to simplify the model, the incorporation of 8 
nucleotides was expressed as only ‘one’ step (+N8), which resulted in an apparently 
‘slow’ rate of incorporation as 3.4±0.3 s-1. Consequently, the rate of RNA cleavage after 
TTP incorporation was also slower as 4.4 s-1, compared with the 13 s-1 we determined 
previously (Figure 4.3). After the incorporation of 8 nucleotides, the second round of 
RNA cleavage occurred, yielding 29mer cleavage products. The cleavage reactions could 
start from ED34R45 (0.06 s-1) or ED34R38 (4.8 s-1) complexes, but the latter was the 
kinetically dominant pathway, as indicated by the rapid decrease of 38mer products after 
an initial accumulation (Figure 4.8C, green curve). Similarly, the cleavage rate 
determined here (4.8 s-1) was constrained by the kinetic partitioning between RNA 
cleavage and the next round of multiple nucleotide incorporation events (+N4) at an 
apparent rate of 6.3 ± 1.3 s-1. Then, the third round of RNA cleavage could start from 
three substrates, namely, ED38R45 (4.4 s-1), ED38R38 (0.06 s-1), and ED38R29 (0.06s-1). 
Since the amount of 29mer cleavage products remained almost constant after its peak 
value (Figure 4.8C, blue curve), the observed 25mer products was not due to a secondary 
cut of the 29mer products. Therefore, cleavage starting form ED38R45 became the main 
pathway at this time. The final round of RNA cleavage occurred after the incorporation 
of another 5 nucleotide (+N5) at a rate of 5 ± 1.7 s-1. Cleavage reactions started from 4 
precursors, including ED43R45 (4.4 s-1), ED43R38 (0.4 s-1), ED43R29 (0.06 s-1), and ED43R25 
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(0.06 s-1). Cleavages of the 45mer RNA precursor (ED43R45) remained the dominant 
kinetic pathway since the amounts of both 29mer and 25mer cleavage products were 
almost unchanged after their initial formation (Figure 4.8C, blue and yellow curves). 
Cleavage of the ED43R38 precursor corresponded to the slower phase of the disappearance 
of the 38mer products after the initial rise (Figure 4.8C, green curve) at a rate of 0.4 s-1.  
The average rate of nucleotide incorporation was ~28 s-1 (except for TTP). 
However, the 6-fold slower apparent rates were applied in the simulation based on the 
simplified model. In order to maintain the same kinetic partitioning between RNA 
cleavage and nucleotide incorporation activities in a complete model, the average rate of 
RNA cleavage after TTP incorporation could be approximately determined by 4.5×6 = 27 
s-1. Consequently, under processive nucleotide incorporation conditions, the two catalytic 
centers of HIVRT could work simultaneously with the same pace. And the discontinuous 
RNase H activities observed in this study were due to the fact that at least 4 nucleotides 
downstream of the cutting site were required for efficient RNA cleavage to occur. 
 
Table 4.3 Kinetic Parameters Governing RNase H Cleavages during Processive 
Nucleotide Incorporationa 













a The lower and upper limits of each rate constant derived from confidence contour 
analysis of the simulation were listed in the parenthesis. The nomenclature of rate 















Figure 4.8 RNase H Cleavage during Processive Nucleotide Incorporation. (A) RNase H 
activities during processive nucleotide incorporation were explored by performing RNA 
cleavage assays in the presence of all four nucleotides (100 µM). The procedures were 
the same as described previously except that data were collected for 20 s to allow full 
extension and multiple rounds of cleavage to occur. In order to avoid overlaps of bands 
for extension and cleavage products, the two activities were assayed in parallel as 
described above. Positions for the primer (d25), primer extended by one nucleotide (d26), 
and fully extended product (d45) were marked. The same nomenclature as used in Figure 
4.8 was applied here to label positions of full length RNA template (0) and cleaved 
products. Positions for the longest cleavage products formed during each round of 
degradation were marked as +7, +16, +20, and +25. The numbers of nucleotides 
incorporated before each round of RNA degradation were also labeled as 9, 4, and 5, 
respectively. (B) Time courses of processive nucleotide incorporation were simulated 
according to Scheme 4.3, with smooth lines indicating the best fit. Only data within 1 s 
were showed to better display the main content of the data and avoid the long non-zero 
tails of fitting curves. The fitted rates for sequential polymerization steps were 94±6, 
19±1, 33±3, 30±4, 19±2, 35±8, 36±10, 43±15, 27±6, 29±8, 20±5, 23±7, 36±18, 21±7, 
26±12, 21±10, 29±20, 36±34, 20±13, and 10±5 s-1, respectively. The apparent 
incorporation rates for ‘+N8’, ‘+N4’, and ‘+N5’ were then determined as 3.4±0.3, 
6.3±1.3, and 5±1.7 s-1, respectively. (C) The apparent incorporation rates obtained from 
panel B were used in the global analysis of time courses of RNA cleavage according to 
Scheme 4.4. Apparent incorporation rates and fitted rates for each round of RNA 
degradation were summarized in Scheme 4.4 and Table 4.3. Color codes: red, 45mer 
RNA template; green, 1st cleavage (38mer); blue, 2nd cleavage (29mer); yellow, 3rd 





HIV reverse transcription is a complex process that converts the single-stranded 
RNA genome of the virus into the double-stranded DNA (161). This process requires a 
close coordination of the three functions of HIVRT: DNA- and RNA-dependent 
polymerase and RNase H, such that the RNase H activity needs to concomitantly degrade 
the RNA genome during minus-strand DNA synthesis. Therefore, an exploration of the 
potential coordination between the two active sites of HIVRT is of great importance for a 
better understanding of reverse transcription. Despite the abundance of structural and 
biochemical data, whether these two catalytic centers can work simultaneously still 
eludes researchers in this field. In this study, the RNase H activity during single-
nucleotide incorporation was first examined and the results revealed the existence of RT-
DNA/RNA complexes that were able to perform primer extension and template 
degradation activities simultaneously. However, it has been widely accepted that 
polymerase and RNase H activities coordinate spatially but not temporally since the rate 
of polymerization is approximately 7-fold faster than RNA cleavage (20). The RNase H 
activity during processive nucleotide incorporation was then examined and the results 
revealed that the processive polymerization was limited by the slow PPi release (Chapter 
5) whose rate was comparable to RNase H cleavage. Under this scenario, the two 
catalytic centers can coordinate smoothly and harmoniously.  
The potential coupling between the two active sites of HIVRT was first explored 
under single-turnover conditions. Three distinct modes of RNase H cleavage have been 
described, namely, the DNA 3’-end-directed, RNA 5’-end-directed, and the internal 
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cleavages, all of which played important roles in the reverse transcription  (18). And the 
substrates used in this research were designed to study the first mode of RNA cleavage 
since the remaining two modes do not involve the polymerization activity. Nucleotide 
sequence preferences in the vicinity of the cleavage site are another major concern as 
previous studies indicated that the DNA 3’-end-directed RNA cleavages occurred within 
a window of ~6 nucleotides centered on the predicted distance (20-21, 92, 98, 101, 162-
163). In order to remove the sequence biases, the nucleotides near the predicted cleavage 
sites were replaced by a string of Gs since A tracts are straight and stiff and appear to 
contribute to the resistance of the PPT to cleavage (15).  
The incorporation and cleavage data were analyzed by both conventional and 
global data analysis, and the rate constants obtained from both methods were consistent, 
supporting the validity of the model chosen to fit the data globally. The only exception 
was that the rate constant governing the conversion of XD25R45 to YD25R45 (~0.012 s-1, k2 
in Scheme 4.1) was much slower than the rate of slower phase (2±0.8 s-1) derived from 
the conventional fitting of the incorporation data (Figure 4.1C) and had a half-time of 
~60 s. Consequently, the slower phase of TTP incorporation measured within 10 s might 
mainly reflect the dissociation and rebinding of the DNA/RNA hybrid substrate (~0.3 s-1); 
this was supported by the fact that the second slower phase almost disappeared when 
heparin trap was added to prevent rebinding (data not shown). This rationale also 
explained why individual parameters k1 and k2 (Scheme 4.1) were not well constrained in 
the confidence contour analysis although their ratio was constant and accurately 
determined by the simulation (Table 4.2), and a measurement of longer timescale would 
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help to better define those two rates. During ddTTP incorporation, the corresponding rate 
of conversion (XD25R45 to YD25R45) was ~0.04 s-1 (k2 in Scheme 4.2) with a shorter half-
time (~15 s) and therefore the rate constant was better defined by the data and was well-
constrained in the simulation. On the other hand, the slower phase of RNA cleavages 
(Figure 4.1D) still existed even in the presence of heparin albeit with a slightly reduced 
amplitude (data not shown), suggesting that the second phase probably involved both the 
substrate dissociation (and rebinding), as well as the conversion to the RNase H 
competent species (YD25R45 to ED25R45). Since the former  (~0.3 s-1) was defined by the 
burst experiment (data not shown) and locked in the simulation, parameters governing 
this conversion were well-constrained in the confidence contour analysis. Actually, most 
of the parameters were well-defined by our models, as illustrated by the narrow ranges of 
rate constants listed in Table 4.2. Few exceptions were observed for slow reactions, 
including the mismatched extension and secondary RNase H cleavages. 
Three distinct RT-DNA/RNA complexes were identified in the simulation, 
including the bifunctional, polymerase active only, and inactive forms. Although active 
site titration was always performed prior to the assays, 30% or 37% of the RT-
DNA/RNA complexes were not active for TTP or ddTTP incorporation in this study. 
Results of native gel analysis revealed that the DNA primers were in slight excess over 
the RNA templates in our hybrid substrate, and the numbers reported here were corrected 
for the interference from free primers. When a DNA/DNA duplex was used, the 
percentage of nonproductive complexes reduced to ~20% but the 100% activity has never 
been achieved no matter a DNA or RNA template was to be used. HIVRT was reported 
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to adopt dynamic binding orientations on the nucleic acid substrates and could switch 
between these orientations for different functions (96), so the inactive complexes 
identified here might reflect some nonproductive intermediates which have always been 
observed in quantitative studies on HIVRT polymerization kinetics (53, 77, 86, 164).    
Extensive interactions between the nucleic acid substrate and the polymerase 
domain (35) of RT would help to tightly hold the primer 3’ end at the polymerase active 
site. Such interactions, however, appear to be fewer in number in the RNase H site 
domain (51), which might allow the substrate to temporarily swing into then out of the 
RNase H active site, without affecting contacts at the polymerase site (93). Consequently, 
part of the polymerization competent RT-DNA/RNA complexes did not exhibit RNase H 
activity (YD25R45). Around 40% of RT-DNA/RNA complexes were able to perform 
RNase H cleavage while ~70% were extending the primer. Thus, the sum of the two 
activities exceeded 100%, providing evidence for the existence of bifunctional enzyme-
nucleic acid complexes capable of simultaneous polymerization and RNase H hydrolysis. 
If the non-productive forms were excluded from the analysis, we computed that >40% of 
the RT-DNA/RNA complexes could perform both activities simultaneously. 
HIVRT on a nucleic acid substrate is in a dynamic equilibrium between the pre- 
and post-translocation states (129). The molecular details of translocation remains elusive 
but its equilibrium could be adjusted by small-molecule ligands. For example, the PPi 
analogue PFA may be able to trap the pre-translocation state of HIVRT (158) while the 
next cognate nucleotide could stabilize the post-translocation complex. Previous kinetic 
studies have shown that the RNase H activity can be inhibited by these two ligands under 
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steady-state conditions (93, 95, 162), indicating that DNA/RNA hybrids stabilized at the 
polymerase active site were not able to engage the RNase H site simultaneously. 
However, these steady state results could be explained by the effect of the ligands in 
slowing the rates of dissociation and rebinding of the DNA/RNA duplex, and a recent 
study revealed that the binding of PFA did not affect the efficiency of RNase H cleavages 
under single-turnover conditions (93). This issue was revisited in this study using various 
substrates without nucleotide sequence preferences and the results supported the 
conclusion that the DNA/RNA hybrid could engage both active sites simultaneously 
since the ligands capable of stabilizing the polymerase-competent mode did not inhibit 
the RNase H activity. Although the cleavage patterns were affected by these ligands, they 
did not follow the predicted modes, especially when the 26mer primers were tested 
(Figure 4.5B). In the absence of any ligands, RNase H cleavages occurred at 4 distinct 
positions, ranging from -18 to -15. Since previous studies have suggested that the RNase 
H activity of HIVRT acted as an endonuclease with partial 3’-5’ processivity (159-160), 
cleavages at position -16 and -15 might reflect secondary cuts of the 38/37mer cleavage 
products (-18/-17). However, the global data analysis revealed that only the 38mer 
products (-18) underwent negligible level of secondary cleavages (~0.05 s-1). Meanwhile, 
comparable rates were derived for cleavages at positions -18 to -15 (1.5~5 s-1, Scheme 
4.1), so the 36/35mer cleavage products were not due to processive, sequential cleavage 
events; rather they resulted from two independent events. The results were consistent 
with previous observations that the DNA 3’-end-directed RNA cleavages occurred within 
a window of ~6 nucleotides centered on the predicted distance (corresponding to position 
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-20 to -15) (20-21, 92, 98, 101, 162-163). Removal of the nucleotide sequence preference 
only narrowed down the cleavage window to 4 nucleotides, and this low level of 
specificity is probably due to the lack of a structural element around the RNase H active 
site required to bind the DNA/RNA hybrid. Therefore, the RNase H site can temporarily 
slide back and forth on the substrate, which may be achieved through conformational 
changes of the DNA/RNA hybrid (51). Consequently, the RNase H assay is not a reliable 
method to measure the equilibrium of translocation stages since cleavages did not occur 
at the fixed distances reflecting the translocation state but rather within a ‘cleavage 
window’ that is 4 nucleotides long. In addition, both PFA and the next correct nucleotide 
failed to lock the enzyme-nucleic acid complex in a fixed translocation state. 
The nucleotide-induced conformational change is a crucial step during nucleotide 
incorporation and was proposed to govern the specificity and analog discrimination by 
HIVRT (86). However, whether this crucial conformational change affects RNase H 
activity and/or specificity remains unknown. Therefore, we examined how mutants with 
impaired rate and equilibrium constants governing the conformational change would 
influence RNase H cleavages. W71 was chosen to make the mutations since MD 
simulations of the conformational change step (58) suggested that this residue was an 
important contributor to the rate and free energy of the isomerization step. R72 interacts 
with the PPi moiety of the incoming nucleotide and the arginine to alanine substitution 
was reported to significantly impede the PPi release step (37). These three mutations have 
not been observed in NRTIs resistance-associated mutations, probably because they all 
play an import role in polymerization and therefore have high fitness costs. Our results 
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revealed that these mutations impeded the nucleotide-dependent conformational change 
step by 12, 35 and 170-fold, respectively. However, they did not affect the RNase H 
activity, although minor effects on the cleavage pattern were observed. R72A 
significantly reduced the amplitude of the slower phase during RNA cleavage, 
presumably by inhibiting substrate dissociation and/or the conversion to the RNase H 
active form (YD25R45 to ED25R45). These results further supported the ‘working 
simultaneously’ model and argued against the competing model, in which the two active 
sites compete with each other to engage substrates such that impaired polymerization 
activity should have led to enhanced RNase H activity or vice versa.  
Our data have suggested that the two catalytic centers of HIVRT work 
simultaneously and independently from each other, except for the obvious fact that 
continued polymerization provides new substrates for the RNase H active site. Our model 
also provides a possible explanation for the observation that mixing mutants deficient in 
either site could fully restore reverse transcription (95). However, substitutions at W266 
and F61 in HIVRT was able to affect the cleavage specificity and render the RNase H 
unable to generate/remove PPT primer (165-167), implying that the polymerase domain 
might directly involve in the RNase H specificity. 
The rate of polymerization was initially shown to be ~7-fold faster than the 
RNase H cleavage (20) and it was shown that the template was not degraded processively 
in RNA dependent extension assays (19). These observations provided the cornerstone of  
arguments against the ‘working simultaneously’ model. Consequently, the coordination 
between the two active sites was also explored under the processive synthesis condition 
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by pre-steady-state kinetics with global data analysis. Due to the complexity of the model, 
reactions with comparable rates were linked in the simulation to reduce the number of 
parameters to be determined. For instance, rates of RNA cleavage starting from 45mer 
precursors (ED26R45, ED38R45, and ED43R45, except ED34R45) were linked in the simulation. 
Similarly, minor reactions at each round of RNA cleavage were also linked (except 
ED43R38) and yielded a rate of 0.06 s-1. The biphasic decrease of 38mer products after 
their initial rise defined the rates governing the cleavage of ED34R38 and ED43R38 as 4.8 
and 0.4 s-1, respectively. Consequently, the simulation only needed to define 6 parameters 
despite the complexity of the model, which turned out to be all well-constrained (Table 
4.3). Since an enormous number of reactions occurred in the process, a simplified model 
had to be derived for the simulation. For example, multiple incorporation events between 
sequential rounds of RNA cleavage were ‘reduced’ to one kinetic step. This 
simplification, however, resulted in apparently slow rate of nucleotide incorporation, 
which could be problematic without a proper interpretation of the data. First, the ‘real’ 
average rate for polymerization approximately equals the apparent average rate of 
nucleotide incorporation (~4.7 s-1) multiplied by the average number of nucleotides 
incorporated (~6), which is ~28 s-1. Secondly, all non-dead-end species in the model face 
a kinetic partitioning between the polymerization and RNase H cleavage activities (e.g., 
ED26R45) and the ‘real’ polymerization rate is 6-fold faster than the apparent rate applied 
in the simulation. In order to maintain the same kinetic partitioning in a complete model, 
the average rate of RNase H cleavage derived from this simplified model (~4.5 s-1) also 
needs to be multiplied by 6 to approximately yield the ‘real’ rate of RNase H cleavage to 
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be ~27 s-1. Consequently, rates of polymerization and RNase H cleavage were 
comparable to each other. Our data now suggest a model in which processive 
polymerization at ~28 s-1 is coincident with RNase H activity also occurring at ~28 s-1 but 
only after every ~6 nucleotides. Thus, although the RNase H activity appears to be slower 
than polymerization, the rate of hydrolysis at each site is identical to the rate of 
polymerization. Accordingly, the RNase H produces products about 6 nucleotides in 
length, but does not impede the processive motion of the polymerase.  
Previous studies have noted that in single turnover experiments, polymerization 
with an RNA template is much faster than with a DNA template (20). Here we noted that 
the incorporation of the first nucleotide (~105 s-1) was much faster than subsequent 
events. These data suggested that the processive nucleotide incorporation was constrained 
by a rate-limiting step occurred after the chemistry step for the first nucleotide but before 
the binding of the next nucleotide. Further studies supported this rate-limiting step was 
the slow PPi release (Chapter 5). Starting from the second nucleotide, polymerization was 
no longer faster than RNase H cleavage, therefore these two activities could coordinate 
spatially and temporally. Under this circumstance, relative levels of these two activities 
were determined by their kinetic partitioning at each branch point. Therefore, the RNase 
H cleavage tended to occur when the extension paused (94), not because the two 
activities were mutually exclusive,  but because the kinetic partitioning strongly favored 
the cleavage activity when polymerization stalled. However, we also observed that 
template degradation was not processive, although polymerization was as fast as the 
RNase H cleavage. This is consistent with previous observations that the RNase H 
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activity of HIVRT acted as an endonuclease with only partial 3’-5’ processivity (159-
160).  
A recent crystal structure of HIVRT in complex with a DNA/RNA hybrid 
provided some structural basis for this periodical RNase H activity (51). First, there is no 
structural element of RT that continuously threads the RNA to the RNase H active site 
and conformation changes of the DNA/RNA hybrid induced by the sliding of RT along 
the duplex may be required for facilitating the RNA strand to reach the RNase H site. 
Secondly, the chelation environment and charge distribution at the RNase H active site 
changes after the cleavage reaction, which may force the cleaved RNA products to 
temporarily disengage from the RNase H site (51). Moreover, the results suggested that at 
least 4 nucleotides downstream of the cutting site were required for efficient RNA 
cleavage and therefore the next round RNase H cleavage would not occur until at least 4 
nucleotides were incorporated. The oligonucleotide with a minimum length of 4 
nucleotides extending from the 3’ end of the RNA strand to the cleavage site may help to 
thread the RNA strand to the RNase H active site, probably through interactions between 
the oligonucleotide segment and HIVRT near the RNase H site. These interactions, 
however, may not establish until the segment is long enough. The results also suggested a 
possible mechanism for HIVRT to prevent uncontrolled template degradation that may 
cause premature dissociation of the primer strand and termination of synthesis in advance. 
In summary, our results establish a mechanism by which polymerization and 
RNase H activities are coordinated by working independently at comparable rates but 
with different substrate specificity requirements. Binding of the duplex at the polymerase 
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active site affords processive synthesis due to the fast translocation and slow dissociation 
of the duplex from the enzyme such that the net rate is limited by slow pyrophosphate 
release. In contrast, the RNase H activity requires ~4 – 6 base pairs extending beyond the 
active site for optimal binding leading to fast rates of cleavage comparable to the rate of 
polymerization. Although the RNase H reaction is not very efficient at any one site, 
multiple opportunities for cleavage afford efficient net cleavage during processive 
synthesis. The inefficient RNase H reaction may, in fact, be an important feature of the 
enzyme activity so that the enzyme does not binding tightly to the DNA/RNA duplex at 
any one site since that would impede the movement of the duplex. Consequently, the 
polymerase and RNase H activities are seamlessly coordinated without the need for any 
direct communication between the two sites, other than the continuous movement of the 




Chapter 5: Rate-limiting Pyrophosphate Release by HIV Reverse 
Transcriptase and Its Effect on Enzyme Specificity 
	  
5.1 INTRODUCTION 
HIV-1 Reverse Transcriptase (HIVRT) is a DNA/RNA-dependent DNA 
polymerase that plays a central role during viral replication. It contains the polymerase 
and RNase H active sites that are ~60 Å away from each other. In Chapter 4, a rate-
limiting PPi release step was identified, which plays an important role in lowering the 
rate of processive synthesis and synchronizing the two catalytic centers during reverse 
transcription. However, questions remain as to how it would affect the kinetics of 
sequential single nucleotide incorporation events during processive synthesis. The slow 
PPi release has been observed in previous studies of human mitochondrial DNA 
polymerase when incorporating modified or mismatched nucleotides (89-91), where it 
served to reduce the specificity constant. In this chapter, we examine how the slow PPi 
dissociation affects the nucleotide selectivity by HIV-1 RT.  
Previous studies have demonstrated that a nucleotide-induced conformation 
change governs the HIV-1 RT specificity (86). Measurement of the rates of 
polymerization and pyrophosphate release in single turnover experiments with DNA 
templates showed that pyrophosphate (PPi) dissociation was fast following nucleotide 
incorporation so that it did not contribute to enzyme specificity (kcat/Km). In the current 
study, kinetic parameters governing nucleotide incorporation and PPi release were 
determined using an RNA template. 
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HIV-1 RT has been an important target for antiretroviral therapy due to its critical 
roles in reverse transcription (60-61). Nowadays, drug resistance associated mutations in 
the RT gene have been identified for all NRTIs approved by the US FDA (67). The low 
fidelity of HIV-1 RT has been proposed to make HIV-1 replication particularly error-
prone (168-169), allowing the virus to develop resistance to antiretroviral drugs rapidly 
(170). Indeed, the fidelity of HIV-1 RT has been reported to be 10-fold lower than the 
RTs from other origins (171-174). However, the true fidelity of HIV-1 RT and its relative 
contribution to the high sequence variation of HIV are still being debated. Fidelity 
measured in vitro using purified HIV-1 RT vary widely with different conditions (20, 52, 
169, 175-179), which, however, are typically in the 10-4 range (per nucleotide addition). 
But in vivo studies have reported mutation frequencies ranging from 1.4×10-5 to ~4×10-5 
per nucleotide per replication cycle (27-29), which are 10- to 20-fold lower than the error 
rate of HIV-1 RT measured in vitro. Recently, Achuthan et al.(180) claimed that they 
reconciled, at least in part, these discrepancies by showing that HIV-1 RT is not more 
error prone than other RTs at physiological concentration of Mg2+ (0.25 mM). However, 
the authors only emphasized a particular mis-incorporation (C:A) and their kinetic 
analysis was flawed, while more comprehensive data from this lab has revealed an 
opposite trend where lower [Mg2+] resulted in reduced fidelity (Gong and Johnson, 
unpublished results). Previous data from this lab have shown that slow PPi release 
provided a novel type of proofreading mechanism by allowing for the reversal of 
chemistry (89-90), but this occurred only in rare cases. In this study, the kinetics of 
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incorrect nucleotide incorporation were further examined to evaluate if slow PPi release 
could bring the in vitro results in closer agreement with the in vivo data.      
5.2 MATERIALS AND METHODS 
DNA and RNA Substrates for Kinetic Studies 
DNA primers and templates (Table 5.1) were ordered from Integrated DNA 
Technologies (IDT) and purified by gel extraction. The 45 nt RNA templates with semi-
random sequence (r45) or containing a string of Gs (r45pG) were ordered from IDT with 
RNase free HPLC purification. Dideoxy-terminated DNA primer (d25dd) was made 
through enzymatic synthesis using RT and purified by gel extraction. Primers used in 
quench flow assays were 5’-32P -labeled with T4 polynucleotide kinase (NEB). 
Annealing of primers and templates was carried out by mixing the two oligonucleotides 
at a 1:1.2 molar ratio (excess template) and incubating at 95°C for 5 min (DNA primers 
and RNA templates were incubated at 67°C for 8 min), followed by slow cooling to room 
temperature.	  
Quench Flow Kinetic Assays 
Kinetics of nucleotide incorporations were measured by rapidly mixing a pre-
formed enzyme-p/t complex (175 nM WT_HIVRT and 75 nM primer/template) with 
various concentrations of nucleotide using a KinTek RQF-3 (KinTek Corp.). Substrates 
(nucleic acids and nucleotides) and RT proteins (labeled or unlabeled) may vary as 
specified in corresponding text and figure legends. Kinetics of pyrophosphorolysis were 
measured by hand mixing methods in which a pre-formed enzyme-DNA/RNA complex 
(100 nM MDCC-labeled WT_HIVRT and 150 nM d26/r45) was mixed with various 
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concentrations of PPi. Processive nucleotide incorporation was measured by rapidly 
mixing a pre-incubated enzyme-p/t complex (175 nM WT_HIVRT and 75 nM 
primer/template) with 100 µM of each nucleotide as specified in the text and 
corresponding figure legends. 
Stopped Flow Kinetic Assays 
Stopped flow assays were performed to measure the kinetics of a single turnover 
reactions to define the rates of TTP binding and incorporation. Various concentrations of 
TTP were rapidly mixed with a pre-formed enzyme-DNA/RNA complex (100 nM 
MDCC-labeled WT_HIVRT and 150 nM d25/r45) and the reactions were monitored by 
stopped-flow fluorescence methods. Similar experiments were performed at lower 
temperatures (5, 10, 15, 20, and 25 °C) and the measured rates were extrapolated to 
estimate the rate of fingers closure at 37°C, which was too fast to measure directly. To 
determine the nucleotide dissociation rate, 200 nM enzyme-DNAdd/RNA (200 nM 
MDCC-labeled WT_HIVRT and 300 nM d25dd/r45 (Table 5.1)) was pre-incubated with 2 
µM of TTP, then the preformed ternary complex was mixed with 1 µM of unlabeled 
enzyme-DNA/RNA duplex to serve as a trap for free nucleotide. The change in 
fluorescence of the labeled enzyme provided the rate of opening and nucleotide release. 
A coupled fluorescence assay described elsewhere (125) was used to measure the kinetics 
of pyrophosphate (PPi) release. Briefly, the preformed enzyme-DNA/RNA duplex (200 
nM of MDCC-labeled WT_HIVRT and 300 nM d25/r45) was rapidly mixed with 1 mM 
TTP in the presence of 0.6 µM of pyrophosphatase (PPase), including the Pi “mop” 
containing 1 mM of 7-methylguanosine (7-MEG) and 0.2 IU/mL purine nucleoside 
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phosphorylase (PNPase), as well as 0.5 µM of fluorescently labeled E.coli phosphate 
binding protein (PBP). Control experiments were also performed using DNA template or 
unlabeled RT protein under specified conditions. 
 
Table 5.1 DNA/RNA Hybrids for Kinetic Assays 
d25/r45: 
            d25: 5’-GCCTCGCAGCCGTCCAACCAACTCA-3’ 
     r45: 3’-CGGAGCGUCGGCAGGUUGGUUGAGUAGCAGCUAGGUUACGGCAGG-5’ 
d25pC/r45pG: 
            d25pC: 5’-GCCTCCCCCCCCCCCAACCAACTCA-3’ 
             r45pG: 3’-CGGAGGGGGGGGGGGUUGGUUGAGUAGCAGCUAGGUUACGGCAGG-5’ 
d25dd/r45: 
            d25dd: 5’-GCCTCGCAGCCGTCCAACCAACTCAdd-3’ 
     r45  : 3’-CGGAGCGUCGGCAGGUUGGUUGAGUAGCAGCUAGGUUACGGCAGG-5’ 
d26/r45: 
            d26: 5’-GCCTCGCAGCCGTCCAACCAACTCAT-3’ 
     r45: 3’-CGGAGCGUCGGCAGGUUGGUUGAGUAGCAGCUAGGUUACGGCAGG-5’ 
d25/d45: 
            d25: 5’-GCCTCGCAGCCGTCCAACCAACTCA-3’ 
     d45: 3’-CGGAGCGTCGGCAGGTTGGTTGAGTAGCAGCTAGGTTACGGCAGG-5’ 
d25/d45tgc: 
            d25   : 5’-GCCTCGCAGCCGTCCAACCAACTCA-3’ 
     d45tgc: 3’-CGGAGCGTCGGCAGGTTGGTTGAGTTGCAGCTAGGTTACGGCAGG-5’ 
d25/d45gtc: 
            d25   : 5’-GCCTCGCAGCCGTCCAACCAACTCA-3’ 
     d45gtc: 3’-CGGAGCGTCGGCAGGTTGGTTGAGTGTCAGCTAGGTTACGGCAGG-5’ 
 
RNA template and DNA primers used in this study are shown. The templating nucleotide 
used in the studies are shown in bold and underscored.  
 




PPi Release is Fast following DNA polymerization with a DNA Template 
Figure 5.1A shows the time dependence of nucleotide incorporation measured by 
rapid chemical quench flow methods at several nucleotide concentrations. Figure 5.1B 
shows the time dependence of the fluorescence change measured by stopped flow during 
pyrophosphate (PPi) release, coupled to hydrolysis and then binding of phosphate to the 
fluorescently labeled phosphate binding protein. The data were fit globally, as illustrated 
by the smooth curves in each figure, to derive the rate constants summarized in Scheme 
5.1 and Table 5.3. The apparent binding affinity of TTP (Kd,app) was 3.5 ± 0.4 µM, and 
kpol was 24 ± 0.1 s-1, yielding a kpol/Kd,app value as 6.9 ± 0.8 µM-1s-1. The time course of 
PPi release was coincident with the rate of the chemistry step and, accordingly 
confidence contour analysis set a lower limit of 500 s-1 for the rate constant governing 
PPi release. 
Processive nucleotide incorporation assays were performed with two different 
templates to explore whether there is a significant difference in the rate constants of the 
first and following nucleotide incorporations (Figure 5.1C-F). The data were fit to a 
sequential incorporation model as shown in Scheme 5.2, where XD25D45 is a 
nonproductive complex. Rates for the first, second, and third nucleotide incorporations 
were 23 ± 2, 17 ± 4, and 36 ± 10 s-1 for d25/d45tgc, as well as 14 ± 1, 26 ± 3, and 30 ± 5 s-1 
for d25/d45gtc. These results contradict the existence of a rate-limiting step after 
chemistry, which was consistent with the fast PPi release rate (> 500 s-1) measured in the 
single turnover experiment. 
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Figure 5.1 PPi Release is not a Rate-limiting Step during Nucleotide(s) Incorporation 
when DNA Templates were used.	   (A) Rapid quench flow assays were performed by 
mixing a pre-formed enzyme-DNA complex (175 nM MDCC-labeled WT_HIVRT and 
75 nM d25/d45) with various concentrations of TTP (0.5, 1, 2, 5, and 15 µM). (B) 
Kinetics of PPi release were measured by mixing a preformed enzyme-DNA duplex (200 
nM of MDCC-labeled WT_HIVRT and 300 nM d25/d45) with 1 mM of TTP in the 
presence of 0.6 µM of pyrophosphatase (PPase), the Pi “mop” containing 1 mM of 7-
methylguanosine (7-MEG) and 0.2 IU/mL purine nucleoside phosphorylase (PNPase), 
and 0.5 µM of fluorescently labeled E.coli phosphate binding protein (PBP). Fluorescence 
was observed by excitation of MDCC at 425 nm and monitoring emission with a 475 nm 
band-pass filter with a 50 nm bandwidth. (C) Global fitting of processive nucleotide 
incorporation data is shown in panel E. Rates for the first, second, and third nucleotide 
incorporation were 23 ± 2, 17 ± 4, and 36 ± 10 s-1. (D) Global fitting of sequential 
processive nucleotide incorporation data shown in panel F. Rates for the first, second, and 
third nucleotide incorporation were 14 ± 1, 26 ± 3, and 30 ± 5 s-1. Color codes: red, 25 nt 
DNA primer; green, 26 nt product; blue, 27 nt product; yellow, 28 nt product; and cyan, 
31 nt mis-incorporation product. (E) Processive nucleotide incorporation was measured 
by rapidly mixing a pre-incubated enzyme-d25/d45tgc complex (175 nM MDCC-labeled 
WT_HIVRT and 75 nM d25/ d45tgc) with 100 µM of dATP, dCTP, and dGTP. (F) 
Processive nucleotide incorporation was measured by rapidly mixing a pre-incubated 
enzyme-d25/d45gtc complex (175 nM MDCC-labeled WT_HIVRT and 75 nM d25/ d45gtc) 
with 100 µM of dATP, dCTP, and dGTP. Positions of 25 nt primer and extension 




PPi Release Becomes the Rate-limiting Step with a RNA Template  
The kinetics of TTP binding, incorporation, and concomitant PPi release were 
then examined using an RNA template. Five experiments (Figure 5.2) were conducted 
and fit simultaneously to a single model as illustrated by Scheme 5.3. Figure 5.2A shows 
the time dependence of nucleotide incorporation measured by rapid chemical-quench 
flow methods at several nucleotide concentrations. Figure 5.2B shows the time course of 
fluorescence changes upon nucleotide binding and incorporation at various nucleotide 
concentrations. Figure 5.2C shows the time course of fluorescence increase during 
nucleotide dissociation from the enzyme-DNAdd/RNA-TTP ternary complex and then 
being trapped by unlabeled enzyme-DNA/RNA duplex. Figure 5.2D shows the time 
dependence of the fluorescence change measured by stopped-flow during pyrophosphate 
(PPi) release, coupled to hydrolysis and then binding of phosphate to the fluorescent Pi 
sensor. Figure 5.2E shows the time dependence of pyrophosphorolysis measured by hand 
quenching at several PPi concentrations. All of the data in Figure 5.2 were fit globally, as 
illustrated by the smooth curves in each figure, to derive the rate constants summarized in 
Table 5.2. Among those rate constants, k2 was derived from a global fitting of 
temperature-dependent TTP incorporation data (Figure 5.3), which was then fixed in the 
fitting of all five experiments shown in Figure 5.2. 
 





The experiments shown in Figure 5.2B were repeated at lower temperatures to 
derive the maximum rate of nucleotide-induced conformational change (k2) since it was 
too fast to be measured at 37°C. Traditionally, the extrapolation was achieved by 
Arrhenius plot (Chapter 2, Figure 2.3C). Herein, a new feature of KinTek Explorer 
capable of fitting data using temperture-dependent rate constants was employed to obtain 
the rate constants at 37°C (Figure 5.3). Briefly, a series of experiments covering a range 
of temperatures (5, 10, 15, 20, and 25 °C) were performed, then the family of curves were 
fit simultaneously to a single set of rate constants (Scheme 5.3) at the reference 
temperature (37°C) and a corresponding set of activation energy terms to cover the range 
of temperatures. A maximum rate of 3200 ± 90 s-1 at 37°C was obtained from the fitting.        
The value of k2 was then fixed in the fitting of all five experiments shown in 
Figure 5.2 such that all remaining rate constants were derived from the global data fitting 
(Table 5.2). The ground state dissociation constant (1/K1) was determined as 520 ± 5 µM. 
Next, the rate of TTP release from a pre-formed ternary complex was measured by 
mixing the closed complex with unlabeled trap (Figure 5.2C). 3’-dideoxy-terminated 
primer was used in this assay to block the chemistry step. Since the ground state binding 
of TTP is a fast equilibrium process, re-opening of the ternary complex is the rate-
limiting step for TTP dissociation and was defined by the assay. This yielded a k-2 value 
of 3±0.01 s-1, which was well constrained in the global fitting according to confidence 
contour analysis (not shown). The rate of chemistry was 250 ± 5 s-1, which was 10-fold 
faster than the rate obtained with a DNA template (24 ± 0.1 s-1, Figure 5.1A and Scheme 
5.1). The rate of PPi release was examined using a coupled assay previously developed in 
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our lab (125). Briefly, PPi released from the reaction was hydrolyzed by the 
pyrophosphatase (PPase), yielding inorganic phosphate, which then bound to the 
fluorescently labeled E.coli phosphate binding protein (PBP) to give the fluorescence 
signal. The kinetics of PPi hydrolysis and Pi binding to MDCC-PBP were calibrated as 
previously described (Chapter 2). Interestingly, the fitting afforded a PPi release rate of 
58 ± 0.4 s-1 that was ~4-fold slower than the rate of chemistry. Therefore, product release 
became the rate-limiting step (Figure 5.2D). Thanks to the slow PPi release step, the rate 
constant governing the reversal of chemistry (k-3) was able to be accurately determined as 
3 ± 0.3 s-1, by measuring the kinetics of pyrophosphorolysis (Figure 5.2E). The 
experiment also defined a second order rate constant for PPi rebinding of 1.8 ± 0.4      
µM-1s-1. 
 
Table 5.2 Kinetic Parameters Governing TTP Binding and Incorporation by MDCC 






























0.5±0.01 201±6 37±3 5.4±0.5 46±2 8.1±0.5 5.7±0.2   
a Kd,net = 1/(K1(1+K2)), where K2 = k2/k-2 
b
 The values were obtained from the hyperbolic analysis of TTP concentration 
dependence of incorporation  













Figure 5.2 Global Fitting of TTP Binding and Incorporation by MDCC-labeled 
WT_HIVRT using a RNA template. (A) Rapid quench-flow assays were performed by 
mixing a pre-formed enzyme-DNA/RNA complex (175 nM MDCC-labeled WT_HIVRT 
and 75 nM d25/r45) with various concentrations of TTP (0.5, 2, 5, 10, and 30 µM). (B) 
Stopped flow assays were performed to measure the kinetics of a single turnover of TTP 
binding and incorporation. Various concentrations of TTP (10, 20, 40, 80, 150, 300, and 
600 µM) were rapidly mixed with a pre-formed enzyme-DNA/RNA complex (100 nM 
MDCC-labeled WT_HIVRT and 150 nM d25/r45) for 100 ms. (C) To determine the 
nucleotide dissociation rate, 200 nM enzyme-DNAdd/RNA (200 nM MDCC-labeled 
WT_HIVRT, and 300 nM d25dd/r45) was pre-incubated with 2 µM of TTP. The 
preformed ternary complex was then mixed with 1 µM of unlabeled enzyme-DNA/RNA 
duplex to serve as a trap for free nucleotide. (D) A coupled fluorescence assay (125) was 
used to measure the kinetics of pyrophosphate (PPi) release. Briefly, the preformed 
enzyme-DNA/RNA duplex (200 nM of MDCC-labeled WT_HIVRT and 300 nM d25/r45) 
was rapidly mixed with 1 mM of TTP in the presence of 0.6 µM of pyrophosphatase 
(PPase), the Pi “mop” containing 1 mM of 7-methylguanosine (7-MEG) and 0.2 IU/mL 
purine nucleoside phosphorylase (PNPase), as well as 0.5 µM of fluorescently labeled 
E.coli phosphate binding protein (PBP). Fluorescence was observed by excitation of 
MDCC at 425 nm and monitoring emission with a 475 nm band-pass filter with a 50 nm 
bandwidth. (E) Kinetics of pyrophosphorolysis were measured by hand mixing. A pre-
formed enzyme-DNA/RNA complex (100 nM MDCC-labeled WT_HIVRT and 150 nM 
d26/r45) was mixed with various concentrations of PPi (10, 25, 50, 100, and 200 µM). 
Global data analysis of all five experiments was performed to derive rate constants 
governing TTP binding and incorporation, as summarized in Table 5.2 and to generate 




Figure 5.3 Global Fitting of 
Temperature Dependence of TTP 
Binding and Incorporation by MDCC-
labeled WT_HIVRT using a RNA 
Template. (A) The time dependence of 
the fluorescence change was monitored 
after mixing various concentrations of 
TTP (10, 20, 40, 80, 150, 300, and 600 
µM) with a pre-formed enzyme-
DNA/RNA complex (100 nM MDCC-
labeled WT_HIVRT  and 150 nM 
d25/r45) at 37°C for 100 ms. (B) 
Various concentrations of TTP (40, 80, 
150, 300, 600, and 1200 µM) were 
rapidly mixed with a pre-formed 
enzyme-DNA/RNA complex (100 nM 
MDCC-labeled WT_HIVRT  and 150 
nM d25/r45) at 25°C for 100 ms. (C) A 
preformed enzyme-DNA/RNA complex 
(100 nM MDCC-labeled WT_HIVRT  
and 150 nM d25/r45) was rapidly mixed 
with saturating concentration of TTP 
(1.5 mM) for 300 ms at 5 (red), 10 
(green), 15 (blue), and 20°C (yellow). 
Fluorescence was observed by excitation 
of MDCC at 425 nm and monitoring 
emission with a 475 nm band-pass filter 
with a 50 nm bandwidth. Global fitting 
of the experiments performed under six 
temperatures was performed to derive 
the rate constant governing TTP induced 
conformational change (k2) as 3200±90 










Processive nucleotide incorporation was examined to further examine the possible 
consequences of the rate-limiting PPi release step (Figure 5.4). Incorporation assays were 
performed with a 25- or 26-nt primer (Figure 5.4 C-D, top). To limit the reaction only 
three nucleotides were added (no dATP) so the longest extension product was 31 nt, with 
only negligible formation of a 35 nt mis-incorporation product. The data were fit to a 
sequential incorporation model similar to the one shown in Scheme 5.2, but with more 
successive incorporation events. Rates for sequential nucleotide incorporation were 152 ± 
9 (T), 18 ± 1 (C), 22 ± 2 (G), 28 ± 5 (T), 23 ± 5 (C), and 29 ± 8 s-1 (G) with a 25 nt primer 
(Figure 5.4A), and 84 ± 5 (C), 28 ± 2 (G), 29 ± 4 (T), 27 ±4 (C), and 32 ± 7 s-1 (G) with 
the 26 nt primer (Figure 5.4B). As shown in Figure 5.4A, there was a large difference in 
rate constants comparing the first (TTP, 152 ± 9 s-1) and following nucleotides 
incorporation (CGTCG, average rate of 24 ± 10 s-1). Similarly, when a 26 nt primer was 
used, incorporation of the first nucleotide (dCTP, 84 ± 5 s-1) was much faster than the 
following nucleotides (GTCG, average rate of 29 ± 9 s-1), suggesting the existence of a 
rate-limiting step occurring after the formation of the first phosphodiester bond. The 
conclusion was further supported by the observation that RT incorporated dCTP at a 
higher rate (84 ± 5 s-1) when it was the first incoming nucleotide, whereas at a much 
slower rate when it was the second nucleotide to be incorporated (18 ± 1 s-1) during 
processive synthesis. Based on these results, the slow PPi release step was identified as 






Figure 5.4 Slow PPi Release was Supported by Processive Nucleotide Incorporation 
Assays.	  (A) Global data fitting of processive nucleotide incorporation data shown in panel 
C. Rates for sequential nucleotide incorporation were 152 ± 9, 18 ± 1, 22 ± 2, 28 ± 5, 23 
± 5, and 29 ± 8 s-1. Color codes: red, 25 nt DNA primer; light green, 26 nt product; blue, 
27 nt; yellow, 28 nt; cyan, 29 nt; magenta, 30 nt; green, 31 nt; and purple, 35 nt  mis-
incorporation product. (B) Simulation of processive nucleotide incorporation data shown 
in panel D. Rates for sequential nucleotide incorporation were 84±5, 28±2, 29±4, 27±4, 
and 32±7 s-1. Color codes: red, 26 nt DNA primer; light green, 27 nt product; blue, 28 nt; 
yellow, 29 nt; cyan, 30 nt; magenta, 31 nt; and green, 35 nt mis-incorporation product. 
(C-D) Processive nucleotide incorporation was measured by rapidly mixing a pre-
incubated enzyme-DNA/RNA complex (175 nM MDCC-labeled WT_HIVRT and 75 nM 
d25/r45 (C) or d26/r45 (D)) with 100 µM of TTP, dCTP, and dGTP. Sequences of 
oligonucleotides are shown on the top of each panel. Positions of primers and extension 







Rate-limiting PPi Release Is Not due to the MDCC Labeling 
Previous experiments were all performed with a MDCC labeled WT_HIVRT. 
Although control experiments were performed to support that both the mutations and the 
MDCC fluorophore did not affect the incorporation efficiency of HIVRT (86), potential 
effect of MDCC labeling on the PPi release step has not been examined yet. 
Consequently, kinetics of TTP incorporation and concomitant PPi release by unlabeled 
WT_HIVRT were also examined with two different DNA/RNA hybrid substrates (Figure 
5.5). The nucleotide concentration dependence of the rates of TTP incorporation by the 
unlabeled WT_HIVRT in complex with a d25pC/r45pG hybrid defined a rate of 
incorporation (kpol) of 150 ± 10 s-1, an apparent Kd (Kd,app) of 34 ± 4 µM, and a specificity 
constant (kpol/Kd,app) of  4.4 ± 0.6 µM-1s-1 (Figure 5.5A). The rate of PPi release was 28 ± 
1 s-1, as measured by the coupled fluorescence stopped-flow assay (Figure 5.5B). 
Consequently, PPi release was the rate-limiting step regardless of the presence or absence 
of the MDCC labeling. Similar experiments and data analysis were performed with a 
d25/r45 hybrid (Figure 5.5C-D), and the data defined an apparent binding affinity of TTP 
(Kd,app) as 24 ± 1 µM, and a rate of chemistry (kpol) of 192 ± 8 s-1, yielding a kpol/Kd,app 
value as 8 ± 0.5 µM-1s-1. Again, the rate of PPi release (35 ± 1 s-1) was much slower than 
that of chemistry, demonstrating that the rate-limiting PPi release was not an artifact 




Table 5.3 Specificity Constants and Rates of PPi release of TTP Incorporation by 
Various RTs in complex with Different Substrates  







MDCC-WT_HIVRT d25/d45 24±0.1 3.5±0.4 6.9±0.8 >500 
Unlabeled WT_HIVRT d25pC/r45pG 150±10 34±4 4.4±0.6 28±1 
Unlabeled WT_HIVRT d25/r45 192±8 24±1 8±0.5 35±1 
 
 
Processive nucleotide incorporation assays were also performed using unlabeled 
WT_HIVRT in complex with two different DNA/RNA hybrids to further support the 
rate-limiting PPi release step is not due to the MDCC labeling (Figure 5.6). Rates for 
sequential nucleotide incorporation were 98 ± 6 (T), 22 ± 2 (C), 32 ± 4 (G), 33 ± 5 (T), 
21 ± 3 (C), and 27 ± 6 s-1 (G) for the d25pC/r45pG hybrid (Figure 5.6A), as well as 92 ± 11 
(C), 44 ± 7 (G), 34 ± 6 (T), 23 ± 4 (C), and 29 ± 7 s-1 (G) for the d26pC/r45pG hybrid 
(Figure 5.6B). Again, a significant difference in rate constants of the first and following 
nucleotides incorporation was observed (d25pC/r45pG: 98 ± 6 vs 27 ± 9 s-1; and 
d26pC/r45pG: 92 ± 11 vs 32 ± 12 s-1), suggesting that the rate-limiting PPi release step 
occurred after the formation of the first phosphodiester bond during processive syntheis. 
An additional evidence for this conclusion was that RT incorporated dCTP at a higher 
rate (92 ± 11 s-1) when it was the first incoming nucleotide whereas at a much slower rate 




Figure 5.5 Global Fitting of TTP Incorporation and Concominant PPi Release By 
Unlabeled WT_HIVRT. Rapid quench-flow assays were performed by mixing a pre-
formed enzyme-DNA/RNA complex (175 nM unlabeled WT_HIVRT and 75 nM 
d25pC/r45pG (A) or d25/r45 (C)) with various concentrations of TTP (0.25, 0.75, 3, 10, and 
30 µM) (A) or (0.25, 0.75, 3, 10, 30, and 100 µM) (C). Kinetics of PPi release were 
measured by mixing a preformed enzyme-DNA/RNA duplex (300 nM of unlabeled 
WT_HIVRT and 200 nM d25pC/r45pG (B) or d25/d45 (D)) with 25 µM of TTP in the 
presence of 0.6 µM of pyrophosphatase (PPase), the Pi “mop” containing 0.1 mM of 7-
methylguanosine (7-MEG) and 0.02 IU/mL purine nucleoside phosphorylase (PNPase), 
and 0.5 µM of fluorescently labeled E.coli phosphate binding protein (PBP). Fluorescence 
was observed by excitation of MDCC at 425 nm and monitoring emission with a 475 nm 
band-pass filter with a 50 nm bandwidth. Global analysis was performed independently 
for d25pC/r45pG (A-B) and d25/r45 (C-D). Rate constants resulting from global analysis of 




Figure 5.6 Processive Nucleotide Incorporation by Unlabeled WT_HIVRT Also 
Supported Slow PPi Release. (A) Simulation of processive nucleotide incorporation data 
shown in panel C. Rates for sequential nucleotide incorporation were 98 ± 6, 22 ± 2, 32 ± 
4, 33 ± 5, 21 ± 3, and 27 ± 6 s-1. Color codes: red, 25 nt DNA primer; light green, 26 nt 
product; blue, 27 nt; yellow, 28 nt; cyan, 29 nt; magenta, 30 nt; green, 31 nt; and purple, 
35 nt mis-incorporation product. (B) Simulation of processive nucleotide incorporation 
data shown in panel D. Rates for sequential nucleotide incorporation were 92 ± 11, 44 ± 7, 
34 ± 6, 23 ± 4, and 29 ± 7 s-1. Color codes: red, 26 nt DNA primer; light green, 27 nt 
product; blue, 28 nt; yellow, 29 nt; cyan, 30 nt; magenta, 31 nt; and green, 35 nt mis-
incorporation product. Processive nucleotide incorporation was measured by rapidly 
mixing a pre-incubated enzyme-DNA/RNA complex (175 nM unlabeled WT_HIVRT  
and 75 nM d25pC/r45pG (C) or d26pC/r45pG (D)) with 100 µM of TTP, dCTP, and dGTP. 
Sequences of substrates are shown on the top of each panel. Positions of primers and 
extension products with different lengths are marked. Timescales are shown on the 





Incorrect Nucleotide Incorporation Also Revealed Rate-limiting PPi Release 
Rapid quench flow assays were performed to measure the kinetics of dGTP:rA 
mis-incorporation by unlabeled WT_HIVRT in complex with d25/r45 (Figure 5.7A). In 
order to further explore the slow reactions, the same experiments were repeated for 
extended timescales, either 5 (Figure 5.7B) or 30 min (Figure 5.7C). Our previous data 
have shown that the kinetics of mismatch nucleotide binding were complex and most of 
the fluorescent signal disappeared within the 1 ms dead time of the stopped flow 
instrument due to the fast opening rate (58). Consequently, only quench flow assays were 
performed and a simplified mechanism involving one-step substrate binding was applied 
to describe the kinetics of dGTP mis-incorporation (Scheme 5.4). Kinetic parameters 
resulting from global analysis of kinetic data are summarized in Table 5.4. Data shown in 
Figure 5.7A defined the rate of mis-incorporation or kpol (approximates k2) as 0.6 ± 0.03 
s-1 and the apparent nucleotide dissociation constant or Kd,app of 11 ± 2 mM. However, a 
concentration dependence of the amplitude of dGTP incorporation was observed, 
implying that the chemistry step was reversibly linked to nucleotide binding (k-2 = 0.07 ± 
0.01 s-1) and implying the existence of a slow, rate-limiting step after chemistry (89-90). 
Interestingly, the extension reaction revealed an additional slower phase when dGTP mis-
incorporation proceeded for 5 min, where the slow phase was likely to correspond to the 
rate-limiting PPi release (89). Accordingly, the slow phase defined the rate of PPi release 
to be 0.003 ± 0.001 s-1, which was 200-fold slower than the catalytic step and was 
probably limited by the reopening of RT after primer extension. It is likely that the 
enzyme remains in a closed conformation after the chemistry step, in which residues 
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would still be in an alignment to perform catalysis (89). This hypothesis is consistent 
with the fact that the amplitude of the fast phase is dependent on dGTP concentration. 
But once the enzyme reopens and releases PPi, the reaction would precede to a common 
end point since PPi release is essentially irreversible due to the relatively low 
concentration of PPi formed during the course of the reaction (89). To test this, kinetics 
of mis-incorporation were monitored for 30 min (Figure 5.7C). To our surprise, the 
dependence of reaction end point on nucleotide concentration was still observed, which 
fit best with a rebinding rate of 0.02 µM-1s-1. However, any number smaller than this rate 
could generate an acceptable fitting. Experiments performed under longer timescales 
could help to better define the rate.	  
 



























(5.8±1.1) ×10-5 (2.5±0.6) ×10-3 1.1±0.2 (2.4±0.7) ×10-6 24±8 
a  k-3 is not well determined by the data 
b kcat/Km = k1k2k3/(k2k3+k-1(k-2+k3)) 
cDifference between the two specificity constants obtained by including or overlooking 
the slow PPi release step was defined by D = (kpol/Kd,app) / (kcat/Km) 
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Figure 5.7 Global Fitting of dGTP:rA 
Mis-incorporation by Unlabeled WT_ 
HIVRT. (A) Rapid quench flow assays 
were performed by mixing a pre-
formed enzyme-DNA/RNA complex 
(175 nM unlabeled WT_HIVRT and 75 
nM d25/r45) with various 
concentrations of dGTP (0.2, 0.5, 1, 2, 
and 4 mM). Reactions were stopped at 
various timepoints within 10 s by 
addition of 0.5 M EDTA. (B) The same 
experiments were repeated by hand 
quench and data were collected within 
5 min. (C) The same experiments were 
repeated by hand quench and data were 
collected within 30 min. The three 
experiments performed within different 
timescales were fit simultaneously 
according to the one-step binding 
model shown in Scheme 5.4. Rate 
constants derived from the global 




Rate-determining vs Specificity-determining Step 
In this study, the kinetic pathways of correct and incorrect nucleotide 
incorporation were identified (Scheme 5.3 and 5.4). Kinetic parameters governing 
nucleotide binding, incorporation, and concomitant PPi release are listed in Table 5.2 and 
5.4. The data showed that PPi release was the rate-determining step during TTP 
incorporation when an RNA template was used. Previous studies of nucleotide selectivity 
by HIVRT and T7 DNA polymerase identified an important kinetic partitioning between 
chemistry (k3) and the reverse of the conformational change (k-2) that allows 
simplifications to be made when deriving the specificity constant (86-87). Notably, when 
k3 is much greater than  k-2, the specificity constant (kcat/Km) can be simplified to K1k2 
because the closed ternary complex is committed to catalysis. Herein, the kinetic 
partitioning of FD25R45.N state also favors chemistry over nucleotide release (k3 >> k-2). 
However, when chemistry proceeds, a new kinetic partitioning between PPi release (k4) 
and the reverse of chemistry (k-3) also becomes important. Because k4 >> k-3, the 
specificity constant governing the incorporation of a normal nucleotide (TTP) is not 
affected by the slow PPi release; rather it is solely determined by the net rate of binding 
(K1k2). Again, the data demonstrate that nucleotide selectivity by HIVRT is determined 
by the first largely irreversible step, which is the substrate-induced isomerization. The 
free-energy profile for TTP binding and incorporation then illustrates this analysis. In 
Figure 5.8A, the nucleotide-induced conformational change (ED25R45.N to FD25R45.N) 
represents the highest energy barrier relative to the unbound state (ED25R45) and therefore 
determines the enzyme specificity constant (kcat/Km). Although PPi release reflects the 
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highest absolute barrier (relative to the local minimum) and therefore represents the rate-
limiting step (k4 approximates kcat), it does not contribute to enzyme specificity, which is 
further supported by the fact that kpol/Kd,app ≈ kcat/Km (Table 5.2). 
The scenario changes during noncognate nucleotide incorporation, in which the 
product release rate (k3) was shown to reduce kcat/Km, defining the nucleotide specificity 
constant. The slow PPi release rate allows for the reversal of chemisty (k-2), which 
effectively reduces kcat/Km by 24-fold according to the constants defined for dGTP 
incorporation (Table 5.4). The data demonstrated that when k-2 >> k3, an equilibrium is 
established prior to product release, which results in a simplified derivation of specificity 
corresponding to product of the equilibrium constants and the rate of product release 
(K1K2k3) (87). This is further illustrated in the free-energy profile for dGTP incorporation 
(Figure 5.8B) where the product release reflects the highest barrier relative to the 
unbound state and the local minimum. Therefore, slow product release represents the 









Figure 5.8 Free-energy Profiles for TTP (A) and dGTP (B) Incorporation. (A) The free 
energy was calculated as ΔG = RT[ln(kT/h) - ln(kobs)] kcal/mol using rate constants from 
Table 5.2. The constant k is the Boltzmann constant, T is 310 K, h is Planck’s constant 
and kobs is the first-order rate constant. Concentrations of nucleotide and PPi were set as 
100 and 150 µM, respectively. (B) The free-energy profile for dGTP mis-incorporation 






One of the most important results of this report is the identification of rate-
limiting PPi release during TTP incorporation by HIVRT with a DNA/RNA hybrid. PPi 
release has usually been assumed to be fast, so chemistry represents the only rate-limiting 
step for primer extension. As shown in Figure 1B, the rate of PPi release after 
incorporation of TTP using a DNA template must be quite fast (> 500 s-1) since the 
fluorescence signal corresponding to PPi is coincident with the observed chemistry. 
Examination of the kinetics of processive synthesis using a DNA template reveals that 
each incorporation reaction proceeds at a rate approximately equal to the rate of 
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chemistry observed in a single turnover (20, 88). Therefore, there is no significant delay 
after the incorporation of one nucleotide and preceding the binding of the next. The 
inability to show a delay in binding the next nucleotide after a single incorporation event 
(Figure 1C-F) also supports that translocation must be faster than the rate of 
incorporation measured in a single turnover.  
In contrast, the data revealed that PPi product release represents the rate-limiting 
step when an RNA template is used for primer extension (Figure 5.2). This conclusion is 
further supported by the observation of significantly delayed binding of the next 
nucleotide after the first turnover (Figure 5.4). A rate-limiting translocation seems to be 
infeasible although the possibility cannot be fully excluded. Moreover, direct 
measurements of PPi release clearly demonstrate that product release is indeed rate-
limiting. Since actual PPi release should be a fast process, it is reasonable to suppose that 
product release is limited by the isomerization of HIVRT to the open state. This 
hypothesis was supported by the fact that reopening of RT measured by stopped-flow 
assays (Figure 5.2B) is coincident with PPi release measured by our coupled stopped-
flow assay (Figure 5.2D). Although these data do not demonstrate the order of events, it 
is reasonable to propose that enzyme opening precedes and therefore limits the rate of PPi 
release. 
Although slow PPi release has been reported during the incorporation of modified 
or mismatched nucleotides (89-91) by the human mitochondrial DNA polymerase, this is 
the first instance where rate-limiting PPi release is observed using cognate nucleotides. 
Because of the relatively slow PPi release, the reverse rate constant for chemistry (k-3) 
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was measured and a new kinetic partitioning between product release and the reverse 
chemistry was identified. Similarly, this partitioning strongly favors the forward product 
release (k4 >> k-3) and therefore does not contribute to nucleotide selectivity. In chapter 4, 
our data also showed that the rate-limiting PPi release plays an important role to 
coordinate the polymerase and RNase H active sites of HIVRT.  
The most remarkable observation reported here is the exceedingly slow release of 
PPi after incorporation of an incorrect nucleotide. The effect of slow PPi release on the 
efficiency of dGTP incorporation by HIVRT is quite large. The commitment to forward 
catalysis is not made until PPi dissociates from the enzyme, indicating that the specificity 
constant for incorporation should be correspondingly low. An unambiguous measurement 
of kcat/Km found this to be the case and dictates that previous calculation of the 
discrimination ((kcat/Km)TTP/( kcat/Km)dGTP) against dGTP must be revised to (2.4±0.7)×106, 
more than 20-fold greater than previously estimated. Similarly, in the case of AZT and 8-
oxodG incorporation by human mitochondrial DNA polymerase, slow PPi release allows 
for the direct reversal of the chemistry step and reduces kcat for incorporation (89-90). 
This represents a novel mechanism by which a polymerase can increase discrimination 
against an undesirable substrate.  
The 20-fold increase of discrimination that we observed for HIVRT may also fill 
the gap between the fidelity of HIV-1 RT measured by in vitro and in vivo approaches. 
More combinations of mis-incorporation will need to be tested in the future to obtain a 
full picture concerning the effect of slow PPi release on nucleotide selectivity. Similarly, 
slow PPi release was also observed during incorporation of incorrect nucleotides when a 
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DNA template was used. Further studies will be performed to evaluate the extent to 
which the slow PPi release would increase the fidelity of HIV-1 RT during plus strand 
DNA synthesis since unequal error rates were observed with RNA and DNA templates 
(52).  
To get the best estimates for the kinetic parameters governing the incorporation of 
dGTP, the data obtained over different timescales were fit simultaneously (Figure 5.7), 
according to the model shown in Scheme 5.4. The simple model adequately accounts for 
the observed dependence of the amplitude of the fast phase on dGTP concentration. 
Similar concentration dependence has been observed during AZT and 8-oxodG 
incorporation by human mitochondrial DNA polymerase (89-90). The characteristic 
pattern suggests that the binding of dGTP is reversibly linked to product formation, a 
conclusion that requires that PPi release is slow or readily reversible. To explore these 
possibilities, we first examined the kinetics of the reverse reaction using a dGMP-
terminated primer strand. To our surprise, no pyrophosphorolysis reaction was observed. 
The data revealed that RT was able to catalyze the reverse reaction only when a naturally 
terminated primer strand was used (Figure 5.2E). The conformational changes of RT 
during pyrophosphorolysis were not measured, but the fact that we were not able to force 
the reverse reaction to take place by adding relatively high concentration of PPi to the 
RT-DNA/RNA complex (primer terminated with dGMP) suggests that when dGMP is in 
a mismatch with the template strand, PPi is unable to productively associate with the RT-
DNA/RNA complex with sufficient binding energy to organize the active site to promote 
pyrophosphorolysis. These results argued against the hypothesis that a substantial reverse 
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rate constant for phosphate binding and reaction was the cause of the abnormal kinetics 
of dGTP incorporation. Rather the data suggest that slow PPi release is limited by the 
enzyme opening following incorporation of a mismatch, which provides an additional 
checkpoint for improving enzyme fidelity. The slow PPi release provide additional time 
for the reversal of chemistry and release of the bound mismatched nucleotide.    
Currently, we have no direct measurement to demonstrate that the slow phase in 
Figure 5.7B corresponds to the PPi release step. The coupled stopped-flow assay was 
performed to measure the rate of PPi dissociation using dGTP as the substrate. However, 
a considerable overestimation of the rate was likely obtained from the data because the 
presence of the phosphate mop would scavenge traces of phosphate with a faster rate than 
its release from the reaction and therefore result in reduced amplitude (181). This 
explains the failure to get a good fit when including the fluorescence data. In the future, a 
different experimental approach will be used to directly measure the rate of PPi release 
by synthesizing γ-32P-labeled dGTP (90). 
In summary, here we show for the first time that PPi release limits the rate of 
processive RNA-dependent DNA synthesis and improves the overall fidelity of the 
enzyme. These findings enriched our understandings of the kinetic basis for the rate-
determining versus specificity-determining step and allow estimates for the rate of 
reversal of the chemistry step at the active site of the enzyme. Accordingly, these data 
provide the first measurement of the equilibrium constants governing polymerization and 








HIVRT is an RNA- and DNA-dependent DNA polymerase with moderate fidelity. 
Given the lack of proofreading activity, nucleotide selectivity is solely a function of the 
binding and reaction of nucleotide at the polymerase active site. Although geometric 
constraints of the nucleotide binding pocket may play an important role in discriminating 
against non-complementary base pairs (35),  numerous biochemical and structural studies 
have been performed to determine the amino acid residues involved in the binding of the 
incoming nucleotide (35, 182-185). The pocket includes the conserved YMDD motif 
(Y183, M184, D185, and D186), three basic residues that are in the vicinity of the 
phosphates of dNTP (K65, R72, and K219), and the ‘steric gate’ Y115. Other important 
residues include D113 and Q151. Among these residues, D185 and D186 were well 
studied since they have important catalytic functions (185). Residues associated with 
NRTIs resistance also have been extensively studied, e.g., K65 (70, 186), Q151 (187-
189), M184 (190-194), and K219 (108, 195). Despite its functional importance, kinetic 
studies of R72 were only sparse. One study showed that a R72A mutation strongly 
altered the fidelity of HIVRT (196), the kinetic basis for which was unfortunately missing. 
Another study showed that R72 might be involve in the pyrophosphate binding/release 
function of HIV RT (37), probably due to the hydrogen bonding between its guanidinium 
group and the α-phosphate of the incoming nucleotide (35). However, this conclusion 
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was based on indirect evidence so a direct and accurate measurement of the rate of 
pyrophosphate release is of great importance to test the conclusion.  
In this chapter, pre-steady-state kinetic assays and global data analysis were 
performed to determine how the R72A mutation would affect the kinetics of each 
elementary step during nucleotide incorporation. Then, incorporation kinetics of correct 
and incorrect nucleotides were compared to explore the mechanistic basis for the altered 
fidelity by HIVRT_R72A mutant. 
 
 
Figure 6.1 Hydrogen bonding between residue R72 and the α-phosphate of TTP. The 
crystal structure of HIVRT (PDB: 1RTD) in complex with a DNA primer/template (green 
and blue) and TTP (denoted by orange and color coded by element). Binding of TTP 
induces the closure of the finger domain (pink). The TTP base stacks against the base at 
the 3’-end of the primer while the triphosphate wraps around one of the Mg2+ ion 
(orange). Residue R72 (denoted by blue and CPK color coded by element) interacts with 
the α-phosphate through hydrogen bonding. 
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6.2 MATERIALS AND METHODS 
Expression and Purification of Proteins Used in This Study  
HIVRT R72A mutant was expressed, purified and labeled following methods 
previously described (77, 86). Briefly, single mutations were introduced in genes of both 
subunits using a Quikchange Multi kit (Stratagene). The method for the preparation of 
MDCC-labeled PBP used in this study was described previously (154) and its active site 
concentration was determined by fluorescent titration with various concentrations of 
inorganic Pi. 
Pre-steady-state Kinetic Measurements 
Single-nucleotide incorporation was monitored by rapid quench flow and stopped 
flow methods. Chemical quench flow incorporation experiments were performed to 
determine the incorporation efficiency of TTP by R72A mutant. Various concentrations 
of TTP (10, 25, 50, 100, and 200 µM) were rapidly mixed with a preformed enzyme-
DNA/RNA complex (175 nM MDCC-labeled HIVRT_R72A  and 75 nM d25/r45 (Table 
6.1)) using a RQF-3 Rapid Quench Flow (KinTek Corp.). All reactions were conducted 
in 50 mM Tris pH7.5, 100 mM KCl and 10 mM Magnesium acetate (all concentrations 
final) at 37°C and stopped by adding 0.5 M EDTA. Products were separated and 
quantified as described above.  
The time dependence of transient MDCC fluorescence changes corresponding to 
TTP induced enzyme conformational change was monitored using an Auto SF-200x 
(KinTek Corp.). A preformed enzyme-DNA/RNA duplex (100 nM of MDCC-labeled 
HIVRT_R72A and 150 nM d25ddA/r45 (Table 6.1)) was rapidly mixed with various 
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concentrations of TTP (20, 30, 40, 60, 80, 100, 150, and 200 µM) in the stopped flow for 
300 ms. MDCC fluorescence was excited at 425 nm and fluorescence was monitored at 
475 nm with a 50 nm band-pass filter (Semrock). To monitor the fluorescence changes 
corresponding to the chemistry step, a normal primer (not dideoxy-terminated) was used 
to form the enzyme-DNA/RNA binary complex (100 nM of MDCC-labeled 
HIVRT_R72A and 150 nM d25/r45 (Table 6.1)) and mixed with various concentrations 
of TTP (5, 10, 20, 30, 40, 60, 80, 100 and 150 µM) in the stopped flow for a longer time 
scale of 50 s.  
A coupled fluorescence assay described elsewhere (125) was used to measure the 
kinetics of pyrophosphate (PPi) release. Briefly, the preformed enzyme-DNA/RNA 
duplex (150 nM of HIVRT mutant and 100 nM d25/r45) was rapidly mixed with 25 µM 
of TTP in the presence of 0.6 µM of pyrophosphatase (PPase), the Pi “mop” containing 
100 µM of 7-methylguanosine (7-MEG) and 0.02 IU/mL purine nucleoside 
phosphorylase (PNPase), as well as 1.5 µM of fluorescently labeled E. coli PBP. 
 
Table 6.1 DNA/RNA Hybrids for Kinetic Assays 
d25ddA/r45: 
            d25dd: 5’-GCCTCCCCCCCCCCCAACCAACTCAdd-3’ 
             r45  : 3’-CGGAGGGGGGGGGGGUUGGUUGAGUAGCAGCUAGGUUACGGCAGG-5’ 
d25/r45: 
            d25: 5’-GCCTCCCCCCCCCCCAACCAACTCA-3’ 





Quench Flow dGTP:dA Incorporation 
The incorporation efficiency (kpol/Kd,app) of dGTP by HIVRT_R72A was also 
determined by performing quench flow incorporation assays. A preformed enzyme-
DNA/RNA complex (175 nM MDCC-labeled HIVRT_R72A and 75 nM d25/r45 (Table 
6.1)) was rapidly mixed with various concentrations of dGTP (0.5, 1, 2, 4, and 8 mM) 
using a RQF-3 Rapid Quench Flow (Kin Tek Corp.). Reactions were stopped by adding 
0.5 M EDTA at various time points up to 20 min. To evaluate the effect of R72A 
mutation on the fidelity of HIVRT, specificity constants (kpol/Kd,app) of TTP and dGTP 
incorporation by HIVRT_WT protein were also determined through quench flow assays. 
For TTP incorporation, a preformed enzyme-DNA/RNA complex (175 nM HIVRT_WT 
and 75 nM d25/r45 (Table 6.1)) was rapidly mixed with various concentrations of TTP 
(0.5, 1.5, 6, 20, and 60 µM). Reaction times ranged from 0 to 1 s. As to dGTP 
incorporation, a preformed enzyme-DNA/RNA complex (175 nM HIVRT_WT and 75 
nM d25/r45 (Table 6.1)) was rapidly mixed with various concentrations of dGTP (0.1, 
0.2, 0.5, 1, and 2 mM). Reaction times ranged from 0 to10 s.  
Data Analysis 
Quench flow incorporation, stopped flow binding and incorporation, and stopped 
flow PPi release data obtained with HIVRT_R72A were fit globally to a four-step kinetic 
model using KinTek Explorer software to Scheme 6.1. The PPi release step was assumed 
to be irreversible since the data set was insufficient to define the small rate of PPi 
rebinding. Nucleotide incorporation data were analyzed by fitting to the minimum model 
that includes a one-step, rapid-equilibrium nucleotide binding event followed by the rate-
limiting chemistry step (Scheme 6.2). Specificity constant (kpol/Kd,app) values were 
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derived from the simulations. Discrimination is defined by D = (kpol/Kd,app)TTP / 
(kpol/Kd,app)dGTP. The influence of enzyme specificity by introducing the R72A mutation is 
then defined by I = DR72A/DWT. 
 
Scheme 6.1 Two-step Nucleotide Binding, Incorporation, and PPi Release 
	  
 






Kinetic Characterization of HIVRT_R72A Mutant 
Stopped flow assays were first performed to measure the kinetics of a single 
turnover of TTP incorporation (Figure 6.2A). Various concentrations of TTP (5, 10, 20, 
30, 40, 60, 80, 100 and 150 µM) were rapidly mixed with a preformed enzyme-
DNA/RNA complex (100 nM MDCC-labeled HIVRT_R72A and 150 nM d25/r45). In 
contrast to what we observed before, only a decrease of fluorescence was recorded, with 
a half-life around 6 s at the highest concentration of TTP. The slow drop of fluorescent 
signal was not consistent with the nucleotide induced fast closure of HIVRT fingers 
domain. Consequently, TTP-induced conformational change was measured with a 
dideoxy-terminated primer to block the chemistry step (Figure 6.2B). Various 
concentrations of TTP (20, 30, 40, 60, 80, 100, 150, and 200 µM) were mixed with a 
preformed enzyme-DNAdd/RNA complex (100 nM MDCC-labeled HIVRT_R72A and 
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150 nM d25ddA/r45). Our data showed an increase of fluorescence signal upon the 
binding of TTP, indicating that the drop of fluorescence observed in panel A was 
probably due to the chemistry step. Next, manual quench flow assays were performed to 
measure the apparent binding affinity of TTP (Kd,app) and the rate of polymerization (kpol) 
by HIVRT_R72A mutant (Figure 6.2C). As expected, the chemistry step measured here 
was as slow as the fluorescence decrease in panel A, further supporting that the unusual 
decrease of fluorescence was due to the chemistry step. Finally, a coupled assay was 
performed to measure the kinetics of PPi release (Figure 6.2D) since indirect evidence 
has shown that the R72A mutation significantly affected the PPi release step (37). Global 
data analysis of all four experiments was performed to derive rate constants governing 
TTP binding and incorporation. The TTP ground-state binding constant (1/K1) was 
determined as 92 ± 3 µM, which was 3-fold tighter than its binding to a WT protein (77). 
The forward (k2) and reverse (k-2) rates for the conformational change were 127 ± 2 and 
32 ± 1 s-1, which defined a K2 value of 4 ± 0.2 which was 170-fold smaller than that of 
TTP incorporation by WT_HIVRT-MDCC (690±67) (77), suggesting that R72 might 
play a crucial role in the nucleotide induced isomerization step. Rates of chemistry and 
PPi release were determined as 0.18 ± 0.003 and 0.04 ± 0.008 s-1, respectively. The rate 
of chemistry was reduced by 190-fold due to the R72A substitution. The rate of PPi 
release during TTP incorporation by WT_HIVRT protein was too fast to be accurately 
determined and a lower limit of 500 s-1 was obtained from the confidence contour 
analysis (Chapter 5). However, the R72A mutation dramatically impaired PPi release, 
making its rate 4-fold slower than that of chemistry. 
204	  
	  
The net binding affinity of TTP (Kd,net) as a result of two-step nucleotide binding 
was calculated as 1/(K1(1+K2) = 18 ± 1 µM, which was 45-fold weaker than its binding 
to a WT_HIVRT protein. The reverse conformational change rate (32 ± 1 s-1) is greater 
than the rate of chemistry (0.18 ± 0.003 s-1), which allows the two-step binding 
mechanism come to equilibrium, leading to a reduced Kd,app value (21 ± 0.3 µM) that 
resembles the net Kd. The rate of polymerization (kpol) is 0.12 ± 0.001 s-1, yielding a 
kpol/Kd,app value as (6 ± 0.1)×10-3	   µM-1 s-1. Rate of PPi release (0.04 ± 0.008 s-1) is 
comparable to the reverse chemistry step rate (0.07 ± 0.002 s-1), suggesting that PPi 
removal may also contribute to enzyme specificity. The specificity constant (kcat/Km) was 
calculated as kcat/Km = k1k2k3k4/(k2k3k4+k-1(k-2k-3+k-2k4+k3k4)) = (3 ± 0.2)×10-3 µM-1s-1, 
with a kcat value of 0.023 ± 0.001 s-1 and a Km value as 8 ± 0.3 µM. All kinetic parameters 
were summarized in Table 6.2. 
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Table 6.2 Kinetic Parameters Governing TTP Binding and Incorporation by 





























18±1 0.12±0.001 21±0.3 (6±0.1)×10-3 0.023±0.001 8±0.3 (3±0.2)×10-3   
a Kd,net = 1/(K1(1+K2)) 
b kcat/Km = k1k2k3k4/(k2k3k4+k-1(k-2k-3+k-2k4+k3k4)) 
 
Kinetics of Mismatch Incorporation and Enzyme Specificity 
Kinetics of dGTP:dA misincorporation by R72A mutant were examined by the 
manual quench flow method (Figure 6.3A). A preformed enzyme-DNA/RNA complex 
(175 nM MDCC-labeled HIVRT_R72A and 75 nM d25/r45) was mixed with various 
concentrations of dGTP (0.5, 1, 2 and 4 mM). The concentration-dependence of dGTP 
incorporation was analyzed by fitting to the minimum model shown in Scheme 6.2. The 
Kd,app was 1.3 ± 0.1 mM, and the kpol was 0.002 ± 0.0004 s-1, yielding a kpol/Kd,app value as 
(1.5 ± 0.3)×10-6 µM-1s-1. The specificity constants (kpol/Kd,app) governing TTP and dGTP 
incorporation by HIVRT_R72A were (6 ± 0.1)×10-3	   and (1.5 ± 0.3)×10-6 µM-1s-1, 
respectively. These values produced a net discrimination [(kpol/Kd,app)TTP / (kpol/Kd,app)dGTP] 
of (4 ± 0.8)×103 (Table 6.3). 
The incorporation of TTP (Figure 6.3B) and dGTP (Figure 6.3C) by WT_HIVRT 
was also examined to evaluate the extent to which the R72A mutation could affect the 
enzyme specificity. Briefly, a preformed enzyme-DNA/RNA complex (175 nM MDCC-
labeled WT_HIVRT and 75 nM d25/r45) was mixed with various concentrations of 
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nucleotides (TTP: 0.25, 0.75, 3, 10, 30 µM; or dGTP: 0.1, 0.2, 0.5, 1, and 2 mM). The 
specificity constants (kpol/Kd,app) governing TTP and dGTP incorporation by WT_HIVRT 
were 6.5 ± 0.8 and (5.2 ± 1.2)×10-4 µM-1s-1, respectively. These values defined the dGTP 
discrimination by the WT_HIVRT of (1.3 ± 0.3)×104. The influence of R72A mutation 
on enzyme specificity is defined by I = DR72A/DWT = (4 ± 0.8)×103/ (1.3 ± 0.3)×104 = 0.3 ± 
0.1 ,  indicating that R72A decreased the specificity of HIVRT by ~3-fold (Table 6.3). 
 
Table 6.3 Specificity and Discrimination for WT and R72A HIVRT  




HIVRT_R72A TTP 0.12±0.001 21±0.3 (6±0.1)×10-3   
 dGTP 0.002±0.0004 1300±100 (1.5±0.3)×10-6  (4±0.8)×103  
HIVRT_WT TTP 142±12 22±2 6.5±0.8   
 dGTP 1.3±0.2 2500±400 (5.2±1.2)×10-4 (1.3±0.3)×104 0.3±0.1 
aD = [(kpol/Kd,app)TTP / (kpol/Kd,app)dGTP] 












Figure 6.2 Kinetic characterization of MDCC-labeled HIVRT R72A mutant by global 
analysis of TTP binding, incorporation and PPi release.  (A) The time dependence of the 
fluorescence change during TTP incorporation was monitored after mixing various 
concentrations of TTP (5, 10, 20, 30, 40, 60, 80, 100 and 150 µM) with a preformed 
enzyme-DNA/RNA complex (100 nM MDCC-labeled HIV RT_R72A and 150 nM 
d25/r45). (B) TTP induced conformational change was measured with dideoxy-
terminated primer to prohibit the following chemistry step. Various concentrations of 
TTP (20, 30, 40, 60, 80, 100, 150, and 200 µM) were mixed with a preformed enzyme-
DNAdd/RNA complex (100 nM MDCC-labeled HIVRT_R72A  and 150 nM d25ddA/r45). 
(C) The concentration-dependence of TTP incorporation was measured using the manual 
quench flow method. Various concentrations of TTP (10, 25, 50, 100, and 200 µM) were 
mixed with a preformed enzyme-DNA/RNA complex (175 nM MDCC-labeled 
HIVRT_R72A and 75 nM d25/r45). (D) Rate of PPi release during TTP incorporation 
was monitored by rapidly mixing 25 µM of TTP with a preformed enzyme-DNA/RNA 
complex (150 nM MDCC-labeled HIVRT_R72A and 100 nM d25/r45) in the presence of 
1.5 µM of MDCC-PBP and 0.6 µM of PPase. Fluorescence was observed by excitation of 
MDCC at 425 nm and monitoring emission with a 475 nm band-pass filter with a 50 nm 
bandwidth. Global data analysis of all four experiments was performed to derive rate 
constants governing TTP binding and incorporation. The TTP ground-state binding 
constant (1/K1) was determined as 92 ± 3 µM. The forward (k2) and reverse (k-2) rates for 
the conformational change was 127 ± 2 and 32 ± 1 s-1, which defined a K2 value of 4 ± 
0.2 that was 170-fold smaller than that of WT HIVRT-MDCC (690 ± 67) (77). Rates of 





Figure 6.3. Specificity and 
Discrimination for WT and R72A HIVRT. 
(A) Kinetics of dGTP:dA 
misincorporation by R72A mutant were 
examined by the manual quench flow 
method. A preformed enzyme-
DNA/RNA complex (175 nM MDCC-
labeled HIVRT_R72A and 75 nM 
d25/r45) was mixed with various 
concentrations of dGTP (0.5, 1, 2 and 4 
mM). The concentration-dependence of 
dGTP incorporation was analyzed by 
fitting to the minimum model shown in 
Scheme 6.2. The Kd,app was 1.3 ± 0.1 
mM, and the kpol was 0.002 ± 0.0004 s-1, 
yielding a kpol/Kd,app value as (1.5 ± 
0.3)×10-6 µM-1s-1. The incorporation of 
TTP (B) and dGTP (C) by WT_HIVRT 
was also examined to evaluate the extent 
to which the R72A mutation could affect 
the enzyme specificity. Briefly, a 
preformed enzyme-DNA/RNA complex 
(175 nM MDCC-labeled WT_HIVRT 
and 75 nM d25/r45) was mixed with 
various concentrations of TTP (0.25, 
0.75, 3, 10, 30 µM) or dGTP (0.1, 0.2, 
0.5, 1, and 2 mM). The specificity 
constants (kpol/Kd,app) governing TTP and 
dGTP incorporation by WT_HIVRT 
were 6.5 ± 0.8 and (5.2 ± 1.2)×10-4    
µM-1s-1, respectively. The kinetic 
parameters were summarized in Table 








In this chapter, the HIVRT_R72A mutant was kinetically characterized, which 
revealed that this mutation affected nucleotide binding, conformational change, chemistry, 
and PPi release to different extents. Since nucleotide-induced conformational changes 
played an important role in enzyme specificity, this mutation also resulted in decreased 
fidelity. 
First, several quench flow and stopped flow assays were performed, together with 
global data analysis, to define the kinetic pathway of TTP incorporation by R72A mutant. 
In the stopped flow assays to measure kinetics of TTP binding and incorporation, an 
unusual pattern of fluorescence change was observed: the fluorescence increased when 
the binding of nucleotide induced fingers closure while decreased when the ternary 
complex reopened after chemistry (Figure 6.2A-B). This assignment was further 
supported by the fact that the fluorescence signal decreased with the same rate as the 
catalytic step (Figure 6.2A and C). This unusual pattern was previously observed during 
dATP:dA mis-incorporation by HIVRT (58), and MD simulations in the same study 
predicted a disordered, higher free energy state distinct from the closed state induced by 
the binding of a correct nucleotide. An less favorable conformational change step (K2 = 4 
± 0.2) was also observed in this study during TTP incorporation by R72A mutant, 
suggesting that the fingers domain of this mutant might adopt a similar conformation that 
disfavors catalysis and promotes release. Structural studies of DNA polymerases reveal 
that the binding of an incorrect nucleotide can induce an intermediate conformation that 
is distinct from the established ‘open’ and ‘closed’ states (197-198). This ‘partially closed’ 
state might represent the fingers conformation of the R72A mutant after the binding of 
TTP and result in the high fluorescent state.  
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Previous studies have shown that the R72A substitution impaired both catalytic 
and PPi release steps during nucleotide incorporation (37). While data presented in this 
chapter demonstrated that the mutation affected all steps in the kinetic pathway for TTP 
incorporation. The ground state binding of TTP was 3-fold tighter whereas the 
isomerization step was 170-fold less favorable so that the overall net binding was 45-fold 
weaker. Structural details for the impaired nucleotide-induced isomerization step are still 
unknown. However, a nearby residue W71 also plays an important role in this step, 
suggesting that this region is crucial for the induced-fit mechanism and therefore remains 
conserved during evolution. As expected, the rate of chemistry was reduced by 190-fold, 
while PPi release was even slower and became the rate-limiting step.  
In the field of DNA polymerase, kpol/Kd,app (instead of kcat/Km) has been widely 
accepted as the specificity constant, which is valid when nucleotide binding is a one-step, 
rapid equilibrium process and when chemistry is the only rate-limiting step for product 
formation. However, this substitution is no longer appropriate when PPi release becomes 
the rate-limiting step. For instance, the kpol/Kd,app value  is 2-fold larger than kcat/Km due to 
the rate-limiting PPi release step (Table 6.2). This issue is detailed in chapter 5 and is 
demonstrated again here. 
Data presented in this chapter revealed that R72A mutation reduced the fidelity of 
HIVRT by ~3-fold, which is consistent with the important role of induce-fit in enzyme 
specificity. However, a previous study proposed that R72A substitution increased the 
fidelity and the mutant was a base substitution antimutator (196). This increased 
nucleotide selectivity, however, was sequence dependent, which might explain the 
reduced fidelity observed here. Also, previous data have shown that slow PPi release 
provided extra fidelity (Chapter 5). Unfortunately, this step was too slow to be accurately 
measured during mis-incorporation (due to the presence of Pi mop), especially in the case 
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of R72A mutation that slowed the PPi release step further. In the future, a new assay will 
be developed to measure this extremely slow PPi release step by attaching a 32P label on 
the γ-phosphate of the incoming nucleotide so that kinetics of PPi release can be resolved 
by quench flow assays that are insensitive to Pi contaminations. 
              







1. Barre-Sinoussi, F., Chermann, J. C., Rey, F., Nugeyre, M. T., Chamaret, S., 
Gruest, J., Dauguet, C., Axler-Blin, C., Vezinet-Brun, F., Rouzioux, C., 
Rozenbaum, W., and Montagnier, L. (1983) Isolation of a T-lymphotropic 
retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS), 
Science 220, 868-871. 
2. Gallo, R. C., Sarin, P. S., Gelmann, E. P., Robert-Guroff, M., Richardson, E., 
Kalyanaraman, V. S., Mann, D., Sidhu, G. D., Stahl, R. E., Zolla-Pazner, S., 
Leibowitch, J., and Popovic, M. (1983) Isolation of human T-cell leukemia virus 
in acquired immune deficiency syndrome (AIDS), Science 220, 865-867. 
3. WHO. (2015) Global summary of the AIDS epidemic - 2014  URL: 
http://www.who.int/hiv/data/epi_core_july2015.png?ua=1. 
4. Lucas, S., and Nelson, A. M. (2015) HIV and the spectrum of human disease, J 
Pathol 235, 229-241. 
5. WHO. (2015) Global health sector response to HIV, 2000-2015: focus on 
innovations in Africa  URL: 
http://apps.who.int/iris/bitstream/10665/198065/1/9789241509824_eng.pdf?ua=1. 
6. Pepin, J. (2011) The origins of AIDS, Cambridge University Press. 
7. Chinen, J., and Shearer, W. T. (2002) Molecular virology and immunology of 
HIV infection, J Allergy Clin Immunol 110, 189-198. 
8. Ratner, L., Haseltine, W., Patarca, R., Livak, K. J., Starcich, B., Josephs, S. F., 
Doran, E. R., Rafalski, J. A., Whitehorn, E. A., Baumeister, K., and et al. (1985) 
Complete nucleotide sequence of the AIDS virus, HTLV-III, Nature 313, 277-284. 
9. Fanales-Belasio, E., Raimondo, M., Suligoi, B., and Butto, S. (2010) HIV 
virology and pathogenetic mechanisms of infection: a brief overview, Ann Ist 
Super Sanita 46, 5-14. 
10. Emerman, M., and Malim, M. H. (1998) HIV-1 regulatory/accessory genes: keys 
to unraveling viral and host cell biology, Science 280, 1880-1884. 
11. Freed, E. O. (1998) HIV-1 gag proteins: diverse functions in the virus life cycle, 
Virology 251, 1-15. 
12. Freed, E. O. (2001) HIV-1 replication, Somat Cell Mol Genet 26, 13-33. 
13. Sierra, S., Kupfer, B., and Kaiser, R. (2005) Basics of the virology of HIV-1 and 
its replication, J Clin Virol 34, 233-244. 
14. Hu, W. S., and Hughes, S. H. (2012) HIV-1 reverse transcription, Cold Spring 
Harb Perspect Med 2. 
15. Sarafianos, S. G., Das, K., Tantillo, C., Clark, A. D., Jr., Ding, J., Whitcomb, J. 
M., Boyer, P. L., Hughes, S. H., and Arnold, E. (2001) Crystal structure of HIV-1 
reverse transcriptase in complex with a polypurine tract RNA:DNA, EMBO J 20, 
1449-1461. 
16. Esposito, F., Corona, A., and Tramontano, E. (2012) HIV-1 Reverse Transcriptase 
Still Remains a New Drug Target: Structure, Function, Classical Inhibitors, and 
214	  
	  
New Inhibitors with Innovative Mechanisms of Actions, Mol Biol Int 2012, 
586401. 
17. Sarafianos, S. G., Marchand, B., Das, K., Himmel, D. M., Parniak, M. A., Hughes, 
S. H., and Arnold, E. (2009) Structure and function of HIV-1 reverse transcriptase: 
molecular mechanisms of polymerization and inhibition, J Mol Biol 385, 693-713.	  
18. Schultz, S. J., and Champoux, J. J. (2008) RNase H activity: structure, specificity, 
and function in reverse transcription, Virus Res 134, 86-103. 
19. DeStefano, J. J., Buiser, R. G., Mallaber, L. M., Myers, T. W., Bambara, R. A., 
and Fay, P. J. (1991) Polymerization and RNase H activities of the reverse 
transcriptases from avian myeloblastosis, human immunodeficiency, and 
Moloney murine leukemia viruses are functionally uncoupled, J Biol Chem 266, 
7423-7431. 
20. Kati, W. M., Johnson, K. A., Jerva, L. F., and Anderson, K. S. (1992) Mechanism 
and fidelity of HIV reverse transcriptase, J Biol Chem 267, 25988-25997. 
21. DeStefano, J. J., Mallaber, L. M., Fay, P. J., and Bambara, R. A. (1994) 
Quantitative analysis of RNA cleavage during RNA-directed DNA synthesis by 
human immunodeficiency and avian myeloblastosis virus reverse transcriptases, 
Nucleic Acids Res 22, 3793-3800. 
22. Gotte, M., Fackler, S., Hermann, T., Perola, E., Cellai, L., Gross, H. J., Le Grice, 
S. F., and Heumann, H. (1995) HIV-1 reverse transcriptase-associated RNase H 
cleaves RNA/RNA in arrested complexes: implications for the mechanism by 
which RNase H discriminates between RNA/RNA and RNA/DNA, EMBO J 14, 
833-841. 
23. Huber, H. E., and Richardson, C. C. (1990) Processing of the primer for plus 
strand DNA synthesis by human immunodeficiency virus 1 reverse transcriptase, 
J Biol Chem 265, 10565-10573. 
24. Luo, G. X., Sharmeen, L., and Taylor, J. (1990) Specificities involved in the 
initiation of retroviral plus-strand DNA, J Virol 64, 592-597. 
25. Rezende, L. F., and Prasad, V. R. (2004) Nucleoside-analog resistance mutations 
in HIV-1 reverse transcriptase and their influence on polymerase fidelity and viral 
mutation rates, Int J Biochem Cell Biol 36, 1716-1734. 
26. Svarovskaia, E. S., Cheslock, S. R., Zhang, W. H., Hu, W. S., and Pathak, V. K. 
(2003) Retroviral mutation rates and reverse transcriptase fidelity, Front Biosci 8, 
d117-134. 
27. Mansky, L. M. (1996) Forward mutation rate of human immunodeficiency virus 
type 1 in a T lymphoid cell line, AIDS Res Hum Retroviruses 12, 307-314. 
28. Mansky, L. M., and Temin, H. M. (1995) Lower in vivo mutation rate of human 
immunodeficiency virus type 1 than that predicted from the fidelity of purified 
reverse transcriptase, J Virol 69, 5087-5094. 
29. Abram, M. E., Ferris, A. L., Shao, W., Alvord, W. G., and Hughes, S. H. (2010) 
Nature, position, and frequency of mutations made in a single cycle of HIV-1 
replication, J Virol 84, 9864-9878. 
215	  
	  
30. di Marzo Veronese, F., Copeland, T. D., DeVico, A. L., Rahman, R., Oroszlan, S., 
Gallo, R. C., and Sarngadharan, M. G. (1986) Characterization of highly 
immunogenic p66/p51 as the reverse transcriptase of HTLV-III/LAV, Science 231, 
1289-1291. 
31. Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., and Steitz, T. A. (1992) 
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed 
with an inhibitor, Science 256, 1783-1790. 
32. Jacobo-Molina, A., Ding, J., Nanni, R. G., Clark, A. D., Jr., Lu, X., Tantillo, C., 
Williams, R. L., Kamer, G., Ferris, A. L., Clark, P., and et al. (1993) Crystal 
structure of human immunodeficiency virus type 1 reverse transcriptase 
complexed with double-stranded DNA at 3.0 A resolution shows bent DNA, Proc 
Natl Acad Sci U S A 90, 6320-6324. 
33. Zheng, X., Perera, L., Mueller, G. A., DeRose, E. F., and London, R. E. (2015) 
Asymmetric conformational maturation of HIV-1 reverse transcriptase, Elife 4. 
34. Zheng, X., Pedersen, L. C., Gabel, S. A., Mueller, G. A., DeRose, E. F., and 
London, R. E. (2016) Unfolding the HIV-1 reverse transcriptase RNase H domain 
- how to lose a molecular tug-of-war, Nucleic Acids Res 44, 1776-1788. 
35. Huang, H., Chopra, R., Verdine, G. L., and Harrison, S. C. (1998) Structure of a 
covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications 
for drug resistance, Science 282, 1669-1675. 
36. Singh, K., Marchand, B., Kirby, K. A., Michailidis, E., and Sarafianos, S. G. 
(2010) Structural Aspects of Drug Resistance and Inhibition of HIV-1 Reverse 
Transcriptase, Viruses 2, 606-638. 
37. Sarafianos, S. G., Pandey, V. N., Kaushik, N., and Modak, M. J. (1995) Site-
directed mutagenesis of arginine 72 of HIV-1 reverse transcriptase. Catalytic role 
and inhibitor sensitivity, J Biol Chem 270, 19729-19735. 
38. Steitz, T. A., and Steitz, J. A. (1993) A general two-metal-ion mechanism for 
catalytic RNA, Proc Natl Acad Sci U S A 90, 6498-6502. 
39. Nakamura, T., Zhao, Y., Yamagata, Y., Hua, Y. J., and Yang, W. (2012) 
Watching DNA polymerase eta make a phosphodiester bond, Nature 487, 196-
201. 
40. Vyas, R., Reed, A. J., Tokarsky, E. J., and Suo, Z. (2015) Viewing Human DNA 
Polymerase beta Faithfully and Unfaithfully Bypass an Oxidative Lesion by 
Time-Dependent Crystallography, J Am Chem Soc 137, 5225-5230. 
41. Freudenthal, B. D., Beard, W. A., Shock, D. D., and Wilson, S. H. (2013) 
Observing a DNA polymerase choose right from wrong, Cell 154, 157-168. 
42. Cowan, J. A., Ohyama, T., Howard, K., Rausch, J. W., Cowan, S. M., and Le 
Grice, S. F. (2000) Metal-ion stoichiometry of the HIV-1 RT ribonuclease H 
domain: evidence for two mutually exclusive sites leads to new mechanistic 
insights on metal-mediated hydrolysis in nucleic acid biochemistry, J Biol Inorg 
Chem 5, 67-74. 
216	  
	  
43. Nowotny, M., Gaidamakov, S. A., Crouch, R. J., and Yang, W. (2005) Crystal 
structures of RNase H bound to an RNA/DNA hybrid: substrate specificity and 
metal-dependent catalysis, Cell 121, 1005-1016. 
44. Nowotny, M., and Yang, W. (2006) Stepwise analyses of metal ions in RNase H 
catalysis from substrate destabilization to product release, EMBO J 25, 1924-1933. 
45. Yang, W., Lee, J. Y., and Nowotny, M. (2006) Making and breaking nucleic acids: 
two-Mg2+-ion catalysis and substrate specificity, Mol Cell 22, 5-13. 
46. Arnold, E., Jacobo-Molina, A., Nanni, R. G., Williams, R. L., Lu, X., Ding, J., 
Clark, A. D., Jr., Zhang, A., Ferris, A. L., Clark, P., and et al. (1992) Structure of 
HIV-1 reverse transcriptase/DNA complex at 7 A resolution showing active site 
locations, Nature 357, 85-89. 
47. Ding, J., Das, K., Hsiou, Y., Sarafianos, S. G., Clark, A. D., Jr., Jacobo-Molina, 
A., Tantillo, C., Hughes, S. H., and Arnold, E. (1998) Structure and functional 
implications of the polymerase active site region in a complex of HIV-1 RT with 
a double-stranded DNA template-primer and an antibody Fab fragment at 2.8 A 
resolution, J Mol Biol 284, 1095-1111. 
48. Xiong, Y., and Eickbush, T. H. (1990) Origin and evolution of retroelements 
based upon their reverse transcriptase sequences, EMBO J 9, 3353-3362. 
49. Julias, J. G., McWilliams, M. J., Sarafianos, S. G., Arnold, E., and Hughes, S. H. 
(2002) Mutations in the RNase H domain of HIV-1 reverse transcriptase affect the 
initiation of DNA synthesis and the specificity of RNase H cleavage in vivo, Proc 
Natl Acad Sci U S A 99, 9515-9520. 
50. Rausch, J. W., Lener, D., Miller, J. T., Julias, J. G., Hughes, S. H., and Le Grice, 
S. F. (2002) Altering the RNase H primer grip of human immunodeficiency virus 
reverse transcriptase modifies cleavage specificity, Biochemistry 41, 4856-4865. 
51. Das, K., Martinez, S. E., Bandwar, R. P., and Arnold, E. (2014) Structures of 
HIV-1 RT-RNA/DNA ternary complexes with dATP and nevirapine reveal 
conformational flexibility of RNA/DNA: insights into requirements for RNase H 
cleavage, Nucleic Acids Res 42, 8125-8137. 
52. Boyer, J. C., Bebenek, K., and Kunkel, T. A. (1992) Unequal human 
immunodeficiency virus type 1 reverse transcriptase error rates with RNA and 
DNA templates, Proc Natl Acad Sci U S A 89, 6919-6923. 
53. Kerr, S. G., and Anderson, K. S. (1997) RNA dependent DNA replication fidelity 
of HIV-1 reverse transcriptase: evidence of discrimination between DNA and 
RNA substrates, Biochemistry 36, 14056-14063. 
54. Lapkouski, M., Tian, L., Miller, J. T., Le Grice, S. F., and Yang, W. (2013) 
Complexes of HIV-1 RT, NNRTI and RNA/DNA hybrid reveal a structure 
compatible with RNA degradation, Nat Struct Mol Biol 20, 230-236. 
55. Hsiou, Y., Ding, J., Das, K., Clark, A. D., Jr., Hughes, S. H., and Arnold, E. (1996) 
Structure of unliganded HIV-1 reverse transcriptase at 2.7 A resolution: 
implications of conformational changes for polymerization and inhibition 
mechanisms, Structure 4, 853-860. 
217	  
	  
56. Rodgers, D. W., Gamblin, S. J., Harris, B. A., Ray, S., Culp, J. S., Hellmig, B., 
Woolf, D. J., Debouck, C., and Harrison, S. C. (1995) The structure of unliganded 
reverse transcriptase from the human immunodeficiency virus type 1, Proc Natl 
Acad Sci U S A 92, 1222-1226. 
57. Sarafianos, S. G., Das, K., Clark, A. D., Jr., Ding, J., Boyer, P. L., Hughes, S. H., 
and Arnold, E. (1999) Lamivudine (3TC) resistance in HIV-1 reverse 
transcriptase involves steric hindrance with beta-branched amino acids, Proc Natl 
Acad Sci U S A 96, 10027-10032. 
58. Kirmizialtin, S., Nguyen, V., Johnson, K. A., and Elber, R. (2012) How 
conformational dynamics of DNA polymerase select correct substrates: 
experiments and simulations, Structure 20, 618-627. 
59. Sarafianos, S. G., Clark, A. D., Jr., Das, K., Tuske, S., Birktoft, J. J., Ilankumaran, 
P., Ramesha, A. R., Sayer, J. M., Jerina, D. M., Boyer, P. L., Hughes, S. H., and 
Arnold, E. (2002) Structures of HIV-1 reverse transcriptase with pre- and post-
translocation AZTMP-terminated DNA, EMBO J 21, 6614-6624. 
60. Havlir, D. V., and Richman, D. D. (1996) Viral dynamics of HIV: implications 
for drug development and therapeutic strategies, Ann Intern Med 124, 984-994. 
61. Mitsuya, H., Yarchoan, R., and Broder, S. (1990) Molecular targets for AIDS 
therapy, Science 249, 1533-1544. 
62. Perno, C. F., Yarchoan, R., Cooney, D. A., Hartman, N. R., Gartner, S., Popovic, 
M., Hao, Z., Gerrard, T. L., Wilson, Y. A., Johns, D. G., and et al. (1988) 
Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication 
in fresh and cultured human peripheral blood monocytes/macrophages by 
azidothymidine and related 2',3'-dideoxynucleosides, J Exp Med 168, 1111-1125. 
63. Johnson, A. A., Ray, A. S., Hanes, J., Suo, Z., Colacino, J. M., Anderson, K. S., 
and Johnson, K. A. (2001) Toxicity of antiviral nucleoside analogs and the human 
mitochondrial DNA polymerase, J Biol Chem 276, 40847-40857. 
64. Lee, H., Hanes, J., and Johnson, K. A. (2003) Toxicity of nucleoside analogues 
used to treat AIDS and the selectivity of the mitochondrial DNA polymerase, 
Biochemistry 42, 14711-14719. 
65. Kewn, S., Hoggard, P. G., Henry-Mowatt, J. S., Veal, G. J., Sales, S. D., Barry, M. 
G., and Back, D. J. (1999) Intracellular activation of 2',3'-dideoxyinosine and drug 
interactions in vitro, AIDS Res Hum Retroviruses 15, 793-802. 
66. Palella, F. J., Jr., Delaney, K. M., Moorman, A. C., Loveless, M. O., Fuhrer, J., 
Satten, G. A., Aschman, D. J., and Holmberg, S. D. (1998) Declining morbidity 
and mortality among patients with advanced human immunodeficiency virus 
infection. HIV Outpatient Study Investigators, N Engl J Med 338, 853-860. 
67. Johnson, V. A., Brun-Vezinet, F., Clotet, B., Gunthard, H. F., Kuritzkes, D. R., 
Pillay, D., Schapiro, J. M., and Richman, D. D. (2010) Update of the drug 
resistance mutations in HIV-1: December 2010, Top HIV Med 18, 156-163. 
68. Johnson, V. A., Calvez, V., Gunthard, H. F., Paredes, R., Pillay, D., Shafer, R., 
Wensing, A. M., and Richman, D. D. (2011) 2011 update of the drug resistance 
mutations in HIV-1, Top Antivir Med 19, 156-164. 
218	  
	  
69. Clavel, F., and Hance, A. J. (2004) HIV drug resistance, N Engl J Med 350, 1023-
1035. 
70. Das, K., Bandwar, R. P., White, K. L., Feng, J. Y., Sarafianos, S. G., Tuske, S., 
Tu, X., Clark, A. D., Jr., Boyer, P. L., Hou, X., Gaffney, B. L., Jones, R. A., 
Miller, M. D., Hughes, S. H., and Arnold, E. (2009) Structural basis for the role of 
the K65R mutation in HIV-1 reverse transcriptase polymerization, excision 
antagonism, and tenofovir resistance, J Biol Chem 284, 35092-35100.	  
71. Parikh, U. M., Bacheler, L., Koontz, D., and Mellors, J. W. (2006) The K65R 
mutation in human immunodeficiency virus type 1 reverse transcriptase exhibits 
bidirectional phenotypic antagonism with thymidine analog mutations, J Virol 80, 
4971-4977. 
72. Garforth, S. J., Domaoal, R. A., Lwatula, C., Landau, M. J., Meyer, A. J., 
Anderson, K. S., and Prasad, V. R. (2010) K65R and K65A substitutions in HIV-
1 reverse transcriptase enhance polymerase fidelity by decreasing both dNTP 
misinsertion and mispaired primer extension efficiencies, J Mol Biol 401, 33-44. 
73. Larder, B. A., Kemp, S. D., and Harrigan, P. R. (1995) Potential mechanism for 
sustained antiretroviral efficacy of AZT-3TC combination therapy, Science 269, 
696-699. 
74. Jérôme Courcambeck, R. P., Jérôme Deval, Boulbaba Selmi, Bruno Canard, 
Philippe Halfon, Michael D. Miller and Gérard Pèpe Molecular Mechanism of 
Resistance of Tenofovir against HIV RT K65R Strain and Mechanism of 
Resistance Suppression by M184V Mutation. 
75. Gotte, M., Arion, D., Parniak, M. A., and Wainberg, M. A. (2000) The M184V 
mutation in the reverse transcriptase of human immunodeficiency virus type 1 
impairs rescue of chain-terminated DNA synthesis, J Virol 74, 3579-3585. 
76. Tu, X., Das, K., Han, Q., Bauman, J. D., Clark, A. D., Jr., Hou, X., Frenkel, Y. V., 
Gaffney, B. L., Jones, R. A., Boyer, P. L., Hughes, S. H., Sarafianos, S. G., and 
Arnold, E. (2010) Structural basis of HIV-1 resistance to AZT by excision, Nat 
Struct Mol Biol 17, 1202-1209. 
77. Kellinger, M. W., and Johnson, K. A. (2011) Role of induced fit in limiting 
discrimination against AZT by HIV reverse transcriptase, Biochemistry 50, 5008-
5015. 
78. Ray, A. S., Murakami, E., Basavapathruni, A., Vaccaro, J. A., Ulrich, D., Chu, C. 
K., Schinazi, R. F., and Anderson, K. S. (2003) Probing the molecular 
mechanisms of AZT drug resistance mediated by HIV-1 reverse transcriptase 
using a transient kinetic analysis, Biochemistry 42, 8831-8841. 
79. Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H. (2001) Selective 
excision of AZTMP by drug-resistant human immunodeficiency virus reverse 
transcriptase, J Virol 75, 4832-4842. 
80. Sluis-Cremer, N., Arion, D., Parikh, U., Koontz, D., Schinazi, R. F., Mellors, J. 
W., and Parniak, M. A. (2005) The 3'-azido group is not the primary determinant 
of 3'-azido-3'-deoxythymidine (AZT) responsible for the excision phenotype of 
AZT-resistant HIV-1, J Biol Chem 280, 29047-29052. 
219	  
	  
81. Spence, R. A., Kati, W. M., Anderson, K. S., and Johnson, K. A. (1995) 
Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside 
inhibitors, Science 267, 988-993. 
82. Esnouf, R., Ren, J., Ross, C., Jones, Y., Stammers, D., and Stuart, D. (1995) 
Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside 
inhibitors, Nat Struct Biol 2, 303-308. 
83. Wang, J., Zhang, G., Bambara, R. A., Li, D., Liang, H., Wu, H., Smith, H. M., 
Lowe, N. R., Demeter, L. M., and Dykes, C. (2011) Nonnucleoside reverse 
transcriptase inhibitor-resistant HIV is stimulated by efavirenz during early stages 
of infection, J Virol 85, 10861-10873. 
84. Johnson, K. A. (1993) Conformational coupling in DNA polymerase fidelity, 
Annu Rev Biochem 62, 685-713. 
85. Johnson, K. A. (2010) The kinetic and chemical mechanism of high-fidelity DNA 
polymerases, Biochim Biophys Acta 1804, 1041-1048. 
86. Kellinger, M. W., and Johnson, K. A. (2010) Nucleotide-dependent 
conformational change governs specificity and analog discrimination by HIV 
reverse transcriptase, Proc Natl Acad Sci U S A 107, 7734-7739. 
87. Tsai, Y. C., and Johnson, K. A. (2006) A new paradigm for DNA polymerase 
specificity, Biochemistry 45, 9675-9687. 
88. Patel, S. S., Wong, I., and Johnson, K. A. (1991) Pre-steady-state kinetic analysis 
of processive DNA replication including complete characterization of an 
exonuclease-deficient mutant, Biochemistry 30, 511-525. 
89. Hanes, J. W., Thal, D. M., and Johnson, K. A. (2006) Incorporation and 
replication of 8-oxo-deoxyguanosine by the human mitochondrial DNA 
polymerase, J Biol Chem 281, 36241-36248. 
90. Hanes, J. W., and Johnson, K. A. (2007) A novel mechanism of selectivity against 
AZT by the human mitochondrial DNA polymerase, Nucleic Acids Res 35, 6973-
6983. 
91. Batabyal, D., McKenzie, J. L., and Johnson, K. A. (2010) Role of histidine 932 of 
the human mitochondrial DNA polymerase in nucleotide discrimination and 
inherited disease, J Biol Chem 285, 34191-34201. 
92. Gopalakrishnan, V., Peliska, J. A., and Benkovic, S. J. (1992) Human 
immunodeficiency virus type 1 reverse transcriptase: spatial and temporal 
relationship between the polymerase and RNase H activities, Proc Natl Acad Sci 
U S A 89, 10763-10767. 
93. Beilhartz, G. L., Wendeler, M., Baichoo, N., Rausch, J., Le Grice, S., and Gotte, 
M. (2009) HIV-1 reverse transcriptase can simultaneously engage its DNA/RNA 
substrate at both DNA polymerase and RNase H active sites: implications for 
RNase H inhibition, J Mol Biol 388, 462-474. 
94. Purohit, V., Roques, B. P., Kim, B., and Bambara, R. A. (2007) Mechanisms that 
prevent template inactivation by HIV-1 reverse transcriptase RNase H cleavages, 
J Biol Chem 282, 12598-12609. 
220	  
	  
95. Shaw-Reid, C. A., Feuston, B., Munshi, V., Getty, K., Krueger, J., Hazuda, D. J., 
Parniak, M. A., Miller, M. D., and Lewis, D. (2005) Dissecting the effects of 
DNA polymerase and ribonuclease H inhibitor combinations on HIV-1 reverse-
transcriptase activities, Biochemistry 44, 1595-1606. 
96. Abbondanzieri, E. A., Bokinsky, G., Rausch, J. W., Zhang, J. X., Le Grice, S. F., 
and Zhuang, X. (2008) Dynamic binding orientations direct activity of HIV 
reverse transcriptase, Nature 453, 184-189.	  
97. Liu, S., Abbondanzieri, E. A., Rausch, J. W., Le Grice, S. F., and Zhuang, X. 
(2008) Slide into action: dynamic shuttling of HIV reverse transcriptase on 
nucleic acid substrates, Science 322, 1092-1097. 
98. Suo, Z., and Johnson, K. A. (1997) Effect of RNA secondary structure on the 
kinetics of DNA synthesis catalyzed by HIV-1 reverse transcriptase, Biochemistry 
36, 12459-12467. 
99. Suo, Z., and Johnson, K. A. (1998) DNA secondary structure effects on DNA 
synthesis catalyzed by HIV-1 reverse transcriptase, J Biol Chem 273, 27259-
27267. 
100. Kim, S., Schroeder, C. M., and Xie, X. S. (2010) Single-molecule study of DNA 
polymerization activity of HIV-1 reverse transcriptase on DNA templates, J Mol 
Biol 395, 995-1006. 
101. Suo, Z., and Johnson, K. A. (1997) Effect of RNA secondary structure on RNA 
cleavage catalyzed by HIV-1 reverse transcriptase, Biochemistry 36, 12468-12476. 
102. Suo, Z., and Johnson, K. A. (1997) RNA secondary structure switching during 
DNA synthesis catalyzed by HIV-1 reverse transcriptase, Biochemistry 36, 
14778-14785. 
103. Isel, C., Lanchy, J. M., Le Grice, S. F., Ehresmann, C., Ehresmann, B., and 
Marquet, R. (1996) Specific initiation and switch to elongation of human 
immunodeficiency virus type 1 reverse transcription require the post-
transcriptional modifications of primer tRNA3Lys, EMBO J 15, 917-924. 
104. Lanchy, J. M., Keith, G., Le Grice, S. F., Ehresmann, B., Ehresmann, C., and 
Marquet, R. (1998) Contacts between reverse transcriptase and the primer strand 
govern the transition from initiation to elongation of HIV-1 reverse transcription, 
J Biol Chem 273, 24425-24432. 
105. Liu, S., Harada, B. T., Miller, J. T., Le Grice, S. F., and Zhuang, X. (2010) 
Initiation complex dynamics direct the transitions between distinct phases of early 
HIV reverse transcription, Nat Struct Mol Biol 17, 1453-1460. 
106. Le Grice, S. F. (1993) Human immunodeficiency virus reverse transcritptase, pp 
163-191, Cold Spring Harbor laboratory Pess, NY. 
107. Telesnitsky, A., and Goff, S. P. (1997) Reverse Transcriptase and the Generation 
of Retroviral DNA. 
108. Larder, B. A., and Kemp, S. D. (1989) Multiple mutations in HIV-1 reverse 




109. Larder, B. A., Bloor, S., Kemp, S. D., Hertogs, K., Desmet, R. L., Miller, V., 
Sturmer, M., Staszewski, S., Ren, J., Stammers, D. K., Stuart, D. I., and Pauwels, 
R. (1999) A family of insertion mutations between codons 67 and 70 of human 
immunodeficiency virus type 1 reverse transcriptase confer multinucleoside 
analog resistance, Antimicrob Agents Chemother 43, 1961-1967. 
110. De Antoni, A., Foli, A., Lisziewicz, J., and Lori, F. (1997) Mutations in the pol 
gene of human immunodeficiency virus type 1 in infected patients receiving 
didanosine and hydroxyurea combination therapy, J Infect Dis 176, 899-903. 
111. de Jong, J. J., Goudsmit, J., Lukashov, V. V., Hillebrand, M. E., Baan, E., 
Huismans, R., Danner, S. A., ten Veen, J. H., de Wolf, F., and Jurriaans, S. (1999) 
Insertion of two amino acids combined with changes in reverse transcriptase 
containing tyrosine-215 of HIV-1 resistant to multiple nucleoside analogs, AIDS 
13, 75-80. 
112. Masquelier, B., Race, E., Tamalet, C., Descamps, D., Izopet, J., Buffet-Janvresse, 
C., Ruffault, A., Mohammed, A. S., Cottalorda, J., Schmuck, A., Calvez, V., Dam, 
E., Fleury, H., and Brun-Vezinet, F. (2001) Genotypic and phenotypic resistance 
patterns of human immunodeficiency virus type 1 variants with insertions or 
deletions in the reverse transcriptase (RT): multicenter study of patients treated 
with RT inhibitors, Antimicrob Agents Chemother 45, 1836-1842. 
113. Tamalet, C., Yahi, N., Tourres, C., Colson, P., Quinson, A. M., Poizot-Martin, I., 
Dhiver, C., and Fantini, J. (2000) Multidrug resistance genotypes (insertions in 
the beta3-beta4 finger subdomain and MDR mutations) of HIV-1 reverse 
transcriptase from extensively treated patients: incidence and association with 
other resistance mutations, Virology 270, 310-316. 
114. Menendez-Arias, L., Matamoros, T., and Cases-Gonzalez, C. E. (2006) Insertions 
and deletions in HIV-1 reverse transcriptase: consequences for drug resistance 
and viral fitness, Curr Pharm Des 12, 1811-1825. 
115. Matamoros, T., Franco, S., Vazquez-Alvarez, B. M., Mas, A., Martinez, M. A., 
and Menendez-Arias, L. (2004) Molecular determinants of multi-nucleoside 
analogue resistance in HIV-1 reverse transcriptases containing a dipeptide 
insertion in the fingers subdomain: effect of mutations D67N and T215Y on 
removal of thymidine nucleotide analogues from blocked DNA primers, J Biol 
Chem 279, 24569-24577. 
116. Cases-Gonzalez, C. E., Franco, S., Martinez, M. A., and Menendez-Arias, L. 
(2007) Mutational patterns associated with the 69 insertion complex in multi-
drug-resistant HIV-1 reverse transcriptase that confer increased excision activity 
and high-level resistance to zidovudine, J Mol Biol 365, 298-309. 
117. Boyer, P. L., Sarafianos, S. G., Arnold, E., and Hughes, S. H. (2002) Nucleoside 
analog resistance caused by insertions in the fingers of human immunodeficiency 
virus type 1 reverse transcriptase involves ATP-mediated excision, J Virol 76, 
9143-9151. 
118. Lennerstrand, J., Hertogs, K., Stammers, D. K., and Larder, B. A. (2001) 
Correlation between viral resistance to zidovudine and resistance at the reverse 
222	  
	  
transcriptase level for a panel of human immunodeficiency virus type 1 mutants, J 
Virol 75, 7202-7205. 
119. Mas, A., Parera, M., Briones, C., Soriano, V., Martinez, M. A., Domingo, E., and 
Menendez-Arias, L. (2000) Role of a dipeptide insertion between codons 69 and 
70 of HIV-1 reverse transcriptase in the mechanism of AZT resistance, EMBO J 
19, 5752-5761. 
120. Meyer, P. R., Lennerstrand, J., Matsuura, S. E., Larder, B. A., and Scott, W. A. 
(2003) Effects of dipeptide insertions between codons 69 and 70 of human 
immunodeficiency virus type 1 reverse transcriptase on primer unblocking, 
deoxynucleoside triphosphate inhibition, and DNA chain elongation, J Virol 77, 
3871-3877.	  
121. Winters, M. A., Coolley, K. L., Girard, Y. A., Levee, D. J., Hamdan, H., Shafer, 
R. W., Katzenstein, D. A., and Merigan, T. C. (1998) A 6-basepair insert in the 
reverse transcriptase gene of human immunodeficiency virus type 1 confers 
resistance to multiple nucleoside inhibitors, J Clin Invest 102, 1769-1775. 
122. Meyer, P. R., Matsuura, S. E., Mian, A. M., So, A. G., and Scott, W. A. (1999) A 
mechanism of AZT resistance: an increase in nucleotide-dependent primer 
unblocking by mutant HIV-1 reverse transcriptase, Mol Cell 4, 35-43. 
123. Lennerstrand, J., Stammers, D. K., and Larder, B. A. (2001) Biochemical 
mechanism of human immunodeficiency virus type 1 reverse transcriptase 
resistance to stavudine, Antimicrob Agents Chemother 45, 2144-2146. 
124. Mas, A., Vazquez-Alvarez, B. M., Domingo, E., and Menendez-Arias, L. (2002) 
Multidrug-resistant HIV-1 reverse transcriptase: involvement of ribonucleotide-
dependent phosphorolysis in cross-resistance to nucleoside analogue inhibitors, J 
Mol Biol 323, 181-197. 
125. Hanes, J. W., and Johnson, K. A. (2008) Real-time measurement of 
pyrophosphate release kinetics, Anal Biochem 372, 125-127. 
126. Meyer, P. R., Matsuura, S. E., So, A. G., and Scott, W. A. (1998) Unblocking of 
chain-terminated primer by HIV-1 reverse transcriptase through a nucleotide-
dependent mechanism, Proc Natl Acad Sci U S A 95, 13471-13476. 
127. Tong, W., Lu, C. D., Sharma, S. K., Matsuura, S., So, A. G., and Scott, W. A. 
(1997) Nucleotide-induced stable complex formation by HIV-1 reverse 
transcriptase, Biochemistry 36, 5749-5757. 
128. Curr, K., Tripathi, S., Lennerstrand, J., Larder, B. A., and Prasad, V. R. (2006) 
Influence of naturally occurring insertions in the fingers subdomain of human 
immunodeficiency virus type 1 reverse transcriptase on polymerase fidelity and 
mutation frequencies in vitro, J Gen Virol 87, 419-428. 
129. Marchand, B., and Gotte, M. (2003) Site-specific footprinting reveals differences 
in the translocation status of HIV-1 reverse transcriptase. Implications for 
polymerase translocation and drug resistance, J Biol Chem 278, 35362-35372. 
130. Gotte, M., Maier, G., Gross, H. J., and Heumann, H. (1998) Localization of the 
active site of HIV-1 reverse transcriptase-associated RNase H domain on a DNA 
223	  
	  
template using site-specific generated hydroxyl radicals, J Biol Chem 273, 10139-
10146. 
131. Traut, T. W. (1994) Physiological concentrations of purines and pyrimidines, Mol 
Cell Biochem 140, 1-22. 
132. Meyer, P. R., Matsuura, S. E., Tolun, A. A., Pfeifer, I., So, A. G., Mellors, J. W., 
and Scott, W. A. (2002) Effects of specific zidovudine resistance mutations and 
substrate structure on nucleotide-dependent primer unblocking by human 
immunodeficiency virus type 1 reverse transcriptase, Antimicrob Agents 
Chemother 46, 1540-1545. 
133. Nguyen, L. A., Daddacha, W., Rigby, S., Bambara, R. A., and Kim, B. (2012) 
Altered strand transfer activity of a multiple-drug-resistant human 
immunodeficiency virus type 1 reverse transcriptase mutant with a dipeptide 
fingers domain insertion, J Mol Biol 415, 248-262. 
134. Le Grice, S. F. (1993) Human immunodeficiency virus reverse transcritptase, pp 
163-191, Cold Spring Harbor laboratory Pess, NY. 
135. Telesnitsky, A., and Goff, S. P. (1997) Reverse Transcriptase and the Generation 
of Retroviral DNA,  In Retroviruses, J.M. Coffin, S.H.Hughes, and H. E. Varmus 
ed., pp 121-160, Cold Spring Harbor Press, NY. 
136. World Health Organization.  Scaling Up Antiretroviral Therapy  in Renounce 
Limited Settings: Treatment Guidelines for a Public Health Approach -2003. URL: 
http://www.who.int/hiv/pub/prev_care/en/ScalingUp_E.pdf. 
137. Rooke, R., Parniak, M. A., Tremblay, M., Soudeyns, H., Li, X. G., Gao, Q., Yao, 
X. J., and Wainberg, M. A. (1991) Biological comparison of wild-type and 
zidovudine-resistant isolates of human immunodeficiency virus type 1 from the 
same subjects: susceptibility and resistance to other drugs, Antimicrob Agents 
Chemother 35, 988-991. 
138. Kellam, P., Boucher, C. A., and Larder, B. A. (1992) Fifth mutation in human 
immunodeficiency virus type 1 reverse transcriptase contributes to the 
development of high-level resistance to zidovudine, Proc Natl Acad Sci U S A 89, 
1934-1938. 
139. Kerr, S. G., and Anderson, K. S. (1997) Pre-steady-state kinetic characterization 
of wild type and 3'-azido-3'-deoxythymidine (AZT) resistant human 
immunodeficiency virus type 1 reverse transcriptase: implication of RNA directed 
DNA polymerization in the mechanism of AZT resistance, Biochemistry 36, 
14064-14070. 
140. Krebs, R., Immendorfer, U., Thrall, S. H., Wohrl, B. M., and Goody, R. S. (1997) 
Single-step kinetics of HIV-1 reverse transcriptase mutants responsible for virus 
resistance to nucleoside inhibitors zidovudine and 3-TC, Biochemistry 36, 10292-
10300. 
141. Meyer, P. R., Smith, A. J., Matsuura, S. E., and Scott, W. A. (2004) Effects of 
primer-template sequence on ATP-dependent removal of chain-terminating 




142. Victorova, L., Sosunov, V., Skoblov, A., Shipytsin, A., and Krayevsky, A. (1999) 
New substrates of DNA polymerases, FEBS Lett 453, 6-10. 
143. Meyer, P. R., Smith, A. J., Matsuura, S. E., and Scott, W. A. (2006) Chain-
terminating dinucleoside tetraphosphates are substrates for DNA polymerization 
by human immunodeficiency virus type 1 reverse transcriptase with increased 
activity against thymidine analogue-resistant mutants, Antimicrob Agents 
Chemother 50, 3607-3614. 
144. Meyer, P. R., Matsuura, S. E., Schinazi, R. F., So, A. G., and Scott, W. A. (2000) 
Differential removal of thymidine nucleotide analogues from blocked DNA 
chains by human immunodeficiency virus reverse transcriptase in the presence of 
physiological concentrations of 2'-deoxynucleoside triphosphates, Antimicrob 
Agents Chemother 44, 3465-3472. 
145. Meteer, J. D., Schinazi, R. F., Mellors, J. W., and Sluis-Cremer, N. (2014) 
Molecular mechanism of HIV-1 resistance to 3'-azido-2',3'-dideoxyguanosine, 
Antiviral Res 101, 62-67. 
146. Meteer, J. D., Koontz, D., Asif, G., Zhang, H. W., Detorio, M., Solomon, S., 
Coats, S. J., Sluis-Cremer, N., Schinazi, R. F., and Mellors, J. W. (2011) The base 
component of 3'-azido-2',3'-dideoxynucleosides influences resistance mutations 
selected in HIV-1 reverse transcriptase, Antimicrob Agents Chemother 55, 3758-
3764. 
147. Hostomsky, Z., Hostomska, Z., Hudson, G. O., Moomaw, E. W., and Nodes, B. R. 
(1991) Reconstitution in vitro of RNase H activity by using purified N-terminal 
and C-terminal domains of human immunodeficiency virus type 1 reverse 
transcriptase, Proc Natl Acad Sci U S A 88, 1148-1152. 
148. Evans, D. B., Brawn, K., Deibel, M. R., Jr., Tarpley, W. G., and Sharma, S. K. 
(1991) A recombinant ribonuclease H domain of HIV-1 reverse transcriptase that 
is enzymatically active, J Biol Chem 266, 20583-20585. 
149. Stammers, D. K., Tisdale, M., Court, S., Parmar, V., Bradley, C., and Ross, C. K. 
(1991) Rapid purification and characterisation of HIV-1 reverse transcriptase and 
RNaseH engineered to incorporate a C-terminal tripeptide alpha-tubulin epitope, 
FEBS Lett 283, 298-302. 
150. Smith, J. S., and Roth, M. J. (1993) Purification and characterization of an active 
human immunodeficiency virus type 1 RNase H domain, J Virol 67, 4037-4049. 
151. Stahl, S. J., Kaufman, J. D., Vikic-Topic, S., Crouch, R. J., and Wingfield, P. T. 
(1994) Construction of an enzymatically active ribonuclease H domain of human 
immunodeficiency virus type 1 reverse transcriptase, Protein Eng 7, 1103-1108. 
152. Keck, J. L., and Marqusee, S. (1995) Substitution of a highly basic helix/loop 
sequence into the RNase H domain of human immunodeficiency virus reverse 
transcriptase restores its Mn(2+)-dependent RNase H activity, Proc Natl Acad Sci 
U S A 92, 2740-2744. 
153. Nowotny, M., Gaidamakov, S. A., Ghirlando, R., Cerritelli, S. M., Crouch, R. J., 
and Yang, W. (2007) Structure of human RNase H1 complexed with an 
RNA/DNA hybrid: insight into HIV reverse transcription, Mol Cell 28, 264-276. 
225	  
	  
154. Auerbach, S. D., and Johnson, K. A. (2005) Alternating site ATPase pathway of 
rat conventional kinesin, J Biol Chem 280, 37048-37060. 
155. Johnson, K. A., Simpson, Z. B., and Blom, T. (2009) FitSpace explorer: an 
algorithm to evaluate multidimensional parameter space in fitting kinetic data, 
Anal Biochem 387, 30-41. 
156. Johnson, K. A., Simpson, Z. B., and Blom, T. (2009) Global kinetic explorer: a 
new computer program for dynamic simulation and fitting of kinetic data, Anal 
Biochem 387, 20-29. 
157. Schultz, S. J., Zhang, M., and Champoux, J. J. (2010) Multiple nucleotide 
preferences determine cleavage-site recognition by the HIV-1 and M-MuLV 
RNases H, J Mol Biol 397, 161-178.	  
158. Marchand, B., Tchesnokov, E. P., and Gotte, M. (2007) The pyrophosphate 
analogue foscarnet traps the pre-translocational state of HIV-1 reverse 
transcriptase in a Brownian ratchet model of polymerase translocation, J Biol 
Chem 282, 3337-3346. 
159. DeStefano, J. J., Buiser, R. G., Mallaber, L. M., Bambara, R. A., and Fay, P. J. 
(1991) Human immunodeficiency virus reverse transcriptase displays a partially 
processive 3' to 5' endonuclease activity, J Biol Chem 266, 24295-24301. 
160. Krug, M. S., and Berger, S. L. (1989) Ribonuclease H activities associated with 
viral reverse transcriptases are endonucleases, Proc Natl Acad Sci U S A 86, 
3539-3543. 
161. Beilhartz, G. L., and Gotte, M. (2010) HIV-1 Ribonuclease H: Structure, Catalytic 
Mechanism and Inhibitors, Viruses 2, 900-926. 
162. Furfine, E. S., and Reardon, J. E. (1991) Reverse transcriptase.RNase H from the 
human immunodeficiency virus. Relationship of the DNA polymerase and RNA 
hydrolysis activities, J Biol Chem 266, 406-412. 
163. Champoux, J. J., and Schultz, S. J. (2009) Ribonuclease H: properties, substrate 
specificity and roles in retroviral reverse transcription, FEBS J 276, 1506-1516. 
164. Wohrl, B. M., Krebs, R., Goody, R. S., and Restle, T. (1999) Refined model for 
primer/template binding by HIV-1 reverse transcriptase: pre-steady-state kinetic 
analyses of primer/template binding and nucleotide incorporation events 
distinguish between different binding modes depending on the nature of the 
nucleic acid substrate, J Mol Biol 292, 333-344. 
165. Gao, H. Q., Boyer, P. L., Arnold, E., and Hughes, S. H. (1998) Effects of 
mutations in the polymerase domain on the polymerase, RNase H and strand 
transfer activities of human immunodeficiency virus type 1 reverse transcriptase, 
J Mol Biol 277, 559-572. 
166. Powell, M. D., Beard, W. A., Bebenek, K., Howard, K. J., Le Grice, S. F., Darden, 
T. A., Kunkel, T. A., Wilson, S. H., and Levin, J. G. (1999) Residues in the 
alphaH and alphaI helices of the HIV-1 reverse transcriptase thumb subdomain 
required for the specificity of RNase H-catalyzed removal of the polypurine tract 
primer, J Biol Chem 274, 19885-19893. 
226	  
	  
167. Mandal, D., Dash, C., Le Grice, S. F., and Prasad, V. R. (2006) Analysis of HIV-1 
replication block due to substitutions at F61 residue of reverse transcriptase 
reveals additional defects involving the RNase H function, Nucleic Acids Res 34, 
2853-2863. 
168. Nowak, M. (1990) HIV mutation rate, Nature 347, 522. 
169. Preston, B. D., Poiesz, B. J., and Loeb, L. A. (1988) Fidelity of HIV-1 reverse 
transcriptase, Science 242, 1168-1171. 
170. Kantor, R., Shafer, R. W., Follansbee, S., Taylor, J., Shilane, D., Hurley, L., 
Nguyen, D. P., Katzenstein, D., and Fessel, W. J. (2004) Evolution of resistance 
to drugs in HIV-1-infected patients failing antiretroviral therapy, AIDS 18, 1503-
1511. 
171. Boutabout, M., Wilhelm, M., and Wilhelm, F. X. (2001) DNA synthesis fidelity 
by the reverse transcriptase of the yeast retrotransposon Ty1, Nucleic Acids Res 
29, 2217-2222. 
172. Avidan, O., Meer, M. E., Oz, I., and Hizi, A. (2002) The processivity and fidelity 
of DNA synthesis exhibited by the reverse transcriptase of bovine leukemia virus, 
Eur J Biochem 269, 859-867. 
173. Bakhanashvili, M., and Hizi, A. (1993) Fidelity of DNA synthesis exhibited in 
vitro by the reverse transcriptase of the lentivirus equine infectious anemia virus, 
Biochemistry 32, 7559-7567. 
174. Roberts, J. D., Preston, B. D., Johnston, L. A., Soni, A., Loeb, L. A., and Kunkel, 
T. A. (1989) Fidelity of two retroviral reverse transcriptases during DNA-
dependent DNA synthesis in vitro, Mol Cell Biol 9, 469-476. 
175. Roberts, J. D., Bebenek, K., and Kunkel, T. A. (1988) The accuracy of reverse 
transcriptase from HIV-1, Science 242, 1171-1173. 
176. Rezende, L. F., Drosopoulos, W. C., and Prasad, V. R. (1998) The influence of 
3TC resistance mutation M184I on the fidelity and error specificity of human 
immunodeficiency virus type 1 reverse transcriptase, Nucleic Acids Res 26, 3066-
3072. 
177. Boyer, P. L., and Hughes, S. H. (2000) Effects of amino acid substitutions at 
position 115 on the fidelity of human immunodeficiency virus type 1 reverse 
transcriptase, J Virol 74, 6494-6500. 
178. Ji, J. P., and Loeb, L. A. (1992) Fidelity of HIV-1 reverse transcriptase copying 
RNA in vitro, Biochemistry 31, 954-958. 
179. Ji, J., and Loeb, L. A. (1994) Fidelity of HIV-1 reverse transcriptase copying a 
hypervariable region of the HIV-1 env gene, Virology 199, 323-330. 
180. Achuthan, V., Keith, B. J., Connolly, B. A., and DeStefano, J. J. (2014) Human 
immunodeficiency virus reverse transcriptase displays dramatically higher fidelity 
under physiological magnesium conditions in vitro, J Virol 88, 8514-8527. 
181. Brune, M., Hunter, J. L., Corrie, J. E., and Webb, M. R. (1994) Direct, real-time 
measurement of rapid inorganic phosphate release using a novel fluorescent probe 




182. Tantillo, C., Ding, J., Jacobo-Molina, A., Nanni, R. G., Boyer, P. L., Hughes, S. 
H., Pauwels, R., Andries, K., Janssen, P. A., and Arnold, E. (1994) Locations of 
anti-AIDS drug binding sites and resistance mutations in the three-dimensional 
structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug 
inhibition and resistance, J Mol Biol 243, 369-387. 
183. Sarafianos, S. G., Pandey, V. N., Kaushik, N., and Modak, M. J. (1995) 
Glutamine 151 participates in the substrate dNTP binding function of HIV-1 
reverse transcriptase, Biochemistry 34, 7207-7216. 
184. Kaushik, N., Harris, D., Rege, N., Modak, M. J., Yadav, P. N., and Pandey, V. N. 
(1997) Role of glutamine-151 of human immunodeficiency virus type-1 reverse 
transcriptase in RNA-directed DNA synthesis, Biochemistry 36, 14430-14438. 
185. Kaushik, N., Rege, N., Yadav, P. N., Sarafianos, S. G., Modak, M. J., and Pandey, 
V. N. (1996) Biochemical analysis of catalytically crucial aspartate mutants of 
human immunodeficiency virus type 1 reverse transcriptase, Biochemistry 35, 
11536-11546. 
186. Chunduri, H., Crumpacker, C., and Sharma, P. L. (2011) Reverse transcriptase 
mutation K65N confers a decreased replication capacity to HIV-1 in comparison 
to K65R due to a decreased RT processivity, Virology 414, 34-41. 
187. Shirasaka, T., Kavlick, M. F., Ueno, T., Gao, W. Y., Kojima, E., Alcaide, M. L., 
Chokekijchai, S., Roy, B. M., Arnold, E., Yarchoan, R., and et al. (1995) 
Emergence of human immunodeficiency virus type 1 variants with resistance to 
multiple dideoxynucleosides in patients receiving therapy with 
dideoxynucleosides, Proc Natl Acad Sci U S A 92, 2398-2402. 
188. Ueno, T., and Mitsuya, H. (1997) Comparative enzymatic study of HIV-1 reverse 
transcriptase resistant to 2',3'-dideoxynucleotide analogs using the single-
nucleotide incorporation assay, Biochemistry 36, 1092-1099. 
189. Ueno, T., Shirasaka, T., and Mitsuya, H. (1995) Enzymatic characterization of 
human immunodeficiency virus type 1 reverse transcriptase resistant to multiple 
2',3'-dideoxynucleoside 5'-triphosphates, J Biol Chem 270, 23605-23611. 
190. Pandey, V. N., Kaushik, N., Rege, N., Sarafianos, S. G., Yadav, P. N., and Modak, 
M. J. (1996) Role of methionine 184 of human immunodeficiency virus type-1 
reverse transcriptase in the polymerase function and fidelity of DNA synthesis, 
Biochemistry 35, 2168-2179. 
191. Wainberg, M. A., Drosopoulos, W. C., Salomon, H., Hsu, M., Borkow, G., 
Parniak, M., Gu, Z., Song, Q., Manne, J., Islam, S., Castriota, G., and Prasad, V. 
R. (1996) Enhanced fidelity of 3TC-selected mutant HIV-1 reverse transcriptase, 
Science 271, 1282-1285. 
192. Gu, Z., Gao, Q., Li, X., Parniak, M. A., and Wainberg, M. A. (1992) Novel 
mutation in the human immunodeficiency virus type 1 reverse transcriptase gene 
that encodes cross-resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine, J 
Virol 66, 7128-7135. 
193. Schinazi, R. F., Lloyd, R. M., Jr., Nguyen, M. H., Cannon, D. L., McMillan, A., 
Ilksoy, N., Chu, C. K., Liotta, D. C., Bazmi, H. Z., and Mellors, J. W. (1993) 
228	  
	  
Characterization of human immunodeficiency viruses resistant to oxathiolane-
cytosine nucleosides, Antimicrob Agents Chemother 37, 875-881. 
194. Tisdale, M., Kemp, S. D., Parry, N. R., and Larder, B. A. (1993) Rapid in vitro 
selection of human immunodeficiency virus type 1 resistant to 3'-thiacytidine 
inhibitors due to a mutation in the YMDD region of reverse transcriptase, Proc 
Natl Acad Sci U S A 90, 5653-5656. 
195. Larder, B. A., Coates, K. E., and Kemp, S. D. (1991) Zidovudine-resistant human 
immunodeficiency virus selected by passage in cell culture, J Virol 65, 5232-5236. 
196. Lewis, D. A., Bebenek, K., Beard, W. A., Wilson, S. H., and Kunkel, T. A. (1999) 
Uniquely altered DNA replication fidelity conferred by an amino acid change in 
the nucleotide binding pocket of human immunodeficiency virus type 1 reverse 
transcriptase, J Biol Chem 274, 32924-32930. 
197. Wu, E. Y., and Beese, L. S. (2011) The structure of a high fidelity DNA 
polymerase bound to a mismatched nucleotide reveals an "ajar" intermediate 
conformation in the nucleotide selection mechanism, J Biol Chem 286, 19758-
19767. 
198. Krahn, J. M., Beard, W. A., and Wilson, S. H. (2004) Structural insights into 
DNA polymerase beta deterrents for misincorporation support an induced-fit 
mechanism for fidelity, Structure 12, 1823-1832.	  
	  
 
